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ABSTRACT  
Kidney damage in cystic fibrosis (CF) patients is most commonly caused by antibiotics, 
such as aminoglycosides, which are used to treat Pseudomonas aeruginosa (PA). I 
conducted a survey of UK CF centres which showed a high rate of use of 
aminoglycosides in patients with no evidence of PA. I also conducted a Cochrane 
systematic review to assess the benefits and harms of strategies that may reduce or 
prevent kidney damage that is caused by intravenous antibiotic treatment. First, I 
attended necessary training courses for conducting a systematic review. I then wrote the 
protocol for the review and sent it off for peer review. I responded to the peer review 
comments making necessary adjustments to the protocol and it was then published. I 
then began the review process which involved running the searches and screening the 
results. We identified 54 studies that may be eligible for inclusion in the review. I was 
able to perform quantitative analysis and quality assessment on 4 of these. 2 studies 
looked at different combinations of intravenous antibiotics with no combination being 
more effective at preventing kidney injury. A study addressing time of dosing of 
tobramycin, showed a statistically significant increase in urinary excretion of KIM1 in 
the evening group with a mean difference of 0.73 (95% CIs 0.14 to 1.32), p=0.018 
when compared to the morning group. Another study reviewed the use of nebulised 
tobramycin compared to intravenous tobramycin in acute exacerbations. There was a 
statistically significant increase in urinary excretion of protein, NAG, AAP and β2-
Microglobulin in the intravenous group compared to the nebulised group suggesting 
intravenous tobramycin is more nephrotoxic. Morning dosing of tobramycin and using 
nebulised tobramycin instead of intravenous tobramycin for acute exacerbations may 
reduce kidney injury. Larger studies are needed to assess these strategies further.  
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CHAPTER 1: AIMS AND OBJECTIVES 
1.1 Aims  
This thesis aims to determine the evidence-base for strategies to prevent kidney injury in 
those receiving intravenous antibiotics that have cystic fibrosis (CF). 
1.2 Objectives 
1. Conduct a Cochrane systematic review to determine the evidence-base assessing 
the benefits and harms of strategies (such as altering the type and dose of 
intravenous antibiotics, the avoidance of other nephrotoxic drugs alongside the 
intravenous antibiotics and the use of adjuvant medication including statins and 
fluids) to reduce or prevent kidney injury in people with CF which occurs as a 
result of intravenous antibiotic treatment. 
 
2. Conduct a survey to evaluate the current use of intravenous antibiotics in children 
and adults with CF across centres in the United Kingdom. 
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CHAPTER 2: BACKGROUND OF CYSTIC 
FIBROSIS 
2.1 Overview 
This chapter will cover the background of cystic fibrosis (CF) including its epidemiology, 
aetiology, diagnosis, clinical features, management, prognosis, and reviews research 
addressing future therapies that may be used in the treatment of CF. 
2.2 Introduction  
Cystic fibrosis is an inherited life-limiting condition caused by a mutation in the cystic 
fibrosis transmembrane regulator (CFTR) gene. The disease is inherited in an autosomal 
recessive pattern which means the individual requires two copies of the faulty gene, one 
from each parent, to inherit the disease. The faulty gene causes an absence or reduction 
in the number of CFTR channels which results in stickier mucus in the affected 
individuals compared to the normal population. This affects multiple organ systems 
including the lungs, the pancreas, the gastrointestinal tract, the reproductive tract, and the 
hepatobiliary system.  
2.3 Epidemiology  
In the UK around 1 in 25 people are carriers of a faulty CFTR gene. The Cystic Fibrosis 
Registry in 2016 identified 10,461 people suffering from CF in the UK. This equates to 
about 1 in 2,500 live births each year. The population of those affected by CF is made up 
of 53.2% males and 46.8% females. The median age of those affected in 2016 was 20 
years old.1  
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2.4 Aetiology  
2.4.1 CFTR discovery 
CF was first discovered over 400 years ago, but it was not until 1989 that the CFTR gene 
was discovered by Dr Lap-Chee Tsui and his team.2 It is a large gene that is located on 
the long arm of chromosome seven (7q31.2).3 As mentioned earlier, CF is caused by 
mutations in the CFTR gene. The CFTR gene codes for the CFTR protein which is a 
member of the ABC transporter family (ATP (adenosine triphosphate) -binding cassette). 
It is made up of two repeated units that are joined together by an R domain. Each unit 
contains a membrane-spanning domain (MSD), which are made up of six transmembrane 
regions, and a nucleotide-binding domain (NMD).4  
 
Figure 2.1 - CFTR protein5 
The CFTR channel is mainly found at apical epithelial surfaces including the respiratory 
system, reproductive system, gastrointestinal system, sweat duct and the pancreas. 
However, recent research has suggested it may be found in non-epithelial tissue such as 
smooth muscle cells in the airways, vascular smooth muscle, cardiac myocytes, skeletal 
muscle, neuronal cells, immune cells and possibly erythrocytes.6–13 The levels of CFTR 
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channels in these locations is lower, however, it still may cause some of the symptoms 
experienced in CF which will be discussed later.  
2.4.2 CFTR mutations  
The Cystic Fibrosis Mutation Database (CFTR1) currently lists 2027 mutations in their 
database.14 Phe508del, previously known as ΔF508, is the most common mutation with 
82.4% of CF patients in Europe in 2016 having at least one copy.15 The highest allele 
frequency of Phe508del is found in Denmark.15 Certain mutations have a higher 
prevalence in different countries due to a founder effect. For example, Gly551Asp 
mutation is most frequent in Ireland with an allele frequency of 8.78%.15 The W1282X 
mutation is most frequently found in Israel, particularly in Ashkenazi Jews, with an allele 
frequency of 23.28%.15  
Historically, little attention was paid to the precise genotype. Whilst some genotypes 
were associated with milder disease and pancreatic sufficiency, the type of defect was 
less important. However, over the last decade it has become apparent that certain genetic 
defects are more, or less amenable to treatment with small molecules including CF 
potentiators and CF correctors. These hold considerable promise and may offer 
significant improvements in life expectancy. 
The different mutations can be split into five different classes, however, some mutations 
may fit into more than one category.  
Class I: Defective protein synthesis  
Most types of mutation can result in premature stop codons. These lead to the production 
of an abnormally short protein product. The usual 1480 amino acid protein is therefore 
shorter than expected. These CFTR proteins are not simply defective but the majority of 
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protein product is degraded before it reaches the cell surface. Typically, this results in 
little or no functional CFTR reaching the cell membrane and CFTR activity is very low. 
The genotype from premature stop codons always ends with an ‘X’. Examples of this 
class of mutations include G542X, W128X, R553X and R1162X. 
Class II: Abnormal protein folding, processing, and trafficking 
Missense mutations and in-frame deletions lead to a CFTR protein being created, but it 
is misfolded, so it is then degraded in the endoplasmic reticulum. Therefore, very little or 
no CFTR protein reaches the epithelial cell surfaces. Examples of this class of mutation 
include Phe508del, N1303K and I507del. Phe508del is the most common mutation in 
this class but also out of all the mutations. The Phe508del mutation is where three 
nucleotides coding for phenylalanine at amino acid position 508 are deleted.  
Class III: Defective regulation 
Some missense mutations can cause a CFTR that is created and moves to the cell surface 
but that does not open. It is known as a ‘gating mutation’ as there are normal amounts of 
CFTR at the cell surface, but they are non-functioning. Examples of this class of 
mutations include Gly551Asp, S549N and G1349D. 
Class IV: Decreased conductance 
Some missense mutations lead to a CFTR protein that is created and moves to the 
epithelial cell surface but has a ‘misshaped pore’ preventing movement of Cl- through the 
channel. Examples of this type of mutation include R117H, D1152H and R347P 
Class V: Reduced abundance 
Some missense mutations affect splice sites or the CFTR promoter which means a 
functional CFTR is made and moves to the epithelial cell surfaces but there are reduced 
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amounts of it. Examples of this class of mutation include 3849+10kbC→T, 2789+5G→A 
and A455E.  
Class VI: Reduced stability 
Some mutations can cause an increase in CFTR turnover at the cell surface meaning 
although the CFTR at the cell surface is functional, it is often unstable. Examples of this 
class of mutation include 120del23, N287Y and 4279insA. Many people, including the 
CF Trust, do not recognise this class of mutation perhaps due to its more recent discovery.  
 
Figure 2.2 -  CFTR mutations16 
2.4.2 Role of CFTR protein 
The CFTR protein functions slightly different in sweat glands than other epithelial 
surfaces such as respiratory, pancreatic and airway epithelia.  
CFTR permits two physiologically relevant anions to pass through the cell membrane, 
chloride, and bicarbonate. It is also permeable to other anions of less certain significance 
including iodide, bromide, fluoride and glutathione.5 Flow through the channel is thought 
to be controlled by cAMP (cyclic adenosine monophosphate)-dependent PKA (protein 
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kinase A) phosphorylation of the R domain and also by binding of ATP to the NMD 
regions which both induce conformational changes in the channel.17   
Sweat gland 
The most important anion which can pass through the CFTR is chloride (Cl-). Sweat 
(NaCl and water) is secreted onto the skin surface and when the water evaporates this 
cools the skin down. In the sweat gland epithelium, CFTR absorbs Cl- that is on the 
surface of the skin to control levels of NaCl in the body.18 The CFTR protein also 
regulates the epithelial sodium channel (ENaC). A normal CFTR protein is required for 
ENaC to be able to absorb excess Na+ from the skins surface.19,20 
Individuals with CF have a reduced number or faulty CFTR proteins in the sweat ducts 
hence less Cl- can be absorbed from the skins surface.18,21,22 ENaC activity is reduced in 
CF patients due to a non-functioning CFTR, and so less Na+ is reabsorbed back into the 
body.20 This means that people with CF have more NaCl in their sweat and this is 
something mothers may notice when kissing their baby.  
Intestinal, pancreatic and airway epithelia 
A normal CFTR protein secretes Cl- across the epithelium onto the luminal surface of the 
pancreas, intestines and airways.23 In these locations CFTR normally downregulates 
ENaC function which is to absorb Na+ from the lumen.24 Therefore, with a normally 
functioning CFTR, Cl- is being secreted into the lumen, small amounts of Na+ are being 
absorbed from the lumen and therefore, very little H2O is absorbed from the lumen.   
In individuals with CF there is reduced secretion of Cl- into the lumen of the intestines, 
pancreatic ducts and airways.25,26 With a non-functioning CFTR, it cannot regulate ENaC 
activity as effectively and so this leads to more absorption of Na+ from the lumen.26–28 
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With very little Cl- or Na+ left in the lumen, more H2O is drawn away from the lumen 
back into the cells which leaves a dehydrated mucus coating the epithelial cells.  
2.5 Diagnosis  
2.5.1 Newborn screening  
At five days of age, new-born babies are offered the Guthrie test which screens for nine 
genetic conditions including CF. This test involves taking four drops of blood from the 
babies’ heel and placing them on a card. Parents will receive the results within 6-8 weeks 
but usually sooner if they are found to be positive. In 1979, it was discovered that all 
people with CF had raised levels of serum immunoreactive trypsinogen (IRT) in the first 
few months of life.29 This suggested that dried-blood spot assay may be useful for 
screening for CF. In 1980 screening for CF based on IRT began in East Anglia. Raised 
IRT is not specific for CF and so early screening required a second-tier test which was 
usually to repeat IRT levels a few weeks later. Screening for CF has been carried out 
universally in the UK since October 2007. Since discovery of the CFTR gene, the second-
tier test now involves genetic analysis testing of the blood to look for any CFTR 
mutations if the initial IRT is at or above the 99.5th centile. A cut of at the 99.5th centile 
has been shown to have a sensitivity of 97%.30  
If babies have mutations in both CFTR genes, then it is presumed they have CF and then 
are referred to a specialist for assessment and sweat testing. Babies with only one 
mutation are usually carriers, however, it may be that they carry a rare gene that has not 
been detected and so they should have a second IRT which if normal means they are a 
carrier. If the second IRT is abnormal, then again they should be referred to a specialist 
and for further mutation analysis.31 Babies that are screened are on average diagnosed at 
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1 month but only diagnosed at 6 months if clinically diagnosed.32 Reviews have 
conflicting evidence regarding the benefit of early detection but recent evidence suggests 
there is a decrease in mortality in those that are detected via screening.33 It also improves 
nutritional status as pancreatic enzyme replacement can be started sooner.34 If results are 
inconclusive or false-positive results are received then this can create extra anxiety in the 
parents. However, if babies aren’t screened and start to develop symptoms, this can be 
even more worrying for the parents especially if the diagnosis if missed originally.  
2.5.2 Sweat test 
The gold standard for diagnosis of CF is a sweat test which was first discovered in 1959.35 
After 2 weeks since birth a sweat test can be performed on the infant given they weigh 
more than 2kg and are systemically well at the time of testing. If they weigh less than 
this, it can be difficult to obtain enough sweat. If the infant is experiencing symptoms 
them the sweat testing can be attempted from 7 days of age, however may need to be 
repeated if not enough sweat was collected.36 Sweat production is stimulated on the flexor 
surface of the forearm by iontophoresis of pilocarpine into the skin. Skin that is 
eczematous should be avoided as this can cause a false positive result. The sweat is 
collected on a piece of filter paper over a standardized period of time, usually between 
20-30 minutes. The chloride levels are measured, and these results are interpreted based 
on the age of the child. In all ages groups a sweat chloride of over 60 mmol/L is defined 
as a positive test and this child is likely to have CF. In a child under 6 months of age a 
sweat chloride under 30 mmol/L is defined as a negative test and CF is considered 
unlikely. If they score between 30-60 mmol/L, then this level is classed as intermediate 
and requires further assessment. In someone over age 6 months a level below 40 mmol/L 
is normal, and these patients are unlikely to have CF. However, a level between 40-
60mmol/L in people over 6 months is again classed as intermediate and requires further 
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investigation.36 In the majority of people with CF this test gives a positive result 
confirming the diagnosis, however 1-2% of cases that have CF will have a negative sweat 
test result which may be due to specific mutations.37 Other examples of false negatives 
include corticosteroid use or oedema commonly due to hypoproteinaemia.38 There are 
other causes of a positive sweat test other than CF, these include adrenal insufficiency, 
hypothyroidism, malnutrition, G6PD deficiency and nephrogenic diabetes insipidus, 
however these diseases present differently to CF.  
2.5.3 Faecal elastase 
Once a diagnosis of CF has been confirmed it is necessary to determine whether the 
individual is pancreatic sufficient. This involves collecting a stool sample and detecting 
faecal pancreatic elastase-1 via enzyme-linked immunosorbent assay. Faecal elastase-1 
does not degrade on its journey through the gastrointestinal system and so low levels in 
the stool suggest pancreatic insufficiency.39 However, this is an indirect method of testing 
pancreatic exocrine function and so they are less specific and sensitive when compared 
to a direct method. This is particularly important in those with mild pancreatic insuffiency 
who may be missed because of this.40 Advantages of indirect testing includes it is less 
invasive, less time consuming and less costly.41   
2.5.4 Genetic screening 
Following diagnosis if the individual has any siblings these are tested for CF in case it 
has been missed on screening and other family members can be screened to check for 
carrier status. Being a carrier can cause anxiety and depression as it creates uncertainty 
particularly if they are considering having children.  
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2.5.5 Antenatal testing 
For those that are at increased risk of having a child with CF they may choose to have 
antenatal testing. This involves the fetus being tested for CF by amniocentesis or 
chorionic villus sampling.    
2.6 Respiratory system 
2.6.1 Pathophysiology 
The entire respiratory system is significantly affected by the presence of reduced CFTR 
function. In the upper airway, this results in significant sinus disease. In the lower airway, 
there is a repeated cycle of infection and inflammation that leads to progressive lung 
disease with bronchiectasis and eventual destruction of normal lung parenchyma. This is 
because people with CF are more ‘vulnerable’ to infection. The ‘vulnerability’ arises 
from a weakened host immune response, chronic inflammation, decreased mucociliary 
clearance and a dehydrated mucus layer causing mucus stasis and adhesion eventually 
leading to mucus plugs.  
In normal individuals the airways are rich in antimicrobial proteins including lactoferrin, 
antimicrobial peptides and reactive oxygen species which kill and/or supress 
antimicrobial growth. It is the submucosal glands that secrete these antimicrobial protein, 
however in CF these glands can be obstructed due to mucus plugging and so this secretion 
does not happen as easily.42 Secondly, due to the CFTR dysfunction there is less 
bicarbonate secreted onto the lung epithelial surface and so it is more acidic.43 Studies in 
CF pigs have shown that this acidification can reduce function of one of the antimicrobial 
peptides.44 It is likely that these antimicrobial peptides can only supress bacterial growth 
for a limited period of time and rely on the mucociliary clearance to happen  in order to 
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maintain normal lung sterility.45 Unfortunately in CF there are areas of absent and 
reduced mucociliary clearance.46  
As described above studies have found the presence of CFTR in macrophages. 
Macrophages have an important role in the inflammatory response and killing inhaled 
microbes. CFTR deficient macrophages have been shown to be related to infection in 
mouse models.47 
There is a hypothesis that the CF airways are ‘hyper-inflammatory’ due to 
bronchoalveolar lavage samples from infant CF patients having neutrophilic 
inflammation in the absence of bacterial infection. 48 However, mucus plugging itself can 
cause a pro-inflammatory environment which may be due to how the mucus can trap 
inflammatory cells.49  
Later in CF disease pathogenesis, chronic inflammation promotes airway remodelling 
which involves goblet cell hyperplasia causing mucin hypersecretion, which exacerbates 
the ‘relative’ dehydration of mucus, and airway epithelial thickening.50  
After airway mucus plugging, the airways are then susceptible to infection. It is likely 
that infection arises after mucus plugging as virtually all the bacteria that infect the CF 
airway lumen are contained within the mucus plaques rather than the epithelial surface.51 
Biofilms can form in CF mucus which can trap bacteria and make them more resistant to 
antimicrobial agents and so cannot be eradicated as easily.52 
Airway epithelial cells use the oxygen from the airway lumen for cellular metabolism 
rather that surrounding vasculature. With mucus plugging the epithelium struggle to 
receive this oxygen as the diffusion distance is further. With bacteria infecting the mucus 
and consuming oxygen this further lowers the amount of oxygen available to epithelial 
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cells. This changes the nature of the inflammatory process with levels of certain 
inflammatory mediators rising. The hypoxic environment provides the perfect 
environment for colonisation with anaerobic bacteria known as the CF microbiome. This 
includes organisms such as Prevotella sp, Veillonella sp and Streptococcal sp.53 It is not 
yet known whether the presence of these organisms is pathogenic or not.  
In CF the mesh size of the mucus is a lot smaller than mucus found in normal patients. 
Less neutrophils can migrate through the mesh to reach bacteria in the mucus meaning 
less bacteria are killed. As the mucus is then persistently infected with bacteria this causes 
release of neutrophil chemotaxis agents which bring more neutrophils to the site. This 
persistently high level of neutrophils causes a large amount of antimicrobial substance 
(e.g. elastase) to be released into the lumen. In particular, elastase can cause airway wall 
damage which produces the bronchiectasis seen in CF patients.54  
2.6.2 Respiratory tract infection 
Respiratory infection is the hallmark of CF, and it presents early in life in most 
individuals. Infection with bacteria, viruses and fungi can all result in respiratory 
morbidity, with increased symptoms and reduced lung function. 
Bacterial infection and the CF lung 
In the beginning, CF patients are likely to suffer from intermittent bacterial infection of 
the airways and then as the disease progresses can become chronically infected. Earlier 
in life the most common bacteria seen is Staphylococcus aureus but by late teens the most 
prominent organism is PA.15 In the UK in 2016, 44.2% of adults (≥16 years) had chronic 
PA growth with 32-35 being the most common age group growing it.1 The 2016 annual 
data report demonstrates a statistically significant drop in chronic PA growth in most age 
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groups compared to 2008.1 Other organisms that CF patients may grow include 
Burkholderia cepacia complex, Haemophilus influenzae, Achromobacter xylosoxidans, 
Stenotrophomonas maltophilia and non-tuberculous mycobacterial such as M. avium 
complex and M. abscessus complex.1,55,56  
Viral infection in CF 
As with unaffected individuals, children and adults with CF are more likely to suffer from 
symptomatic viral respiratory tract infections in the autumn and winter. There is no 
evidence that CF patients are more prone to viruses than normal individuals, however, 
the outcome is often worse for them, with more prolonged symptoms, a greater decline 
in lung function and a higher likelihood of hospitalization.57–59 Respiratory viruses can 
be complicated by secondary bacterial infection and it has been suggested that they may 
be related to the first isolation of PA.60,61  
Fungal infection in CF 
Fungal infection and sensitisation with subsequent reaction to fungal spores can lead to 
significant respiratory complications in children and adults with CF. It is thought that 
there is an increased prevalence of growth in Aspergillus due to the antibiotic regimens 
in particular the use of long term prophylactic antibiotics.62,63 Aspergillus causes a range 
of conditions including aspergillus bronchitis, allergic bronchopulmonary aspergillosis 
(ABPA), aspergilloma and aspergillosis. ABPA is a hypersensitivity disease where there 
is an excessive immune response to Aspergillus antigens. This may present acutely with 
a wheeze, cough, dyspnoea, increased sputum production, exercise intolerance and 
reduced pulmonary function on testing. It can be diagnosed with raised serum IgE levels 
and a positive skin prick test to Aspergillus. 
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2.6.3 Respiratory morbidity in CF 
Some patients with CF can be asymptomatic, however, other patients can experience 
cough, dyspnoea, and sputum production most days which are managed with 
medications. There are periods of time when their symptoms are much worse than their 
normal state and this is described as a pulmonary exacerbation. A pulmonary 
exacerbation can present as increased cough, increased dyspnoea, fever, increased 
sputum production, change in colour of the sputum to green/yellow and decreased 
exercise tolerance. During these exacerbations patients may have new X-ray changes and 
decreased pulmonary function on testing and so these episodes need to be managed 
promptly.  
Eventually, patients may develop type 1 (hypoxic) respiratory failure which then causes 
pulmonary hypertension and cor pulmonale. Type 2 (hypoxic and hypercapnic) 
respiratory failure may develop and patients may require non-invasive ventilation. 
Respiratory failure is the leading cause of death in CF patients with up to 65% of mortality 
caused by it.64  
2.6.4 Other respiratory complications 
CF patients may experience other respiratory complications such as sinusitis, nasal 
polyps, pneumothorax, bronchiectasis, atelectasis, haemoptysis, and pulmonary 
hypertension.  
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2.6.5 Management of the respiratory system 
Organisation of care and monitoring 
CF clinics are held on different days for patients that are colonised with PA to those non-
colonised to prevent cross infection. CF patients attend clinics regularly for monitoring 
of their clinical status. During clinics they are seen by several professionals including 
doctors, physiotherapists, dieticians, psychologists, and nurses. The doctor examines the 
patient, enquires about any recent changes in symptoms and monitors their compliance 
with treatments. Figure 2.3 highlights some of the signs that may be seen in a patient with 
CF. Pulmonary function tests are performed each clinic to ensure the patient is not acutely 
unwell and all patients are asked to provide a sputum sample or cough swab.  
 
Figure 2.3 - Clinical signs seen in CF patients16 
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Antibiotics  
Antibiotics can be used in the prophylaxis of infection for example oral flucloxacillin is 
given to children up until the age of 6 and leads to fewer infections with Staphylococcus 
aureus but does not significantly improve clinical outcomes such as lung function.65 Oral 
antibiotic use at the start of a viral respiratory exacerbation is often encouraged to reduce 
the risk of a secondary bacterial infection, however, there is no evidence to support this.66   
When a new organism is grown doctors should start the patient on an eradication regimen 
to prevent deterioration. Eradication regimens vary for different organisms and may vary 
from centre to centre but doctors can use the CF Trust guidelines for direction.66 They 
recommend nebulised colistin and oral ciprofloxacin for the first isolate of PA given the 
patient is well.66  
If eradication fails, patients may develop a chronic infection and inhaled and intravenous 
antibiotics may be used to control the infection. Those with chronic PA should be started 
on twice daily inhaled tobramycin or colistin to prevent a decline in lung function and to 
reduce the need for intravenous antibiotics.66,67 In some centres they may use regular 
courses of intravenous antibiotics (e.g. every 3 months) to prevent deterioration, however, 
there is a lack of evidence to support this.68  
Macrolides may have another role in CF other than being anti-bacterial. It is thought that 
macrolides such as azithromycin and erythromycin may have anti-inflammatory 
properties. A Cochrane review looking at long term use of azithromycin showed that 
when used for over 6 months it can improve respiratory function, decrease risk of 
exacerbations and reduce the need for oral antibiotics.69  
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Intravenous Antibiotics 
For acute infections, a course of oral antibiotics is usually prescribed but intravenous 
antibiotics may be required if the infection is more severe.  
For most organisms a single agent can be used, however for those with chronic PA 
infections with an acute exacerbation it is recommended to use two agents (a β-lactam or 
an anti-pseudomonal penicillin along with an aminoglycoside).66,70 Courses of antibiotics 
are usually prescribed for two weeks but can be given for longer if required. 
Intravenous antibiotics can be administered via an intravenous cannula; however, venous 
access can become troublesome after many courses. In this case, a vascular access device 
may be required such as a peripheral inserted central catheter (PICC) or an implantable 
device such as a port. Ports can be used for longer term delivery of medications and can 
last for years. They are placed under the skin and so a needle is required to access them.  
In those with chronic infection or in those experiencing regular exacerbations they will 
require more frequent courses of intravenous antibiotics. As well as this if the infection 
is difficult to clear, patients may require more prolonged courses of intravenous 
antibiotics too. As with all medications, antibiotics can have many side effects. In 
particular, aminoglycosides are known to cause long term damage to the kidneys and can 
affect hearing. Kidney damage is a major concern, which will be discussed in further 
detail in the next chapter.  
Physiotherapy 
The physiotherapist’s role is to educate the patients in chest care which includes airway 
clearance techniques and to encourage regular exercise. There are many airway clearance 
techniques, but physio can advise on choice of treatments to individualise care. This could 
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be active cycle of breathing, autogenic drainage, postural drainage and percussion, 
Aerobika Flutter or Acapella. They also monitor patients’ lung function to recognise 
deterioration in patients and collect sputum to encourage early detection and treatment of 
acute infections.  
Mucolytics 
Mucolytics are medicines that can loosen the mucus, making it less sticky and easier to 
clear by coughing or mucociliary clearance. Dornase alfa is a highly purified solution of 
recombinant human deoxyribonuclease (rhDNase) which is an enzyme that can break 
down DNA. This reduces the stickiness of the sputum making it easier to clear. A 
Cochrane systematic review demonstrated that Dornase alfa was able to improve the 
FEV1 by 9.51% (95% CI 0.67 to 18.35) when compared to placebo in trials when used 
for up to one month.71 It also showed that it can reduce the number of pulmonary 
exacerbations in people with CF however evidence is conflicting regarding whether it 
improves quality of life.71  
Nebulised hypertonic saline is also commonly used as a mucolytic however it does not 
have as strong an evidence base. By depositing hypertonic saline into the airways, water 
may travel down an osmotic gradient across the epithelial cells into the lumen of the 
airways rehydrating the mucus.72 7% hypertonic saline has been shown to improve lung 
function in the short term, however, has not shown the same effects in the long term.73 It 
can improve quality of life and can reduce frequency of pulmonary exacerbations.73 
Anti-inflammatory agents  
Corticosteroids have a potential role in CF due to their anti-inflammatory effects. Oral 
steroids may slow the progression of lung disease, however, they should be used with 
caution due to the risk of bone disease which is already more prevalent in CF patients.74 
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There is insufficient evidence to recommend inhaled corticosteroids for reducing 
inflammation in CF.75 
Non-steroidal anti-inflammatory agents (NSAIDs) have been shown to slow the rate of 
decline in lung function in patients with CF.76 However, NSAIDs can have important side 
effects including gastritis and ulcers and can potentially be nephrotoxic.  
Bronchodilators 
CF causes an obstructive respiratory disease pattern and so patients may benefit from 
bronchodilators.77 Evidence is limited regarding their use but they are often prescribed to 
CF patients.78 However, it does add to the already heavy treatment burden and so 
adherence may be poor.  
Lung transplant 
Eventually patients with respiratory failure that are not responding to medical therapy 
will require lung transplantation, although many patients will die while on the waiting 
list. There are some contraindications to transplantation including HIV, hepatitis B and 
active tuberculosis (TB). In some centres Burkholderia cepacia and multiple drug 
resistant PA infections may be regarded as contraindications too.79 Survival is variable 
and depends on multiple factors but one study showed a 1 year survival of 82% and 10 
year survival of 51%.80  
2.7 Pancreas 
2.7.1 Pathophysiology 
The pancreas secretes a bicarbonate rich isotonic fluid and digestive enzymes into the 
pancreatic lumen. The fluid secreted into the pancreatic lumen dilutes the pancreatic 
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enzymes and helps them move faster into the intestinal lumen. The bicarbonate rich fluid 
help to neutralize the acidic gastric contents when they reach the duodenum.  
2.7.2 Pancreatic insufficiency 
With less Cl- secretion due to dysfunctional CFTR, the mucus is thicker and less HCO3- 
is secreted in the pancreatic luminal fluid, making it more acidic.81 The pancreatic ducts 
get obstructed meaning transport of the bicarbonate and enzymes from the pancreas to 
the intestines is reduced. With reduced flow of bicarbonate to the duodenum the intestinal 
pH is more acidic which can denature the few lipase enzymes that do manage to reach 
the intestinal tract.82 As the enzymes get stuck in the pancreas, they then begin to destroy 
the pancreatic ducts themselves and eventually the acini, replacing it with fat. This is 
known as pancreatic insufficiency. 
Pancreatic insufficiency is prevalent in up to 87% of the CF population and the risk 
increases with age.83 By identifying the genotype of a CF patient, the risk and severity of 
pancreatic insufficiency can be calculated. If the patient carries two ‘severe’ mutations it 
is likely that they will be pancreatic insufficient.84 If the patient carries at least one ‘mild’ 
mutation such as Class IV and V mutations, they are unlikely to be pancreatic insufficient, 
however it cannot be ruled out completely.84,85 Pancreatic insufficient individuals have 
reduced levels of amylase, protease and lipase causing inability to break down complex 
carbohydrates, proteins and fats respectively. This presents with abdominal pain and 
distension, diarrhoea, steatorrhea, floating stools, flatus, insatiable appetite, 
malabsorption, and weight loss. 
As described above, CF patients can have poor fat absorption which is due to pancreatic 
insufficiency. The vitamins that are absorbed with fat (A, D, E and K) are therefore also 
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poorly absorbed and pancreatic insufficient CF patients may become deficient in these 
vitamins.86 
2.7.3 Cystic fibrosis-related diabetes 
Eventually, surrounding tissue including endocrine tissue such as β cells are destroyed 
and this can lead to cystic fibrosis-related diabetes (CFRD). When β cells are destroyed 
there is impaired insulin secretion leading to insulinopaenia. This leads to an impaired 
glucose tolerance which is known as the pre-diabetic state. However even in CF patients 
with a normal glucose tolerance test they can be relatively insulinopaenic.87 This may be 
due to the fact that alpha (α) cells may also be destroyed in CFTR. Alpha cells produce 
glucagon which help with hepatic gluconeogenesis and with reduced glucagon in the 
blood less glucose is released in to the blood. With further destruction of β cells, CFRD 
can occur, commonly between the ages of 18-21 years.88,89 In 2016 the UK CF annual 
registry report identified 7212 patients aged 10 or over on treatment for CFRD which 
equates to 29.5% of the CF population (over or equal to 10).1 The prevalence of CFRD 
is greater in female than it is in men and it tends to present earlier in females which may 
be due to an earlier onset of puberty and the associated increase of insulin resistance at 
this time.89,90 As the onset is usually insidious in nature, the classic features of diabetes 
(polyuria, polydipsia, weight loss) are uncommon with only a third presenting in this 
way.89 Others that are diagnosed may be identified through screening.  
2.7.4 Pancreatitis 
Pancreatitis is a rare complication of CF with an incidence of 1.24%.91 It is much more 
common in patients that are pancreatic sufficient and occurs in up to 20% of these 
patients.92 The pathogenesis for this is mainly unknown, however, it is thought that the 
reduced flow of bicarbonate leading to a more acidic duct can activate trypsinogen to 
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trypsin. This active trypsin may cause autodigestion and local inflammation.93 
Pancreatitis in CF patients presents the same way as it does in a non-CF patient with 
abdominal pain usually in the epigastric region that may radiate to the back, nausea, 
vomiting and sometimes fever.  
2.7.5 Management 
Pancreatic insufficiency 
During each clinic appointment the patients weight, height and BMI are taken and in 
paediatrics they plot these on a growth chart. Dieticians are needed in the management 
of CF patients to ensure they are gaining weight sufficiently by advising on food intake. 
CF patients have a greater energy demand than normal individuals and it may be hard to 
meet this with food alone.94,95 Therefore, the dietician may recommend high-calorie 
supplement energy drinks and if that does not work the patient may need tube feeding.96  
CF patients that are pancreatic insufficient are required to take Pancreatic Enzyme 
Replacement Therapy (PERT). This comes in the form of Creon which are capsules that 
contain enzymes including protease, amylase and lipase. The dietician plays an important 
role in educating regards to Creon dose and will monitor patients’ symptoms to decide if 
they require more or less PERT.  
Pancreatic insufficient patients should have their vitamin A, D and E levels monitored 
once a year but more frequently if they have been previously deficient. In some centres 
they give vitamins supplementation prophylactically but in other centres they will only 
give vitamin supplementation if the levels are low. The Cystic Trust recommends that 
Vitamin D, E and K supplementation should be given routinely if the patient is pancreatic 
insufficient whereas Vitamin A should only be supplemented if their levels are low.96  
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Cystic fibrosis-related diabetes 
The CF Trust recommends that CFRD is screened for annually in those with CF over 10 
years old by performing an oral glucose tolerance test (OGTT).70 As the child reaches 
late teens or if they experience symptoms of hyperglycaemia such as weight loss, polyuria 
and polydipsia they are screened more regularly. An impaired glucose tolerance test is 
common and can be normal for a CF patient. A ‘diabetic OGTT’ can also return to normal 
in some cases. Therefore, clinicians may choose to undergo further testing such as 
continuous glucose monitoring before commencing treatment. Treatment of CFRD is 
with insulin and they are reviewed regularly at a specialist CF diabetic clinic to ensure 
they are on the correct regimen.  
2.8 Gastrointestinal tract 
2.8.1 Meconium ileus 
Meconium ileus is the earliest manifestation of CF which is a type of bowel obstruction 
that occurs in the neonatal period. It is caused by dysfunctional CFTR channels resulting 
in reduced bicarbonate secretion and hence a more acidic intestinal luminal pH.97 The 
mucus in the gut is therefore thick and dehydrated. Meconium ileus is seen in up to 20% 
of neonatal CF patients and is more common in those with more ‘severe’ genotypes (class 
I-III mutations) and those that are pancreatic insufficient 98,99 However, there are cases of 
it occurring in CF patients that are pancreatic sufficient and also in non-CF patients. It 
can present in the antenatal period seen on ultrasound scans as a hyperechoic bowel. It 
can also present when feeding is initiated with bilious emesis and abdominal distension 
or with the delayed passage of meconium. The first presentation may also be of 
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perforation with peritonitis and signs of shock.100 Meconium ileus may cause volvulus 
which is where the intestines twist on its mesentery preventing blood supply to it. 
2.8.2 Constipation 
Constipation is often confused with Distal Intestinal Obstruction Syndrome (DIOS), 
however, their pathophysiology is different. Constipation may occur due to factors 
unrelated to CF as it can do in normal individuals such as low fibre diet and poor fluid 
intake. In CF constipation may be associated with high doses of pancreatic 
supplements.101,102  
2.8.3 Distal intestinal obstruction syndrome  
Distal intestinal obstruction syndrome (DIOS) occurs in 10-22% of CF patients over their 
lifetime and has a recurrence rate of up to 50%.103,104 The mucus in the intestines is thicker 
and stickier in CF patients and it combines with viscid faecal material. This creates a 
mass that is often found in the distal ileum and caecum and when it sticks to the intestinal 
walls can be difficult to pass.105 The mass can either block the lumen fully (complete 
DIOS) or partially (incomplete DIOS). DIOS presents with abdominal pain, right iliac 
fossa mass, constipation and later on bilious vomiting if there is complete obstruction.   
2.8.4 Other gastrointestinal complications 
A rectal prolapse is defined as a circumferential, full-thickness protrusion of the rectal 
wall through the anal orifice.106 There is very little literature regarding rectal prolapses 
but a study in 1958 found that 22.6% of patients with CF will experience it.107  Factors 
that contribute to rectal prolapse in CF patients include voluminous faeces with poorly 
digested food, frequent bowel movements,  and increased intra-abdominal pressure due 
to pulmonary hyperinflation and coughing.107,108 
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With thick mucus accumulating in the intestines, bacteria can colonise the intestines 
irregularly which is known as small bowel bacterial overgrowth. Symptoms of this are 
non-specific and include bloating, abdominal pain, and malabsorption.  
CF patients have an increased risk of gastrointestinal tract cancers perhaps due to the 
chronic inflammation.109 There is also an increased risk of hepatobiliary and pancreatic 
malignancies compared to the normal population.110 
It is thought that other GI complications are more common in CF patients including 
intussusception, appendicitis, gastro-oesophageal reflux disease (GORD) and peptic 
ulceration. 111–114 
2.8.5 Management of constipation and DIOS 
Management of constipation involves increasing fibre intake, ensuring optimal hydration 
and the use of laxatives. DIOS is managed with laxatives and fluids initially, although it 
may progress to require colonoscopy with local installation of Gastrograffin or even 
surgery.115,116    
2.9 Hepatobiliary system 
2.9.1 Cystic fibrosis-associated liver disease 
It is thought that up to 37% of CF patients develop cystic fibrosis-associated liver disease 
(CFALD) and it is now the third leading cause of death among CF patients.117 It is usually 
a complication that presents in childhood or early teens and it represents a more severe 
phenotype of CF. Some patients will be asymptomatic, but it can progress to multilobular 
cirrhosis with or without portal hypertension. Patients may experience jaundice, varices, 
ascites, coagulation abnormalities and encephalopathy.  
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2.9.2 Gallbladder disease 
Gallbladder disease is prevalent in around 4% of CF patients and presents in similar ways 
to in non-CF patients.118 Gallstones in CF may be associated with biliary stasis due to 
thickened secretions and abnormal bile acid synthesis with high levels of cholesterol.119 
2.9.3 Management 
CF patients are examined regularly for signs of liver disease such as hepatomegaly and 
splenomegaly. Liver disease is also monitored for once a year as part of their annual 
review by abdominal ultrasound and liver function tests. Ursodeoxycholic acid is often 
used in CFALD as it can improve bile acid flow which may be helpful in CF patients 
whose bile ducts are blocked with thick secretions.120 However, a Cochrane review 
showed that the evidence is inconclusive regarding its use as we cannot speculate that as 
it reduces liver enzymes it must reduce liver damage.121 Patients who develop cirrhosis 
will inevitably require a liver transplantation.  
2.10 Reproductive system 
The majority of men with CF are infertile (over 98%) due to congenital bilateral absence 
of the vas deferens and concomitant absence of the seminal vesicles.122,123 This may be 
due to abnormally viscous secretions in the fetus due to the defective CFTR channel and 
this may impact the embryonic development of these tissues. It is important that young 
men are still advised to use contraception to prevent other problems including sexually 
transmitted diseases.  
On the other hand, women with CF have an anatomically normal reproductive tract. 
However, they do go through puberty later than non-CF patients, with the average age of 
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menarche being 14.4 years compared to 12.9 years in the general population.124 This may 
be due them having a lower BMI which can also cause anovulatory cycles and secondary 
amenorrhoea. It has been demonstrated that women with CF have stickier cervical mucus 
which may reduce the passage of sperm through the tract.125 However, they should still 
be given appropriate advice regarding contraception as most women with CF are fertile.    
2.11 Bone disorders 
There is a wide variation in reported prevalence of bone disease in CF with some studies 
reporting up to 70% of individuals with CF having reduced bone density (osteopaenia or 
osteoporosis) and up to 24% may have osteoporosis.126,127 There are several factors in CF 
that may contribute to this including vitamin D deficiency, low BMI, calcium deficiency, 
chronic inflammation, CFTR dysfunction in osteoclasts and osteoblasts, cystic fibrosis-
related diabetes and steroid use.128–133 
2.12 Psychological problems 
Children with CF spend a lot of time in hospitals for clinic appointments and inpatient 
admissions. They are required to undergo many medical procedures and interventions 
such as venepuncture, cough swabs, chest percussion and examination from a young age. 
This can create anxiety and stress for the children and may also create resentment towards 
their doctor.  
Cystic fibrosis can have a major impact on the family of the child with the condition. 
Other siblings that do not have CF may become jealous as parents may have to spend a 
lot more time with the child with CF for physiotherapy and appointments.134 Parents may 
have to take more time off work for appointments and periods of illness. They may choose 
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to resign and to become a full-time carer for their child especially if they have a more 
severe phenotype. This can create financial stress on the family although they can seek 
help with this. As the individual with CF gets older they may also struggle themselves 
with unemployment and increased sick leave.  
During school years, children with CF may feel as though they do not fit in with their 
peers. This may be due to the fact they may struggle to keep up with sports, are required 
to take Creon and other medications and produce excessive sputum. This may cause the 
child to feel embarrassed and ashamed and this can lead to low self-confidence.  
Rates of anxiety and depression may be higher in CF patients when compared to normal 
individuals however the evidence in conflicting.134,135 Psychological management is 
necessary from an early age in CF patients and psychologists regularly see these patients 
to ensure they are getting the correct support.  
2.13 Prognosis 
Median life expectancy rose to 43.5 years of age in 2016 compared to 32.2 years in 
1998.1,136 If the life expectancy continues to rise at this rate, then we can expect people 
with CF to live much longer.  
One factor that affects prognosis is gender, for example the median life expectancy in 
2016 for a male was 47.1 years compared to 40.1 years for a female. The predominant 
hormone found in females is 17β-estradiol (E2) and this has been shown to decrease 
chloride secretion which dehydrates the airway surface liquid further.137 Oestrogen 
promotes alginate production by PA and causes mucoid conversion of PA which both 
increase resistance to antibiotics and hence clearance from the lungs.138 When there are 
higher levels of oestrogen levels during the menstrual cycle, there are more respiratory 
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exacerbations. This may be due to high levels of oestrogen causing more mucoid 
conversion.139 Interestingly, women on the combined oral contraceptive pill are less 
likely to experience respiratory exacerbations.139 Studies have suggested that women 
become colonized with certain organisms such as PA, MRSA, Haemophilus influenzae, 
Aspergillus species, earlier in their lives than men.138 Once chronically infected with PA 
they are likely to decline quicker and have poorer survival rates.140 
Genotype can also affect prognosis with people with the Phe508del mutation having more 
severe disease and poorer prognosis.141 Other mutations have been implicated with less 
serious disease and better prognosis. Those with absent or greatly reduced levels of the 
CFTR protein such as those with Class I-III mutations have poorer prognosis than those 
with Class IV-VI mutations.142 However when discussing with parents of a new-born 
child recently diagnosed with CF, you must be careful as disease severity and prognosis 
can be very variable. However being homozygous for Phe508del is high attributable to 
pancreatic insufficiency with more than 99% having it.141 Pancreatic insufficient patients 
are twice as likely to have severe lung disease with reduced FEV1 than those who are 
pancreatic sufficient.143 Pancreatic insufficiency causes nutritional deficits which again 
is a risk factor for poorer prognosis.  
Those chronically infected with organisms such as PA, Staphylococcus aureus and 
Burkholderia cepacia complex show greater decline in FEV1 which itself is a risk factor 
for poorer prognosis.144 Many CF related complications can also have an impact on 
prognosis. Cystic fibrosis-related diabetes also increases the rate of decline in lung 
function and these patients often have poorer nutritional status which both reduce 
prognosis.88 Cystic fibrosis-associated liver disease is the third most common cause of 
death in CF patients with a mortality rate of 2.5%.144 
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2.14 The future 
2.14.1 Genotype specific small molecule therapy 
With understanding that CF is caused by reduced, absent or poorly functioning CFTR 
channel on epithelial surfaces this suggests a potential solution would be drugs that 
modulate CFTR function. Three main approaches have been suggested with the most 
successful being ‘potentiators’ which increase the function of the CFTR channels that are 
already there on the epithelial cells. The next approach is ‘correctors’ which allow 
delivery of more CFTR channels to the surface of the cell. Finally, ‘production correctors’ 
allow more production of the CFTR channel.  
These three approaches would be used dependant on the class of mutation. For example, 
as we know in Class III and IV mutations the CFTR channels reach the cell surface but 
are dysfunctional, therefore potentiators could be used in these two classes to increase 
chance of the channel opening. The most common type of class III mutation is the 
Gly551Asp mutation, previously known as G551D, which accounts for about 4% of all 
CFTR mutated alleles.145 In vitro, potentiators increase the likelihood of the Gly551Asp 
CFTR channel opening, allowing more successful chloride transport.146   
The most common CFTR mutation is Phe508del and is found in around 90% of people 
with CF, on at least one of their chromosomes.145 This is a class II mutation which causes 
a misfolding of the CFTR protein and therefore it is degraded intracellularly before it can 
even reach the surface.147 However, in vitro studies have shown that if the cells are treated 
pharmacologically or if the cell temperature is lowered then more CFTR is able to reach 
the cell surface.148 Therefore a ‘corrector’ approach may be needed for this type of 
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mutation. When Phe508del CFTR is able to reach the surface it then behaves similarly to 
a class III mutation, by not opening and so a ‘potentiator’ could be useful too.149 
Ivacaftor  
Ivacaftor (VX-770) was identified through high-throughput screening and its success in 
vitro led to phase II clinical trials on patients with Gly551Asp mutations, which showed 
a partial improvement in nasal potential difference and significant reduction in sweat 
chloride levels after 28 days in those receiving 150mg of ivacaftor compared to placebo. 
This reduction in sweat chloride levels suggests that the ivacaftor was successful at 
potentiating the CFTR channels. There was no significant difference in FEV1 in those on 
ivacaftor compared to placebo, however, a major limitation of this study was the small 
study sample (39 participants).150    
Following on from this two larger Phase III clinical trials; ENVISION and STRIVE, were 
undertaken evaluating the efficacy on patients with Gly551Asp mutations.151,152 Both 
trials were double blinded RCTs where participants were randomly assigned to receive 
either placebo or 150mg of ivacaftor every 12 hours during a 48 period. The difference 
between them was STRIVE look at patients aged 12 years and over, whereas ENVISION 
looked at children aged 6-11 years. I will focus on the results of STRIVE as it was much 
larger study, so it is more likely to be representative. The results of both studies were 
however very similar with both studies showing a significant improvement in lung 
function with ivacaftor. In STRIVE there was a change in the percent of predicted FEV1 
from baseline through to week 48 that was 10.5 percentage points greater with ivacaftor 
than placebo (P<0.0001). STRIVE showed that participants receiving ivacaftor were 55% 
less likely to experience a pulmonary exacerbation at week 48 than those receiving 
placebo (P<0.001). This finding was not seen in the ENVISION study, however this may 
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be due to the younger age of participants and milder disease in those in this study. Both 
studies demonstrated a rapid reduction in sweat chloride levels with ivacaftor meaning 
that it is working effectively as a potentiator to open the CFTR channel and allow 
reabsorption of more chloride. STRIVE showed an average reduction in sweat chloride 
levels of 48.7 mmol/L compared with 0.8mmol/L in the placebo group at 24 weeks. 
Ivacaftor can reduce the number of days spent in hospital and can reduce the number of 
exacerbations requiring intravenous antibiotics.152 It can also improve respiratory 
symptoms and aid weight gain.151,152 In both studies there were a similar number and 
nature of adverse effects in both the treatment group and placebo group suggesting there 
are no concerns regards to safety of ivacaftor.  
There is evidence in vitro, that Ivacaftor is successful in potentiating CFTR function in 
other class III and IV mutations as well.153,154 Further clinical trials have indicated that 
ivacaftor may be useful in patients with non-Gly551Asp CFTR gating mutations 
including G178R, S549N, S549R, G551S, G1244E, S1251N, S1255P and G1349D.155 It 
has been shown to increase FEV1, decrease sweat chloride levels and improve quality of 
life in these patients.155 It may be useful in the class IV mutation R117H but only in those 
with more severe respiratory disease.156  
Ivacaftor has been tested in those homozygous for Phe508del CFTR mutations but 
unfortunately did not have any statistically significant effect on FEV1.
157 This finding 
however may reflect the fact that there is very little CFTR reaching the surface of the 
cells and so there is little CFTR to potentiate. This suggests that these patients may also 
require a ‘corrector’ as well as a ‘potentiator’.  
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Lumacaftor 
Lumacaftor (VX-809) is a CFTR ‘corrector’ that in vitro can improve processing of cells 
that are homozygous for Phe508del which reduces degradation of the CFTR channel and 
hence more are placed on the cell surface.158 An RCT in patients that are homozygous for 
Phe508del showed that Lumacaftor was able to reduce sweat chloride levels compared 
to placebo. There was, however, no statistically significant difference in lung function or 
CFQ-R scores between intervention group and comparison group. This is disappointing, 
however this may be due to a small sample size or down to the fact that although there 
are more CFTR proteins reaching the cell surface they are still not opening effectively.159   
Lumacaftor and ivacaftor  
As mentioned earlier, using a corrector along with a potentiator in CF may be effective 
in patients with the Phe508del CFTR mutation as they allow more CFTR protein is able 
to get to the cell surface and more is able to function. RCTs have demonstrated that 
patients receiving a combination of lumacaftor and ivacaftor compared to placebo have 
a statistically significant increase in predicted FEV1, reduced rate of pulmonary 
exacerbation, increase in BMI and improvement in CFQ-R score.160,161 There have been 
seven episodes overall of deranged liver function which resolved when the medication 
was stopped. Further studies are required in order to look at the long-term effects of this 
treatment.  
2.14.2 Gene therapy 
At its heart, CF is a genetic disease. In common with many single gene disorders, it was 
hoped that correction of the basic cellular defect could be achieved by replacing the 
defective gene.162 However, despite over 30 years of considerable effort, progress with 
gene therapy has disappointing. 
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The main issues are that vectors, such as adenovirus that permit efficient gene penetration 
into the respiratory epithelium have been shown to be remarkably proinflammatory and 
harmful to the lungs. Whereas, safer, non-viral transfection attempts with, for instance, 
liposomal preparations have resulted in limited gene transfection. 
The search for therapeutic advances do continue and there is limited evidence for some 
benefit. A randomised, placebo-controlled trial tested the efficacy of CFTR gene therapy 
administered by nebulizer using the non-viral liposome complex pGM169/GL67A. It 
showed a statistically significant increase in lung function in the gene therapy group when 
compared to placebo. More research in this field is needed to look at long term effect.163  
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CHAPTER 3: RENAL DISEASE IN 
CYSTIC FIBROSIS 
3.1 Introduction 
In this chapter, I will define renal disease and the epidemiology of renal disease in CF 
patients. I will go on to discuss the main causes of this with the most important and 
common being medications, particularly aminoglycoside antibiotics. I will discuss 
detection of renal disease and introduce the main focus of this thesis which is looking at 
strategies to prevent renal disease caused by intravenous antibiotics. People with CF are 
living longer and so it is now more important than ever to prevent long term 
complications, such as renal disease, of medications that are used routinely in CF.    
3.2 Definitions of renal disease 
Damage to the kidneys can result in what is known as an 'acute kidney injury' (AKI), 
which is defined as any of the following:164 
• an increase in serum creatinine of at least 0.3 mg/dL within 48 hours; 
• an increase in serum creatinine to 1.5 times baseline (which is known, or 
presumed, to have occurred within the previous seven days); or 
• urine volume less than 0.5 mL/kg/h for six hours. 
This definition is the KDIGO definition and it is commonly used by nephrologists. There 
are other definitions of AKIs including the RIFLE and AKIN classification which can be 
seen in the image below.   
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Figure 3.1 – RIFLE and AKIN classification of an AKI165 
AKI’s extend hospital stay and often shorten antibiotic treatment courses. It is possible 
for an AKI to resolve and for the individual to regain normal kidney function. However, 
recent evidence suggests an AKI, particularly if a person suffers multiple occurrences, 
may initiate the development of chronic kidney disease (CKD).166 
CKD is defined as abnormalities of kidney structure or function (e.g. albuminuria or 
glomerular filtration rate (GFR) below 60 mL/min/1.73 m²), present for longer than three 
months, with implications for health.167 It has been reported that CKD can have many 
negative implications on a person's life and approximately 25% of people with CKD have 
been found to have depression, which is a higher rate than the general population.168 CKD 
can progress through different stages, ranging from 1 to 5; stage 5 is the most severe and 
is also known as end-stage kidney disease (ESKD) or kidney failure.167 One study in the 
UK estimated that in all patient populations CKD costs the NHS £1.44 billion to £1.45 
billion per year.169 
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Figure 3.2 - Costs attributable to CKD169 
CKD may progress to ESKD, defined as GFR less than 15 mL/min/1.73m². ESKD has 
many complications including anaemia, electrolyte disturbances, bone disorders, 
uraemia, and hypertension. People with ESKD require a form of renal replacement 
therapy (RRT) to correct any electrolyte or metabolic disturbances; RRT encompasses 
kidney transplantation and dialysis. Individuals receiving RRT are less likely to be 
employed than age-matched participants, in particular those receiving haemodialysis, 
which can cause a financial burden for themselves and their family.170 Transplantation is 
preferable as it reduces the mortality risk and improves quality of life (QoL) when 
compared with dialysis.171 
3.3 Epidemiology of renal disease in cystic fibrosis  
A UK study published in 2007 estimated that the incidence of acute renal failure is 
between 4.6 and 10.5 cases per 10 000 people with CF per year.172 
The annual prevalence of chronic kidney disease (CKD) (stage 3 or over) in individuals 
with CF is much higher than that seen in age-matched controls within the general 
population. A study in the US estimated the mean annual prevalence of stage 3 or greater 
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CKD to be 2.3%.173 The overall incidence rate of stage 3 or greater CKD in CF patients 
was 4 events per 1,000 person-years of follow-up.173 Both the prevalence and incidence 
increase with age with the prevalence being as high as 19.2% in patients over the ages of 
55.173 A UK study of adults with CF showed 31-42% had a creatinine clearance that was 
below the normal range, highlighting renal disease may be more prevalent than we 
think.174 A cross sectional retrospective study in Canada identified the incidence of CKD 
as 6% in children aged 2-18 years. However, in this study Prestidge measured GFR by 
plasma disappearance of Technetium-99 m diethylenetriaminepentaacetic acid (mGFR), 
rather than the conventional method of measuring creatinine clearance (eGFR).175 
Soulsby identifies three methods of assessing renal function; using serum creatinine, 
using creatinine clearance and using isotopic or non-isotopic clearance rates.176 Different 
studies have measured for renal function in different ways and so it is impossible to 
collate this information. Each method of assessment comes with its own limitation and 
so novel ways of detecting early renal function decline are needed.  
3.4 Aetiology of renal disease in cystic fibrosis 
The cystic fibrosis transmembrane conductance regulator gene (CFTR) is expressed in 
all segments of the nephron.177 Inactivation of the CFTR protein has been shown to cause 
low molecular weight proteinuria.178 However, the only clinically significant primary 
renal disease seen in CF is nephrocalcinosis. The majority of renal disease in CF is 
secondary, caused by a complication of other organ involvement or chronic infection or, 
most commonly, due to nephrotoxic medications. Renal disease can also be seen in CF 
patients as an incidental comorbidity.  
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3.4.1 Drug nephrotoxicity in CF 
The most common cause of renal disease in CF is drug nephrotoxicity with the most 
commonly implicated drugs being aminoglycoside antibiotics. Aminoglycosides are 
bactericidal antibiotics that bind to the bacterial 30S ribosomal subunit inhibiting protein 
synthesis which is necessary for growth. Aminoglycosides are eliminated from the body 
by renal clearance through glomerular filtration, but some are re-absorbed back into the 
proximal tubule. This is mediated by a receptor called megalin.179 This causes an 
accumulation of aminoglycosides in the proximal tubule epithelial cells. This can result 
in apoptosis and necrosis of these cells due to mitochondrial dysfunction and release of 
reactive oxygen species.180,181 Patients may present with non-oliguric acute renal failure, 
with little change to the urine dipstick results, and can be reversed on cessation of the 
drug.182 People with CF often have increased renal clearance hence requiring higher doses 
of drugs in order to achieve therapeutic levels.183 An association has been found between 
the cumulative lifetime dose of intravenous aminoglycosides and long-term renal 
damage.174 Gentamicin is more harmful to the kidneys and so tobramycin is the 
aminoglycoside of choice in most centres.184 Other intravenous antibiotics can too cause 
kidney damage including beta lactams and colistin, however, aminoglycosides are by far 
the worst.  
Some antibiotics that can be given orally for respiratory infections such as ciprofloxacin, 
azithromycin and beta lactams have been associated with kidney damage.185 It is known 
that nebulised colistin can cause an AKI 186 and there have been cases of nebulised 
tobramycin damaging the kidneys.187 By omitting the use of oral and nebulised antibiotics 
when using intravenous antibiotics, this may reduce the risk of kidney injury.  
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There is evidence that anti-inflammatory drugs can help to slow the rate of lung function 
decline.76 Despite this good evidence, the use of NSAIDs as regular therapy in CF is not 
widespread. This may relate to concerns that ibuprofen can result in nephrotoxicity and 
increase the risks of pulmonary infection.188,189 NSAIDs work by blocking cyclo-
oxygenase (COX) 1 and 2 enzymes, preventing the synthesis of prostaglandins and so 
reducing inflammation. These drugs can cause renal damage by two main mechanisms. 
The first is by causing an immunological reaction which causes acute tubulointerstitial 
nephritis.190 The second mechanism is by inhibiting COX 1 and 2 so reducing the number 
of prostaglandins formed. This means there is less vasodilatation in glomerular capillaries 
and arterioles. With reduced perfusion to the kidney, it is then at a higher risk of ischaemic 
injury due to lack of oxygen and glucose especially in those with pre-existing volume 
depletion.189 
Immunosuppressive therapy following lung transplantation causes renal damage with 
18% of CF patients that have had a lung transplant experiencing it within one year of the 
transplant.191 Calcineurin inhibitors such as cyclosporine affect endothelial cell function, 
decreasing vasodilator (prostaglandins) production and hence increased vasoconstrictor 
(endothelin and thromboxane) production.192 This leads to vasoconstriction of the 
afferent and efferent glomerular arterioles in the kidney, reducing its perfusion which 
predisposes the kidney to renal failure.193,194 
Other drugs that may induce an AKI in a CF patient include ciprofloxacin, proton pump 
inhibitors, diuretics, azithromycin, sulphonamides, colistin, ceftazidime and 
rifampicin.185 
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3.4.2 Nephrocalcinosis and stone formation  
Asymptomatic nephrocalcinosis was seen in up to 92% of patients with CF found at 
autopsy in a study by Katz et al, however, a limitation of this study was that it had a small 
sample size.195 There is also an increased risk of nephrolithiasis with 3-6.3% of CF 
patients suffering from renal stones compared to 1-2% in the normal population, with the 
majority of these stones being calcium oxalate.196,197 Risk factors for stone formation 
include low urine volume, hyper-oxaluria, hyper-calciuria and hyper-uricosuria.195 
Prolonged periods of immobilisation that can occur in CF patients, for example during a 
respiratory infection, can lead to hypercalcaemia and hypercalciuria.198 Both 
prednisolone and loop diuretics such as furosemide increase calcium excretion and lead 
to hypercalciuria and so are both risk factors for stone formation.198 Pancreatic 
insufficiency leads to fat malabsorption which can cause enteric hyperoxaluria. This 
increases the urinary calcium-oxalate saturation hence increasing the risk of stone 
formation.198 Repeated antibiotic use leads to gut decolonisation of Oxalobacter 
formigenes which means gut oxalates cannot be broken down hence you get enteric 
hyperoxaluria. Gut oxalates are absorbed into the blood and can end up in the kidney 
where they get deposited and can form stones.199 Hypercalciuria is seen in 30% with CF 
and may also be due to a renal Cl- channel defect caused by CFTR mutation.182,195  
3.4.3 Diabetic nephropathy 
CFRD is prevalent in 40-50% of adults with CF and with rising life expectancy this figure 
is set to increase.200 It is estimated within 5-10 years of diagnosis, 30-50% of all patients 
with insulin dependent diabetes will develop diabetic nephropathy.182 Patients with 
CFRD are at risk of the same microvascular complications as non-CF diabetics. With 
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incidence of CFRD increasing, so will the incidence of diabetic nephropathy meaning 
more people will require RRT.  
3.4.4 Rare causes of renal pathology in CF 
Inflammation-associated systemic amyloidosis is a complication of CF and in most is 
asymptomatic but can present with nephrotic syndrome if it affects the kidneys.201 It is 
thought that it arises due to a state of chronic infection. The incidence is rising due to the 
increasing life expectancy of patients with CF. One study showed that 33% of CF patients 
had systemic amyloidosis with renal involvement at autopsy, however this study was only 
small.202 If the patient does experience symptoms then the prognosis is poor, although 
colchicine may help.203   
Chronic infection and inflammation lead to high levels of Immunoglobulin A (IgA) in 
the blood. When this IgA is deposited in the kidneys it can cause further immunological 
reactions and lead to glomerulonephritis.182 IgA nephropathy is the most common cause 
of glomerulonephritis in patients with CF.204 The risk of this is increased if there is liver 
disease as this reduces the amount of immune complexes cleared from the blood and so 
there is more to be deposited in kidneys and other organs.205  
Antineutrophil cytoplasmic antibodies (ANCA) can be found in CF patients that 
experience recurrent infections. They can cause vasculitis, a rare complication in CF, 
which is usually predominantly skin involvement only but there have been cases of renal 
involvement.206 
Finally, tubulointerstitial nephritis can also occur in CF patients through an allergic 
reaction to a drug or from an infection. This can present with fever, vomiting, malaise 
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and nausea and there may also be signs of the allergic reaction, if this is the cause, 
including a rash.182 
3.5 Monitoring kidney function in CF patients 
All patients with CF are monitored for renal disease of any aetiology, usually at their 
annual review. Renal disease may be identified by measuring blood pressure, on routine 
bloods or on urine dipstick.     
Renal disease is often asymptomatic in the early stages, the first indication of renal 
disease may be proteinuria on a urine dipstick or abnormalities in eGFR, urea or 
creatinine. However, GFR is insensitive in early renal damage as up to 30% of nephrons 
can stop working before GRF decreases.207 This is because the other nephrons 
compensate by increasing their glomerular filtration.208 Creatinine and electrolytes 
including magnesium are also insensitive.209,210 Therefore research has been conducted 
in search of earlier markers of renal dysfunction caused by aminoglycosides. 
3.6 Detecting renal disease caused by antibiotics  
As mentioned above, aminoglycosides accumulate in the kidneys in the proximal tubule 
epithelial cells which can cause damage to these cells. This is known as acute tubular 
necrosis which can cause leaking of electrolytes, proteins, and certain tubular enzymes.  
Raised levels of tubular enzymes including N-acetyl-β-D-glucosaminidase (NAG), 
alanine amino-peptidase (AAP), neutrophil gelatinase-associated lipocalin (NGAL), 
cystatin C, kidney injury molecule 1 (KIM-1), interleukin-18 (IL-18) and collagen IV 
may indicate nephrotoxicity.211–216 In animal studies, KIM-1 outperforms other markers 
of nephrotoxicity and it is currently the only regulated proximal tubule biomarker that is 
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used in drug development.217,218 Currently, there is very little known about these enzymes 
but we do know they are markers of early kidney damage. An increase in these 
biomarkers does not necessarily indicate a clinically significant decrease in renal 
function. The use of these biomarkers for monitoring raises many questions including 
whether they should be used to make decisions regarding stopping antibiotics. Further 
research is needed to identify how much of an increase in these biomarkers is needed for 
there to be clinically significant renal disease (e.g. decrease in eGRF or rise in creatinine 
and urea). 
Table 1 – Biomarkers of kidney injury 
Alanine amino-peptidase (AAP) Enzyme located on plasma membranes 
including renal tubular epithelial cells.  
Collagen IV Forms the main collagen component of 
the basement membrane including in the 
kidneys. 
Cystatin C This is a protein found in most cells and is 
normally filtered out of the blood by the 
kidneys. 
Interleukin-18 (IL-18) This is a cytokine produced by 
inflammatory cells in the kidneys during 
an acute kidney injury. 
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Kidney injury molecule 1 (KIM-1) This is a transmembrane protein found in 
the proximal tubules with increased 
expression following an injury.  
N-acetyl-β-D-glucosaminidase (NAG) This is an enzyme that is found in high 
concentrations in the lysosomes of 
proximal tubule cells in the kidneys. 
Neutrophil gelatinase-associated lipocalin 
(NGAL) 
This is a protein produced by renal 
epithelium that is damaged. 
 
3.7 How can renal disease caused by antibiotics be 
prevented in cystic fibrosis? 
Whilst kidney damage as a result of antibiotic treatments is common, it is not inevitable. 
We understand how various treatments work, and this suggests several different strategies 
that might be utilised to prevent or minimise nephrotoxicity. We hypothesised that there 
were at least four potential strategies. 
3.7.1 Risk minimisation strategies for individuals requiring 
aminoglycosides 
Children or adults with new or established PA infection often require broad-spectrum 
antibiotics in order to successfully eradicate colonisation or suppress growth during 
pulmonary exacerbations. Aminoglycosides are antibiotics used to treat respiratory 
infections; they can, however, be harmful to the kidneys. There have been several 
important studies examining the effects of varying the duration and frequency of 
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aminoglycoside treatment. Studies have also examined the relative effects of choosing 
one particular aminoglycoside over another. 
Previous Cochrane Reviews have examined the clinical consequences of different 
duration and frequency of intravenous antibiotic regimens.219,220 These concluded that 
there is no evidence to support a recommendation about duration of treatment, but once-
daily dosing is better for kidneys than multiple-daily dosing.  
3.7.2 Comparison of the relative nephrotoxicity of different 
antibiotic regimens  
We may be able to reduce kidney damage in CF patients by identifying strategies using 
different types and doses of intravenous antibiotics that are less nephrotoxic. It is vital, 
however, that the antibiotic regimens are still as effective at clearing the respiratory 
infection. 
3.7.3 Avoidance of concomitant nephrotoxic drugs 
Another strategy to minimise kidney damage may involve the omission of other 
nephrotoxic drugs when using intravenous antibiotics. NSAIDs are useful in reducing 
inflammation in the lungs, however, they can harm the kidneys.76 This damage may be 
exacerbated when prescribed alongside intravenous antibiotics and to reduce this risk the 
duration and frequency of NSAID use needs to be considered. Some oral and nebulised 
antibiotics can also cause kidney damage, by omitting these drugs while using 
intravenous antibiotics it may reduce the risk of kidney injury.  
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3.7.4 Adjuvant therapies to ‘protect the kidneys’ 
Finally, a further strategy involves looking at the use of adjuvant medications or therapies 
alongside intravenous antibiotics. Adjuvant therapy describes treatment used additionally 
to the primary treatment. Statins are primarily used to reduce cardiovascular risk in 
individuals with elevated blood cholesterol. However, they may also be helpful in 
reducing kidney damage in those receiving intravenous antibiotics in CF. Statins work 
by inhibiting an enzyme (HMG-CoA reductase) which preventing the production of 
mevalonate and therefore reducing cholesterol synthesis, hence their use in 
cardiovascular disease. It has been suggested that statins may prevent nephrotoxicity.221 
Inhibition of HMG-CoA reductase results in a depletion of cellular sterols which are 
needed for the megalin-mediated uptake of aminoglycosides into the kidneys. Less 
aminoglycoside is deposited in the renal proximal tubular cells hence reducing necrosis 
of these cells. This was seen in vitro and then in vivo, where animal studies have shown 
that this effect may be limited to certain subgroups of statins with rosuvastatin having a 
greater effect in murine models.222,223 
Adequate hydration is needed for kidneys to function correctly and avoiding dehydration 
might avoid kidney damage. We know from studies examining the use of nephrotoxic 
chemotherapeutic agents that hydration status is important in mitigating the harmful 
effects of toxins on the kidney.224 Certainly adequate hydration or hyperhydration are 
likely to affect the toxicity of any drug treatment. Good hydration will tend to reduce the 
overall concentration of drugs in the body and within the urine. Adequate hydration 
ensures total body water is marginally increased. Thus, the total volume in which most 
drugs are distributed, the volume of distribution, is slightly larger. There is a larger effect 
on the cells located within the kidney as any excess fluid will be excreted as urine. The 
concentration of all water-soluble constituents of the blood will be lower within the 
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glomerular filtrate and therefore there will be a lower drug concentration throughout the 
renal tubules. Enteral or intravenous fluids could be used as an adjuvant therapy alongside 
intravenous antibiotics to reduce the risk of kidney injury.  
3.8 Why is it important to prevent renal disease in 
cystic fibrosis patients? 
With improved outcomes and longer life expectancy for individuals with CF the need to 
protect the kidneys from long-term damage is becoming an important consideration. 
Median life expectancy rose to 47 years of age in 2016 compared to 32.2 years in 
1998.83,136 
2011 was a significant landmark in the UK for individuals with CF.83 For the first time, 
there were more adults than children with CF and the median age of individuals with CF 
has continued to increase. The median age of those affected in 2011 was 18 years old. It 
has moved on from a disease that was fatal during childhood for most to a condition that 
can be actively managed and where survival for many is likely to significantly increase. 
Failure to die from respiratory complications heightens the importance of ‘other system 
disease’. There is a need to rapidly secure less nephrotoxic (and ototoxic) antibiotic 
treatment regimens. We are at a ‘critical moment’ in CF care. A holistic, multisystem 
view of the condition needs to be taken. 
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CHAPTER 4: INTRODUCTION TO 
COCHRANE SYSTEMATIC REVIEWS 
4.1 History of Cochrane systematic reviews 
In 1971, Archie Cochrane published a book, ‘Effectiveness and efficiency’ criticising the 
lack of evidence behind many medical interventions.225 He suggested that there should 
be systematic reviews examining and summarising all the evidence on a particular 
intervention which can then be used to produce guidelines. In 1993 the Cochrane 
Collaboration was set up by Ian Chambers and a group of 70 other colleagues. In 2018, 
the Cochrane Collaboration is now made up of over 37,000 contributors from over 130 
countries. The evidence can be used by healthcare providers and even patients and carers, 
so the reviews should be accessible to all and easy to read. Each review addresses an 
intervention for a certain outcome in a condition. The authors analyse the data from 
randomised control trials, which is the highest level of research, and can use the data in 
a meta-analysis. Cochrane reviews are regarded as the highest standard of evidence and 
are used to write guidelines. 
4.2 Cochrane review group  
Each contributor is affiliated to a group, for example I am affiliated to the Cystic Fibrosis 
and Genetic Disorders Group. The Cochrane Review Group (CRG) sent us a list of 
reviews of important topics highlighting the priorities. They required us to complete a 
title proposal form which was a brief outline of what we intended to review. Kidney 
injury is becoming increasingly important to prevent as people with CF are surviving 
longer. It is an important complication caused by aminoglycoside antibiotics (and 
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sometimes other antibiotics) which are needed for optimal respiratory outcomes. As 
suggested above there are strategies that may reduce the risk of kidney injury and so I 
decided to focus my Cochrane review on this.  
4.3 Systematic review training 
It is recommended that authors attend at I attend Cochrane systematic review author 
training courses. I attended RA1 and RA2 on the 4th and 5th July 2017 respectively. RA1 
focused on the importance of Cochrane reviews and what was to be included in the 
protocol for the review. It also gave an insight into how to use the review software which 
was necessary to start the review. RA 2 reviewed the search process for finding 
potentially relevant studies for the Cochrane review. This included learning about 
databases and how to structure a search strategy. We also looked at the exclusion and 
inclusion criteria for studies and a brief look at the risk of bias. I then attended RA3 and 
RA4 on the 20th and 21st February 2018. RA3 looked at summary statistics, performing 
meta-analysis on dichotomous and continuous data and how to enter this into RevMan. 
We then reviewed risk of bias thoroughly following on from our brief look in RA2 and 
looked at how to identify heterogeneity. RA4 focused on how to analyse non-standard 
data and again how to enter this into RevMan. Finally, we looked at how to use the 
GRADE Pro software and how to create a summary of findings table on this software. I 
found these courses challenging as a lot of the other course delegates had more statistical 
experience than myself as they were further along in their career. However, I ensured I 
asked questions whenever I did not understand something, and this helped. We were also 
provided with the lecture copies of theses training sessions which I made notes on while 
at the training and used when I was writing the protocol and review. I also used the online 
webinars and the Cochrane Handbook for Systematic Reviews of Interventions for further 
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guidance on how to produce a Cochrane Review.226 I was able to contact my CRG 
whenever I was unsure on what to do and in particular found NH and TR, the managing 
editors, invaluable at providing advice.   
I also attended the systematic review seminars at Keele University.  This included a set 
of six different seminars looking at writing a protocol, producing a search strategy, 
screening abstracts, data extraction, quality assessment and meta-analysis. These 
seminars provided a much more basic introduction to understanding a systematic review 
and I felt if I had not attended these then I would have struggled further on the Cochrane 
courses.   
4.4 The protocol 
4.4.1 What is a protocol? 
Before authors can start completing their review they must publish a protocol. The 
protocol is a set of headings that the author must fill in and this is stored in RevMan. As 
authors may have knowledge on the topic areas which they are to review this can 
introduce bias. By defining in the protocol which studies are to be included and excluded 
this prevents authors from including studies that they think will show certain results. 
Authors should not look at results of studies that may be included before defining the 
protocol in order to reduce the risk of review authors’ biases.227 By clearly stating the 
methods in the protocol, it promotes transparency and should be described in a way that 
would allow someone else to carry out the review and get the same results.227  
53 
 
4.4.2 Software 
The most important and helpful software for producing a Cochrane review is Review 
Manager (RevMan).228 This software is free to use for authors writing and editing a 
protocol and then later a review. My systematic review is of an intervention, however, 
RevMan can also be used to produce reviews of other types including overviews of 
reviews, methodology reviews and diagnostic test accuracy reviews. RevMan contains 
headings and subheadings which form a standardised structure for producing a Cochrane 
review. Authors can use these headings to guide what they write about. These headings 
are based on The Methodological Expectations of Cochrane Intervention Reviews 
(MECIR).229 These are a set of standards that protocols and reviews should adhere to and 
can be seen in a guidance box in RevMan if required. The Cochrane Handbook for 
Systematic Reviews of Interventions was also helpful for providing more guidance and 
detail on many areas for example types of studies to include226. RevMan can create 
comparison tables which can be used to show the included studies. It can also perform 
meta-analysis and create graphs to display the results of these. Drafts and final copies of 
reviews and protocols are stored on Archie which is a central database of all ongoing and 
completed reviews.    
The next software I used was EndNote, which I used as my main reference manager.230 
Covidence is another reference manager that I used, however, EndNote was much better 
at removing duplicates.231 Covidence was accessed by myself and WC to screen the 
studies and decide which ones were to be carried through to the next stages. Covidence 
can also be used for data extraction and for assessing risk of bias.  
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4.4.3 Publishing a protocol 
Once the authors have completed the protocol they will then send it to the Cochrane 
review group. It is then sent to the editors for peer review, they will feedback with 
comments of changes that need to be made. This may require several attempts but once 
the editorial board are happy with the final protocol it can then be sent to be published in 
the Cochrane Database of Systematic Reviews (CDSR). By publishing the protocol, other 
contributors can see that this area is already being investigated, so it prevents 
duplication.227 
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CHAPTER 5: METHODS OF THE 
COCHRANE SYSTEMATIC REVIEW  
During this chapter, I have followed the structure of the headings on RevMan as closely 
as possible to give a better insight into what the protocol and review should include. 
5.1 Writing the protocol 
I started writing the protocol in October 2017 and I sent it off to the editorial board on 
the 25th January 2018 for peer review. We received it back with changes to be made and 
sent it off for final submission on the 12th April 2018. It was published on the 22nd May 
2018. Please see appendix 3 for a copy of the published protocol.  
5.1.1 Defining the question 
Before beginning designing a protocol, the author needs to formulate a review question. 
The question should be based on the structure of the acronym PICO – P (Participants), I 
(Interventions), C (Comparison) and O (Outcomes). As described in the previous chapter, 
I had decided to focus my Cochrane review on strategies that may reduce kidney injury 
caused by intravenous antibiotics in CF patients. With this in mind, it was clear that my 
participants would be patients with CF who are receiving intravenous antibiotics. My 
intervention would be any strategy that reduces kidney injury and my comparison would 
be to standard care or placebo. The main outcome is nephrotoxicity, however, I do have 
other outcomes which are described later in this chapter in more detail.   
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5.1.2 Choosing a title 
When choosing a title for the Cochrane review, the handbook suggests a structure which 
is as follows; ‘[Intervention] for [health problem] in [participant group/location].’ Based 
on this structure, I was able to formulate the title ‘Strategies to prevent kidney injury from 
antibiotics in people with cystic fibrosis’. When I first designed the title, I used the word 
‘renal’ rather than kidney, but my managing editor NJ reminded me that it was important 
to use terms that would be easily understood by the general public. This was a helpful 
reminder and I worked harder to make my protocol accessible to all. We did get feedback 
from a consumer during the peer review stage commenting that the word ‘injury’ was 
confusing as she thought it sounded like the kidney injury was due to an accident. 
However, we felt that clinical readers would associate the term ‘injury’ with acute kidney 
injury. I added ‘from antibiotics’ to the title after the peer review stage so that it was 
clearer what the injury was caused by. 
5.1.3 Objectives of the review 
To assess the benefits and harms of strategies (such as altering the type and dose of 
intravenous antibiotics, the avoidance of other nephrotoxic drugs alongside the 
intravenous antibiotics and the use of adjuvant medication including statins and fluids) 
to reduce or prevent kidney injury in people with CF which occurs as a result of antibiotic 
treatment. 
5.1.4 Background for the protocol 
The background of the protocol should include a concise description of the condition and 
may include information such as the epidemiology. Authors must go into detail regarding 
what the intervention is and how it may work. As most of this information was covered 
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in my background of my thesis, I will not repeat it again. The protocol should cover why 
it is important to do this review and as discussed above this is because people with CF 
are living longer and so kidney damage caused by intravenous antibiotics (particularly 
aminoglycosides) is becoming more important to prevent. However, aminoglycosides are 
needed for the best respiratory outcomes, so we must look at strategies that can reduce 
this damage as much as possible. 
5.2 Criteria for considering studies for this review 
5.2.1 Types of studies 
I chose to include randomized control trials (RCTs) which are the main focus for 
Cochrane reviews. An RCT involves randomly allocating participants into one of two 
groups (or more) by methods such as a random number generator. One group will receive 
the intervention under investigation and the other group will receive a comparison or be 
a control group. All participants have an equal chance of being allocated the intervention. 
By allocating participants into groups randomly it tries to ensure that each group overall 
has similar baseline characteristics and so any confounders are equally distributed. This 
reduces the risk of selection bias. With my review being of an intervention, RCTs are the 
most appropriate as they are the highest quality comparative studies.  
Quasi-RCTs are similar to RCTs in the way that they test an intervention on a set of 
outcomes compared to a control or comparison group. However, they differ in the fact 
that in quasi-RCTs, participant allocation to a group is not randomized. In quasi-RCTs 
participants may be allocated to a group by pseudo random sequences such as alternation 
or by date of birth.232 Therefore, participants do not have an equal chance of being in the 
intervention group. This means that the two groups are less likely to have similar baseline 
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characteristics and so this can introduce bias affecting internal validity. We decided to 
assess quasi-RCTs using the Cochrane risk of bias tool and include them if we agreed 
that the groups were similar at baseline. 
Cross over trials can be used in stable, chronic conditions to evaluate the effect of 
interventions.233 A participant is given an intervention and then some time later a different 
intervention is given. This is compared to a parallel trial where each participant receives 
a single intervention and is compared with participants receiving other interventions or a 
control group. With a cross-over trial design each participant acts as a control for 
themselves, removing any baseline participant variation. This means that fewer 
participants are required overall to achieve the same effect. As the participant gets to test 
each intervention, they are then able to decide for themselves which intervention they 
prefer.  Cross-over trials should not be used if the intervention is likely to have a long-
lasting effect as it means they would not be back at baseline when starting the next arm 
of the trial. This is known as ‘carry over’, when the effects of the last intervention are 
persisting into the next intervention. However, this can be minimised by using a ‘washout 
period’ where there is a certain amount of time before the next intervention is started. We 
planned to assess cross-over trials on an individual basis. If we agreed that the treatment 
in the first phase alters their condition meaning they will differ from their initial state 
when entering the next phase, then we planned to exclude the trial unless we were able 
to use data from the first phase only.  
5.2.2 Types of participants 
Intravenous antibiotics that can cause kidney damage, such as aminoglycosides, are most 
commonly used in CF patients due to the recurrent respiratory infections. Therefore, I 
required participants in the studies to have CF, diagnosed by genetic or sweat testing. 
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Although kidney damage is more common in adults, due to the higher cumulative total 
dose of aminoglycosides, I decided to look at adults and children. Children need to be 
included as we need to know if these strategies are safe to use on them. All participants 
within a group must be receiving intravenous antibiotics of any type (planned or 
unplanned), for a respiratory infection, for the study to be included.  
5.2.3 Types of interventions 
I have identified possible strategies to reduce kidney injury such as altering the type/dose 
of intravenous antibiotic, omission of other nephrotoxic drugs (e.g. NSAIDs, oral 
antibiotics and nebulised antibiotics) while on intravenous antibiotics or use of adjuvant 
medications when on them (e.g. fluids or statins). However, I planned to look at any 
strategy that may reduce kidney damage as there may be other strategies that we have not 
thought of. I aimed to compare these strategies with standard clinical care or placebo. 
One peer reviewer identified that I had not made clear what exactly the standard clinical 
care is and therefore I had to add more detail to this section of the protocol. Where the 
intervention is to omit other nephrotoxic drugs (NSAIDs, oral antibiotics and nebulised 
antibiotics) when using intravenous antibiotics, the standard care would be to carry on 
these other nephrotoxic drugs alongside them. Where the intervention is to prescribe a 
different type of antibiotic, in the case of a PA infection, the standard clinical care would 
be use of an aminoglycoside and a beta lactam which is recommended by the UK CF 
Trust.66  
As mentioned earlier previous Cochrane Reviews have examined the clinical 
consequences of different duration and frequency of intravenous antibiotic 
regimens.219,220 As this has been established, we elected not to repeat this analysis and 
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our protocol excluded studies that only examine the relative nephrotoxicity and clinical 
effectiveness of aminoglycoside dosing frequency or duration.  
5.2.4 Types of outcome measures 
The Cochrane Handbook describes the importance of highlighting outcomes that are 
meaningful to both patients and to clinicians. All outcomes that are meaningful should 
be included in the review even if they have not been reported in individual studies. This 
is because it highlights a gap in knowledge and may prompt researchers to address this 
in future studies. It is important that outcomes must include beneficial and undesirable 
effects of the intervention, therefore the clinician or patient can make an informed 
decision. 
Primary outcomes 
Primary outcomes should be the outcomes that the conclusions on the effect of the 
intervention can be drawn from. I included any study where nephrotoxicity was measured 
as an outcome. My primary outcomes are listed below.   
1. Nephrotoxicity (determined by use of invasive and non-invasive biomarkers): 
a) Serum (blood) creatinine levels (change from baseline, with thresholds as defined 
in each trial) 
b) Creatinine clearance (change from baseline, using e.g. the Schwartz Estimate for 
children and the Cockcroft-Gault formula for adults (with thresholds as defined 
in each trial)) 
c) Urinary excretion of protein (change from baseline) 
d) Urinary excretion of biomarkers of proximal tubule toxicity (e.g. kidney injury 
molecule-1, retinal binding protein, beta-2 microglobulin, Clara cell protein, 
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microalbumin, N-Acetyl-Beta-D-glucosaminidase, alkaline phosphatase, alanine 
aminopeptidase, gamma-glutamyl transferase or cystatin C) (change from 
baseline) 
e) Urine output (ml/Kg/h) 
The consumer mentioned in the peer review comments that many of these terms were not 
understandable to a lay person. The editor however commented that in order for a meta-
analysis to be performed these outcome measures need to be clearly specified and so 
needed to remain this way. In order to make it slightly more understandable I added in a 
comment to the protocol describing that any changes in these markers from baseline may 
indicate kidney damage.  
Secondary outcomes 
These are the outcomes that although the main conclusions would not be drawn from, 
they may help to make clinical decisions. My secondary outcomes are listed below.  
1. Eradication of respiratory infection (defined as negative bronchoalveolar lavage, 
sputum, or cough swab cultures at the end of treatment course) 
2. Participant-reported symptom scores (change from baseline) 
3. Lung function parameters (e.g. forced expiratory volume in one second (FEV1), 
forced vital capacity (FVC), FEV1/FVC ratio) (change from baseline) 
4. Participant-reported quality of life scores (e.g. CFQ-R)234 (change from baseline) 
5. Adverse effects of treatment 
Eradication of respiratory infection should be addressed as even though a strategy may 
be reducing kidney injury, it is important it is as effective at clearing the respiratory 
infection. The lung function test is to make sure that the intervention does not cause a 
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deterioration in lung function or in contrast, cause an increase in lung function for some 
reason. Participant reported symptom scores and quality of life scores are important 
outcomes in any systematic review of an intervention. Adverse effects of an intervention 
should always be evaluated.  
5.3 Search method for identification of studies 
In this section I will describe how I went about designing a search strategy and the 
medical databases I searched. I decided that there was to be no restrictions regarding 
language or publication status when deciding whether to include a study. 
5.3.1 Electronic searches 
Bibliographic Databases 
It is mandatory to search CENTRAL and MEDLINE databases and if the review author 
has access, EMBASE too, for relevant studies to be included in the review. Here I will 
describe these databases in more detail.  
• Cochrane Central Register of Controlled Trials (CENTRAL) – This is a 
database developed by the Cochrane collaboration and is the most 
comprehensive list of RCTs with nearly 530,000 citations in January 2008.235,236 
It is published as part of The Cochrane Library and many of the results have 
come from systematic searches of other bibliographic databases (e.g. EMBASE 
and MEDLINE) and from handsearching. CENTRAL also includes citations to 
reports that are not found in other bibliographic databases, citations that are 
available only in conference proceedings and citations that are published in 
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many different languages.237 It can be accessed for free via The Cochrane 
Library to all members of a CRG. 
• MEDLINE – This is a database that contains more than 24 million references 
from 5,200 journals in around 40 different languages.238 It contains citations 
from 1950 onwards and it is available to access for free through PubMed. 
However, I accessed it through Ovid which requires institutional access which 
Keele University provides. MEDLINE indexes citations by adding Medical 
Subject Terms (MeSH) descriptors to them.   
• EMBASE – This is also a biomedical database containing 32 million plus 
records from over 8,500 journals in 30 languages from 1947 onwards.239 
Embase is indexed using Elsevier’s Life Science thesaurus known as Emtree®. I 
thought I would be able to use Ovid to access EMBASE, however I had some 
problems with this, so I was advised to use Healthcare Databases Advanced 
Search (HDAS) instead.  
We also searched grey literature which is literature that is not formally published such as 
conference abstracts, dissertations and research reports using the Open Grey database.240 
It is important to include grey literature as it can make up 10% of referenced studies in a 
Cochrane review.241 
Trial Registries 
• Cystic Fibrosis Trials Register – A search was conducted of this register by the 
CRG’s Information Specialist using the following term: antibiotics. This register 
is made up from electronic searches of CENTRAL, MEDLINE, EMBASE and 
from handsearching two journals – Pediatric Pulmonology and the Journal of 
Cystic Fibrosis.242 Unpublished work is identified by searching the abstract book 
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of three conferences: the International Cystic Fibrosis Conference, the European 
Cystic Fibrosis Conference and the North American Cystic Fibrosis Conference. 
• The World Health Organization International Clinical Trials Registry Platform - 
This registry platform was introduced in May 2007 in order to provide a list of 
ongoing trials and completed trials that could be all seen in one place.243 It uses 
registers that contain trials of a certain standard.  
• US National Institutes of Health Ongoing Trial Register Clinicaltrials.gov - This 
register contains a list of studies that are ongoing or completed that involved 
human participants.244 According to the website, it currently has 267,527 
(05/03/2018) trials listed.  
• International Standard Randomised Controlled Trial Number (ISRCTN) Registry 
– This registry was launched in 2000 and contains trials involving human 
participants that assess a health intervention.245 
5.3.2 Searching other resources  
I also checked the bibliographies of included studies and any relevant systematic reviews 
identified for further references to relevant trials. I planned to contact experts and 
organisations in the field to obtain additional information on relevant trials however this 
was not necessary for my review. 
5.3.3 Designing a search strategy 
Usually NH, the CRG’s Information specialist would design the search strategy for 
reviews in the group. However, she was on maternity leave at the time that I was about 
to design mine. Therefore, I had to design my own. Although this was challenging I had 
attended the Keele University seminars on systematic reviews and one of the facilitators, 
NC, helped with writing the search strategy. NC and NJ advised me not to make the 
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search strategy too narrow at first as they thought this would be a very niche area. As we 
did not know all the possible interventions to minimise kidney injury and there may be 
many of them we did not include this in the search strategy. We also did not include 
kidney injury, the main outcome, in the search strategy as we thought it would make the 
search too narrow. The search strategy was based on the eligibility criteria for the review. 
Please see appendix 3 for the protocol which includes copies of my search strategies for 
the different databases. For each of the criteria it is important to consider all terms and 
abbreviations that may be used for a word, the thesaurus in the databases can be helpful 
to find other terms.  
Condition – In all studies the participants must have cystic fibrosis. I searched the terms 
cystic fibrosis, CF, mucoviscidosis and fibrocystic disease.  
Intravenous Antibiotics – One of my criteria under types of participants was that they 
must be receiving a course of intravenous antibiotics in the study. For this criterion, I 
searched for anti-bacterial agents, antibiotics, antimicrobials, aminoglycosides, and 
different types of aminoglycosides (kanamycin, tobramycin, gentamycin, neomycin, 
amikacin, streptomycin).  
Type of study – For each of the databases you must include a search for randomised 
controlled trials as this is what I described I would look at in my protocol. This filters out 
all studies that are not RCTS. However, this is not necessary to do when searching 
CENTRAL as there are only randomised control trials in the database.    
MeSH Descriptors 
Studies are tagged with subject heading-controlled vocabulary in each of the databases. 
These are known as ‘MeSH descriptors’. This means that when you search for this MeSH 
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term then it picks up all the studies tagged under that overall subject heading. For 
example, one of my MeSH terms was Cystic Fibrosis. In MEDLINE and EMBASE you 
must add a forward slash after the term e.g. “Cystic Fibrosis/”. Whereas in CENTRAL 
you must write “Cystic Fibrosis [Mesh descriptor]” in order to pick up the articles tagged 
under this subject heading. To search for the MeSH terms relevant to my search strategy, 
I used the thesaurus on the databases. For some of the subject headings, e.g. 
Aminoglycosides, I chose to explode them. This means that when the search is looking 
for that MeSH term it will also look for all narrower subject headings under that main 
heading. To do this I simply wrote “exp Aminoglycosides”.  
Suffix variation 
Some words have different suffixes at the end of them for example medic- may end in 
medicine, medicines, medication, or medications. Therefore, to ensure all possible suffix 
variations of the words are picked up on a search I used a truncation such as ‘medic$’. In 
the Cochrane database (CENTRAL) and when using HDAS for Embase, the truncation 
symbol is * rather than $.   
Wildcards 
Some words have different spellings, depending on whether the study was done in the 
United States or the United Kingdom. For example, kanamycin can also be spelt 
kanamycin. In order to ensure all studies with this word spelt either way are picked up, a 
# can be used in the place of the letter that can be changed. For example, in my search 
strategy I used kanam#cin to search for this antibiotic. This is called a wildcard, the 
symbols * and ? can also be used too.    
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Searching for nearby words 
It is necessary to specify that when you ask the interfaces to search for two words that 
you use ‘NEAR’ or ‘ADJ’ in between them. This is because the search may default to 
just finding both words in the document that may be apart and unrelated. For example, in 
my search strategy I used ‘ADJ’, egg cystic$ adj5 fibros$. This would produce results 
that identified studies that had the word cystic up to 5 words away from fibrosis. If the 
words should be next to each other then you can put the phrase in quotation marks e.g. 
“anti biotic” 
Boolean operators 
For each concept, for example one of mine was cystic fibrosis, the search strategy should 
be built up with the controlled vocabulary terms (e.g. MeSH terms) and related 
words/synonyms for each concept. At the end of each concept, the Boolean ‘OR’ operator 
should be used. This means that when the search is run it will pick up any citations with 
any of these different ways of naming cystic fibrosis in. My other concepts are 
intravenous antibiotics and randomised controlled trials and ‘OR’ should be used at the 
end of these too. When I created my search strategy with these three sets of terms, I then 
joined them together with the ‘AND’ operator. This means that my search picked up 
results that included cystic fibrosis and intravenous antibiotics and that are randomised 
controlled trials. However, this can cause problems as if the article does not contain at 
least one term from each of the three sets, it will not be picked up. Therefore, when 
designing the search strategy, it is important that you have considered as many synonyms 
as possible.  
5.4 Data Collection and Analysis 
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5.4.1 Selection of studies 
I entered each strategy into the individual databases and then exported the results onto an 
online software program called Covidence. In total we had 6389 references from the 
search results. Cochrane recommends that authors use a reference management software 
as it provides a place to keep track of all references. Covidence is used to organise the 
references and helps by removing duplicates, in our case it removed 2108 duplicates.  
When writing the protocol, I decided that we would consider trials in any language and 
would translate them as necessary. I also decided we would include studies published as 
full texts, but if there was only an abstract available for a particular study we would 
include it if it presents results. Where there are no results presented within the abstract or 
on any trials registry sites, then we have classified the study as 'Awaiting classification' 
until more information is available. Similarly, with ongoing studies, if the study met our 
inclusion criteria then we included it. 
5.4.2 Screening 
The first stage of screening involved looking at the titles and abstracts of studies on the 
reference list and deciding if they were relevant to the review. WC and myself screened 
the titles and abstracts independently on Covidence as Cochrane recommends that at least 
two people independently screen them.246 On Covidence you have three options; yes, no 
or maybe and each reviewer must vote one of these options for all of the studies on the 
list. When both reviewers voted ‘No’ for a study, this study did not go forward to the next 
stage of screening. Covidence marked ‘Conflict’ for studies where myself and WC did 
not give the same answer. WC and I attempted to resolve these disagreements by 
discussion, but we relied on FG to act as an external arbiter to make the decision if we 
could not agree. In total we had 830 conflicts at this stage of screening.  
69 
 
When myself and WC both voted ‘Yes’ or ‘Maybe’ for a reference, it was taken forward 
to the next stage of screening. We were able to dismiss many studies from the review 
based on the title, for example there were many titles about ‘non-CF bronchiectasis’ and 
so these could be excluded straight away. Where it was not so clear from the title, I would 
look at the abstracts of studies and if these had not been imported then I hand searched 
for the abstract online. There were some abstracts that I was not able to access myself, so 
I had to ask the librarian at Keele University and NJ for help in sourcing these.   
We took 164 studies forward to the next stage of screening. This involved obtaining and 
reading the full texts of these references. At this stage of screening we excluded 110 
irrelevant references. 
We took 54 references through to data extraction which referred to 50 trials. From these 
studies 8 were classified as ‘Awaiting classifications’ as it was not clear whether they 
had addressed nephrotoxicity, so contacted the study authors for more information. There 
were 30 studies that fit all inclusion criteria, however they reported nephrotoxicity as a 
dichotomous outcome, i.e. yes nephrotoxicity occurred, or no nephrotoxicity didn’t 
occur. We have contacted these study authors to ask them to provide continuous data for 
measures of nephrotoxicity such as creatinine etc. If we cannot get hold of the continuous 
data, we will analyse the dichotomous data in due course. We also have 8 classified as 
‘Ongoing trials’ and we have contacted the authors for any data, however, at this stage 
we do not have any results to report from them. Therefore, at this stage we have only 4 
studies that present nephrotoxicity as continuous data that we can analyse. 
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2108 duplicates 
4120 excluded  
8 awaiting classification 
8 ongoing trials  
30 studies awaiting continuous 
data 
110 excluded  
 
Figure 5 – Study flow diagram  
5.4.3 Data extraction and management  
Our CRG provided us with a paper copy of their data extraction form which both myself 
and WC used to extract basic information from the full text version of the included 
studies. Two authors should independently complete the data extraction process for the 
included studies.246 I then checked for any discrepancies between our work and 
transferred this information to the online Covidence data extraction form where I added 
6389 references identified 
through database search
4281 references taken through 
title and abstract screening 
164 references taken through full 
text screening
54 references (referring to 50 
studies)
50 studies taken to data 
extraction
4 studies included in quantitative 
synthesis 
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more detailed information. We collected data on trial designs, participant characteristics, 
intervention and comparator and outcome data. We had to contact all authors for further 
information regarding their trial.  
Data extraction forms are based on the inclusion criteria for the review and extracting the 
data may highlight other studies that should have been excluded. They have headings 
which prompt the authors on what data to extract. The forms also provide a summary of 
the decisions that have been made during the data extraction process. They also provide 
a summary of the data that can then be entered into RevMan ready for analysis.   
5.4.4 Assessment of risk of bias in included studies 
Myself and WC independently used the risk of bias tool as described in the Cochrane 
Handbook for Systematic Reviews of Interventions to assess the risk of bias across seven 
domains.247 We ranked each domain as ‘high risk of bias’, ‘low risk of bias’ or ‘unclear’. 
For all domains, where the methods have not been described clearly, we ranked this as 
‘unclear risk of bias’. We attempted to resolve any disagreements by discussion, but 
where we did not reach a decision, the third author (FG) acted as an external arbiter to 
mediate until we reached a final conclusion. I will now go on to describe the different 
types of bias and which of the Cochrane domains fit into each type. We used Covidence 
to input this data which was then exported to RevMan where it created a table for us. 
Selection bias   
This type of bias arises from any difference in the baseline characteristics of the two 
groups (intervention and control/comparison) due to non-random allocation to a group. 
Sequence generation – This domain looks at how the participants were randomised into 
their groups (intervention or control/comparison). Methods such as a random number 
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table or computer-generated lists are appropriate and have low risk of bias. On the other 
hand, methods that are non-random such as sequence generated by odd or even date of 
birth will have a high risk of bias for this domain.  
Allocation concealment – This domain looks at how the allocation sequence was 
concealed from the researchers and participants. If it is unlikely that the participants or 
investigators enrolling participants could not foresee assignment due to central allocation 
or sequentially numbered drug containers of identical appearances, then this study will 
have a low risk of bias for this domain. Where the allocation may be foreseen, for 
example, they used assignment envelopes that were non-opaque or used alternation then 
this study will have a high risk of bias for this domain.  
Performance bias 
This type of bias arises from the participants or personnel acting differently due to 
knowledge of which group the participant is in. For example, the personnel may give 
more attention to those in the intervention group. 
Blinding of participants and personnel – This domain looks at whether the participants 
and personnel were blinded from knowledge of what group the participants were in 
during the study. The trial should state that participants and personnel were blinded or if 
there was no blinding the outcomes would not have been affected by lack of blinding, in 
order to have a low risk of bias for this domain. If there was no blinding and the outcome 
is likely to be affected by the lack of blinding, then this domain is deemed as high risk of 
bias. 
Detection bias  
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This type of bias arises from the differences in the way outcomes are assessed 
(particularly subjective outcomes) due to the outcome assessors having knowledge as to 
which group the participant was in.  
Blinding of outcome assessment – This domain looks at whether the outcome assessors 
were blinded from knowledge regarding which group a participant was in. Blinding of 
outcome assessment must be ensured for this domain to rank as low risk of bias. If there 
is no blinding but the outcomes would not have been affected by lack of blinding, then 
this can also be ranked as low risk of bias. If there was no blinding and the outcome is 
likely to be affected by the lack of blinding, then this will result in a high risk of bias for 
this domain. 
Attrition bias  
This type of bias arises from there being differences between the number of withdrawals 
from the study between the two groups. 
Incomplete outcome data – This domain looks at the amount, nature, and handling of any 
incomplete outcome data. If there is no missing data, then this gives a low risk of bias for 
this domain. If the missing data is equally distributed across the intervention and control 
group and the reasons in both group are similar, then this can also be classed as low risk 
of bias. If the reason for missing outcome data is likely to be related to true outcome, then 
this leads to a high risk of bias for this domain.   
Reporting bias 
This type of bias arises when the authors do not report all outcomes that they pre-
specified.  
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Selective outcome reporting – This domain looks at whether the outcomes that were 
mentioned in the protocol have been presented in the results of the full paper. If all pre-
specified outcomes have been reported in the full paper, then this means the study is low 
risk of bias for this domain. If not all pre-specified outcomes have been reported then the 
study will have high risk of bias for this domain.  
Other bias  
Other risk of bias - This final domain involves looking for any other potential sources of 
bias in the included studies. If there are no other sources of bias, then it can be classed as 
having a low risk for this domain and high risk if the opposite is true. 
5.4.5 Measures of treatment effect 
There are 5 main types of data described in the Cochrane handbook including; 
dichotomous data, continuous data, ordinal data, counts and rates and time-to-event data. 
My outcome data is all either dichotomous or continuous data, so I will now go on to 
define these types of data.  
Dichotomous data (binary data): Each individual gives an outcome of one of only two 
categories (e.g. yes/no or male/female).  
Continuous data: Quantitative (numerical) data that can take any value in a specified 
range (e.g. height)  
Dichotomous data 
In my review my dichotomous data included the outcomes; adverse effects and 
eradication of respiratory infection. Dichotomous data can be summarised in many ways 
with the most common effect measures being; risk ratio (RR), odds ratio (OR), risk 
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difference and number needed to treat. Risk describes the probability of an event 
occurring. We decided to use the RR (also known as relative risk) to compare the risks 
of an event between the two groups (intervention group vs control group). A RR of 1 
indicates that the risk of the event is the same for the intervention and control group. A 
RR of above 1 indicates the intervention is more likely to give the outcome. A RR below 
1 indicates the intervention is less likely than the control to result in the outcome. We 
used 95% confidence intervals where appropriate.  
The RR is calculated by: 
𝑅𝑖𝑠𝑘 𝑜𝑓 𝑒𝑣𝑒𝑛𝑡 𝑖𝑛 𝑖𝑛𝑡𝑒𝑣𝑒𝑛𝑡𝑖𝑜𝑛 𝑔𝑟𝑜𝑢𝑝 = 
𝑁𝑢𝑚𝑏𝑒𝑟 𝑜𝑓 𝑝𝑎𝑟𝑡𝑖𝑐𝑖𝑝𝑎𝑛𝑡𝑠 𝑖𝑛 𝑖𝑛𝑡𝑒𝑟𝑣𝑒𝑛𝑡𝑖𝑜𝑛 𝑔𝑟𝑜𝑢𝑝 𝑡ℎ𝑎𝑡 𝑒𝑣𝑒𝑛𝑡 𝑜𝑐𝑐𝑢𝑟𝑟𝑒𝑑 𝑖𝑛 
𝑇𝑜𝑡𝑎𝑙 𝑛𝑢𝑚𝑏𝑒𝑟 𝑜𝑓 𝑝𝑎𝑟𝑡𝑖𝑐𝑖𝑝𝑎𝑛𝑡𝑠 𝑖𝑛 𝑖𝑛𝑡𝑒𝑟𝑣𝑒𝑛𝑡𝑖𝑜𝑛 𝑔𝑟𝑜𝑢𝑝
 
 
𝑅𝑖𝑠𝑘 𝑜𝑓 𝑒𝑣𝑒𝑛𝑡 𝑖𝑛 𝑐𝑜𝑛𝑡𝑟𝑜𝑙 𝑔𝑟𝑜𝑢𝑝 =  
𝑁𝑢𝑚𝑏𝑒𝑟 𝑜𝑓 𝑝𝑎𝑟𝑡𝑖𝑐𝑖𝑝𝑎𝑛𝑡𝑠 𝑖𝑛 𝑐𝑜𝑛𝑡𝑟𝑜𝑙 𝑔𝑟𝑜𝑢𝑝 𝑡ℎ𝑎𝑡 𝑒𝑣𝑒𝑛𝑡 𝑜𝑐𝑐𝑢𝑟𝑟𝑒𝑑 𝑖𝑛 
𝑇𝑜𝑡𝑎𝑙 𝑛𝑢𝑚𝑏𝑒𝑟 𝑜𝑓 𝑝𝑎𝑟𝑡𝑖𝑐𝑖𝑝𝑎𝑛𝑡𝑠 𝑖𝑛 𝑐𝑜𝑛𝑡𝑟𝑜𝑙 𝑔𝑟𝑜𝑢𝑝
 
 
𝑅𝑅 =
𝑅𝑖𝑠𝑘 𝑜𝑓 𝑒𝑣𝑒𝑛𝑡 𝑖𝑛 𝑖𝑛𝑡𝑒𝑟𝑣𝑒𝑛𝑡𝑖𝑜𝑛 𝑔𝑟𝑜𝑢𝑝
𝑅𝑖𝑠𝑘 𝑜𝑓 𝑒𝑣𝑒𝑛𝑡 𝑖𝑛 𝑐𝑜𝑛𝑡𝑟𝑜𝑙 𝑔𝑟𝑜𝑢𝑝
 
Peer reviewers highlighted that kidney injury may be presented as dichotomous data i.e. 
kidney injury or no kidney injury. As mentioned this was the case in many studies and 
we are in the process of contacting the study authors for their continuous data if available. 
If this is not possible, then we will calculate the RR. 
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Continuous data 
In my review my continuous data included serum creatinine levels, creatinine clearance, 
urinary excretion of protein, urinary excretion of phospholipid markers of nephrotoxicity, 
urine output, lung function parameters, participant-reported QoL scores, participant-
reported symptom scores. Participant reported QoL and symptom scores are not actually 
continuous data but in Cochrane reviews they are usually analysed as though they are.  
We recorded the mean change and standard deviation (SD) from baseline for each group. 
However, some studies only reported a pre-intervention mean (SD) and post intervention 
mean (SD). We can use these two figures to calculate the mean change for each group. 
However, we cannot calculate the SD of the change and so these results will be reported 
narratively.  
Mean change = Mean post treatment – Mean at baseline  
There are two types of summary statistics that can be used to show the effect size i.e. the 
difference between two groups (intervention vs control).  
The first of these is the mean difference (MD) which is used when an outcome is 
measured on the same scale in all studies. The MD measures the absolute difference 
between the mean value in two groups in a trial. We will calculate 95% confidence 
intervals for each MD.  
MD = Mean change of intervention – mean change of control  
If the MD is 0 then this indicates that the intervention has the exact same effect on the 
outcome as the control. When interpreting the MD, it is important to remember whether 
the outcome is a good one or bad outcome. For example, if the outcome is quality of life, 
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then any value above 0 would indicate that the intervention is better at improving quality 
of life than the control. However, for a bad outcome like biomarkers of proximal tubular 
toxicity, if the MD was above 0 then this would indicate that the intervention was causing 
an increase in urinary excretion of biomarkers of proximal tubular toxicity and this would 
be negative as it would suggest the intervention is giving more kidney damage than the 
control.  
For some outcomes they may be measured on different scales from one study to the next. 
In some cases, this may be easy to resolve as you can convert them all to the same scale 
e.g. if one study uses pounds, but all others use kilograms, then you would convert them 
all to kilograms. However, with some scales we cannot convert them, for example, quality 
of life scales. We do not know what a score of 1 on one scale may equate to one another 
scale. When this occurs, we cannot use the MD and we must standardise the results of 
studies before combining them. In this instance we use the standardised mean difference 
(SMD). The calculation for this is complex, but luckily RevMan calculates most of this 
for you.  
SMD = 
𝑀𝑒𝑎𝑛 𝑜𝑓 𝑖𝑛𝑡𝑒𝑟𝑣𝑒𝑛𝑡𝑖𝑜𝑛 𝑔𝑟𝑜𝑢𝑝−𝑀𝑒𝑎𝑛 𝑜𝑓 𝑐𝑜𝑛𝑡𝑟𝑜𝑙 𝑔𝑟𝑜𝑢𝑝 
𝑃𝑜𝑜𝑙𝑒𝑑 𝑠𝑡𝑎𝑛𝑑𝑎𝑟𝑑 𝑑𝑒𝑣𝑖𝑎𝑡𝑖𝑜𝑛 𝑜𝑓 𝑏𝑜𝑡ℎ 𝑔𝑟𝑜𝑢𝑝𝑠
 
Unfortunately, the SMD does not correct for differences in the direction of the scale. For 
example, a score of 10 on one quality of life scale may indicate the best quality of life, 
whereas a score of 10 on another scale may indicate the worst quality of life. Before 
combining the results of the studies in a meta-analysis you must make sure all the results 
are running in the same direction by multiplying the results of one scale by -1. SMD can 
be difficult to interpret because it is units of standard deviation rather than units of an 
outcome scale. However, a positive SMD indicates when looking at quality of life 
indicates that the intervention has improved the quality of life.   
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5.4.6 Unit of analysis issues 
We decided we would assess cross-over design trials on an individual basis to establish 
how much data we could include in the analysis. If the authors did not take into account 
the cross-over design in the analysis, any carry-over effect or within-person differences 
then we decided not to include them in our analysis. If this was the case, then we planned 
to only include data from the first phase of the trial as if it were a parallel design study. 
However, this would lose the advantage of the cross-over design where participants are 
used as their own controls.248 
In our protocol we decided that if we found multi-arm trials with different active 
treatment arms e.g. statins or fluids, then we would analyse each treatment arm separately 
against placebo.  
5.4.7 Dealing with missing data  
Missing data can cause biased results and so to prevent this, we will contact study authors 
for any more information that we may require. If data is incomplete but partially available 
and we have not been able to contact the authors, then we planned to use the last available 
measurement. In all four studies that we have data extracted from, we have found they 
have given number of withdrawals and reasons for withdrawal. However, we did have to 
contact two study authors to find out which groups the withdrawals were from. If we find 
participants withdrawals are not recorded along with the reasons for withdrawal in any 
further studies, then we will attempt to contact the study authors as this can cause attrition 
bias.  
Intention-to-treat analyses looks at the results of all participants and analyses them based 
on the group they were originally assigned to. It ignores any withdrawals, non-
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compliance or swapping of groups. Ideally study authors will have performed an 
intention-to-treat analysis.  If there was no mention of ITT analysis, then we assumed 
they had not performed one. We planned to undertake ITT analyses ourselves where 
possible, however, most trials did not report the results of participants that withdrew from 
the study.  
5.4.8 Assessment of heterogeneity 
Heterogeneity refers to the differences between studies that are being analysed in the 
systematic review. There are many different types of heterogeneity. Clinical 
heterogeneity involves differences between the participants in the study, the 
interventions, or the outcomes. Whereas methodological heterogeneity refers to 
differences in the study design which may affect the risk of bias. Both clinical and 
methodological heterogeneity can lead to what is known as statistical heterogeneity. This 
is where there are differences in the intervention effects between the studies that is more 
than due to just random error.  
By looking for trials that report the same outcomes it may be possible to include these in 
a meta-analysis. The first crude method to test for heterogeneity is known as ‘the eyeball 
test’. This is where we look at the forest plots of those studies reporting similar outcomes 
and see if their confidence intervals overlap. If their confidence intervals do not overlap, 
then there is heterogeneity. A forest plot shows the summary statistic (e.g. RR or mean 
difference), with a diamond symbol, for each study comparing the same outcome. The 
size of the diamond corresponds to the number of participants. The lines either side of 
the diamond represent the confidence interval which is what we look at to see if there is 
any overlap. A more formal test can be used to assess for heterogeneity and this is known 
as the chi-squared test. A large chi-squared value or a low p-value indicate heterogeneity 
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but should be interpreted with caution if there is a small sample size or if there are only 
a few studies. The chi-squared statistic can be used to work out the I2 which is a 
percentage of the differences in effect estimates that is due to heterogeneity as opposed 
to chance. The Cochrane Handbook for Systematic Reviews of Interventions provides a 
guide to interpret the I2 value:249 
• low (might not be important) = 0% to 40%; 
• moderate = 30% to 60%; 
• substantial = 50% to 90%; and 
• considerable = 75% to 100%. 
5.4.9 Assessment of reporting bias 
We planned to generate a funnel plot to attempt to identify any publication bias in the 
trials if we had at least 10 trials.250 A funnel plot is a scatter plot of the estimated effects 
for the trials identified with the standard error on the vertical axis and effect estimate on 
the horizontal axis. Trials with smaller sample sizes are usually less precise and so their 
estimated effects are usually scattered more widely at the bottom of the plot. Trials with 
larger sample sizes usually have a precise effect estimate and so these trials should be 
scattered around the top close to the vertical line. This creates the shape of a funnel and 
if the plot is symmetrical it suggests there is unlikely to be any reporting bias. 
We planned to compare the trial protocols with the final publication papers to see if there 
was any selective reporting of outcomes in the included trials. If the trial protocols were 
not available, then we decided to compare the outcomes reported in the results section to 
the outcomes reported in the methods section. We planned to extract information on the 
sponsors, sources of funding and competing interests of the authors to look for any 
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external bias. We planned to minimise publication bias by searching trial registries and 
contacted pharmaceutical companies for unpublished data. 
5.4.10 Data synthesis  
Meta-analysis refers to a statistical method that combines data from two or more studies 
to produce an estimate of overall effect. If there is considerable heterogeneity (I2 over 
75%), then a meta-analysis should not be carried out and so we will report these results 
narratively. If there is not considerable heterogeneity, then we will perform meta-analysis 
using the data from the included studies to create forest plots on RevMan. We planned to 
carry out separate meta-analyses for each of the different interventions (e.g. fluids, 
statins) in comparison to the control (placebo or standard clinical care). However, at this 
stage our studies are not looking at the same comparison and so cannot be included in a 
meta-analysis. 
If at a later stage we are able to carry out a meta-analysis, we will use the level of 
heterogeneity to determine which type of analysis model to use. There are two different 
types of statistical models in RevMan known as the fixed effect model and the random 
effects model.  
The fixed effect model assumes that all studies included in the meta-analysis are 
measuring the same true treatment effect and any differences are down to random error. 
We will use the fixed effect model if there is a low level of heterogeneity (i.e. I2 less than 
40%).  
On the other hand, the random effects model assumes that the treatment effect is different 
in all included studies. The treatment effect may vary slightly in studies, for example, 
perhaps if they are looking at different age of participants. We will use the random effects 
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model when there is a higher level of heterogeneity (i.e. I2 over 40%). The random effects 
models allows for heterogeneity between trials and so there will be a larger confidence 
interval meaning it is less precise.  
5.4.11 Subgroup analysis and investigation of heterogeneity  
If we are able to perform a meta-analysis and there is heterogeneity (greater than 40%) 
we can explore this by undertaking subgroup analyses to see if we can determine a cause 
for it. We will do this for our primary outcome (nephrotoxicity) only.  
The subgroups that we will analyse include: 
• individuals receiving planned versus unplanned antibiotic treatment; 
• children (under 18 years old) versus adults. 
By performing subgroup analysis, we will be able to see if the interventions affect these 
certain subgroups differently. For example, we may be able to see how whether being an 
adult effects how effective statins are at preventing kidney disease, compared to how 
effective they are in children.  
5.4.12 Sensitivity analysis 
When screening studies for eligibility for inclusion, sometimes decisions can be tricky as 
to whether to include them or not. A sensitivity analysis looks at removing the studies 
that were borderline for inclusion and then performing the meta-analysis again to see if 
the results are similar. Including studies with high risk of bias in meta-analyses can 
produce results that are not very accurate. Cross-over trials may also produce inaccurate 
results. By excluding these studies and then repeating the meta-analysis we can see 
whether the true effect of the intervention is the same. If the overall result and conclusions 
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are not affected by the different decision, then the results can be regarded with a higher 
degree of certainty. Therefore, I planned to perform sensitivity analyses including and 
excluding trials with high risk of bias and then cross-over trials.  
5.4.13 Summary of findings table  
Cochrane reviews should include a ‘summary of findings table’ which focuses on the 
main outcomes of the review. It should be as simple as possible and include information 
on the magnitude of effect of interventions and a summary of the quality of the evidence. 
The summary of findings table can have a maximum of seven outcomes and these must 
be the most clinically relevant outcomes to patients and health care professionals. I 
originally proposed to have seven outcomes in my protocol, however, peer reviewers 
suggested that I had missed out important outcomes, so we were allowed to include more. 
Our chosen outcomes were: 
• Blood creatinine level 
• Creatinine clearance 
• Urinary excretion of protein 
• Urinary excretion of biomarkers of proximal tubular toxicity 
• Urine output 
• Eradication of respiratory infection (defined as negative bronchoalveolar lavage, 
sputum, or cough swab cultures at the end of treatment course) 
• Adverse effects of treatment 
• Participant-reported symptom scores 
• Participant-reported QoL scores 
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I planned to create a separate table for each treatment comparison (e.g. statins vs placebo 
or fluids vs no fluids).  
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CHAPTER 6: RESULTS OF THE 
COCHRANE SYSTEMATIC REVIEW  
6.1 Results of the search 
We have identified 54 references relating to 50 trials to be included in the review. At the 
moment we can only extract data from 4 of them and I have split these up into their 
different comparisons for analysis.  
6.2 Characteristics of included studies 
6.2.1 Comparison 1 – Intravenous meropenem and tobramycin 
versus intravenous ceftazidime and tobramycin 
Latzin 2008251 
Table 2 - Characteristics of Latzin's study 
Methods RCT 
Parallel design 
Open label 
Duration: 2-3 weeks  
Multicentre 
Country: Germany & Switzerland 
Participants 127 participants. Randomised to receive different IV antibiotic 
combinations in three different scenarios: 
 1. Suppression therapy in those with chronic PA but not 
experiencing an exacerbation; 
2. Acute exacerbation in those with chronic PA infection; and 
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3. Eradication therapy in those with their first isolation of PA. 
Intervention 1: 59 participants; mean (SD) age 17.3 (8.7); 29 males, 
30 females. 
Intervention 2: 59 participants; mean (SD) age 16.9 (7.7); 30 males, 
29 females. 
Interventions Intervention 1: IV meropenem 120 mg/kg/day in 3 doses (of >50kg, 
2g TDS) and IV tobramycin 9- 2 mg/kg/day in 2 doses. 
Intervention 2: IV ceftazidime 200-400 mg/kg/day in 2 or 3 doses and 
IV tobramycin 9-12 mg/kg/day in 2 doses. 
Outcomes Nephrotoxicity (serum creatinine) 
Lung function (FEV1 and FVC) 
Inflammatory markers (CRP and leukocyte count) 
Full blood count 
Liver function 
Adverse effects 
Microbiology 
Notes I contacted Latzin to enquire about their methods of randomisation 
and how they concealed allocation. I also asked him for further 
information regarding his data tables as I struggled to work out how 
he calculated the mean difference. 
 
6.2.2 Comparison 2 – Morning versus evening IV dosing  
Prayle 2016252 
Table 3 - Characteristics of Prayle's study 
Methods RCT 
Parallel design 
Open label 
Duration: 14 days 
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Multicentre 
Country: UK 
Participants 18 participants, aged 5-18 years, with CF that required a course of 
intravenous tobramycin.  
Intervention 1: 9 participants; median (IQR) age 12.5 (12.2-15.5). 
Intervention 2: 9 participants; median (IQR) age 14.5 (12.8-14.9). 
Interventions Participants received intravenous tobramycin alongside at least a 
second intravenous antibiotic. 
Intervention 1: Intravenous tobramycin administered at 08:00 
Intervention 2: Intravenous tobramycin administered at 20:00 
Outcomes Pharmacokinetic measures 
Nephrotoxicity: Urinary excretion of biomarkers of proximal 
tubular toxicity (KIM1, CysC, NAGL, IL-18, NAG) 
Lung function (FEV1 and FVC) 
Weight (kg) 
Melatonin levels 
Notes I contacted Prayle to check that another reference that we identified 
in the search was referring to the same trial which he confirmed it 
was. Prayle stated that 14 urine samples were collected in total and 
so I also enquired as to how many urine samples were obtained for 
each group. 
 
6.2.3 Comparison 3 – Nebulised versus intravenous antibiotics 
Al-Aloul 2014253 
Table 4 - Characteristics of Al-Aloul's study 
Methods RCT 
Cross-over design 
Duration: 14 days 
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Single centre 
Country: UK 
Participants 20 adult (11 male, 9 female) participants with CF that were 
chronically infected with PA and experiencing a pulmonary 
exacerbation were randomised.  
The mean age (SD) of the participants was 22.1 (6.9) and ranged 
from 17-42 years.  
Intervention 1: 10 participants in the first arm, 10 participants in the 
second arm 
Intervention 2: 10 participants in the first arm, 10 participants in the 
second arm 
Interventions During each exacerbation, all patients in both groups also received 
IV colistimethate sodium 2 mega units three times a day. 
Intervention 1: Nebulised tobramycin (TOBI), 300mg/5ml, 
administered using a Pari LC Plus jet nebulizer and a Porta-Neb 
compressor at a dose of 300mg twice a day.  
Intervention 2: Intravenous tobramycin given at mean daily dose of 
8.2mg/kg (SD 1.5) in 2 or 3 divided doses.  
Outcomes Nephrotoxicity: Serum creatinine, serum magnesium, creatinine 
clearance, urinalysis, urinary excretion of protein and urinary 
excretion of biomarkers of proximal tubular toxicity (NAG, AAP, 
β2 Microglobulin, Collagen IV 
Inflammatory markers (C-reactive protein & white cell count) 
Lung function (FEV1 and FVC) 
Microbiology  
Symptom score 
Adverse effects 
Notes I contacted Al-Aloul to determine how he randomised the 
participants and how he concealed allocation. I also enquired as to 
whether he blinded participants and personnel. He reported in the 
study that he was only able to obtain 13 sputum samples, so I 
enquired as to what group these samples were from. Finally, I 
enquired as to whether two other citations that were identified from 
the search were references to the same trial. 
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6.2.4 Comparison 4 – Single IV antibiotic vs combination of IV 
antibiotics 
Conway 1997254 
Table 5 - Characteristics of Conway's study 
Methods RCT 
Parallel design 
Open label 
Duration: 12 days 
Single centre 
Country: UK 
Participants 53 adult participants with CF that were chronically colonised with 
PA experiencing a respiratory exacerbation. 
18 participants entered the study twice due to a further exacerbation 
later on. Of these 18, 9 were originally treated with monotherapy 
and 9 were originally treated with the dual therapy. On subsequent 
entry to the trial they received the opposite treatment to the first 
time they were enrolled. 
Intervention 1: 36 participants; mean (SD) age 21.7 (4.2) years; 17 
females, 19 males. 
Intervention 2: 35 participants; mean (SD) age 21.2 (4.25) years; 12 
females, 23 males. 
Interventions Intervention 1: IV colistin 2MU (160mg) TDS 
Intervention 2: IV colistin 2MU (160mg) TDS along with a second 
IV anti-pseudomonal antibiotic.  
Outcomes Nephrotoxicity: Serum U&Es, creatinine clearance, urine dipstick 
testing 
Lung function (FEV1 and FVC) 
Oxygen saturation 
Clinical score 
90 
 
Chest X-ray scores 
Inflammatory markers: White cell count, % neutrophil count, C-
reactive protein 
Weight (kg) 
Blood drug levels 
Microbiology 
Adverse neurological effects 
Notes As Conway did not report the mean change with groups or mean 
difference between groups we were not able to use his data in our 
analysis. I contacted him to ask if I could have access to individual 
patient data. I also contacted him to see how they randomised 
participants and whether there was any blinding in the trial.  
6.3 Risk of bias in included studies 
I created a risk of bias summary using RevMan which is shown below in figure 6.1. I 
will now go on to explain my reasons for the decisions made on ranking.  
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Figure 6.1 – Risk of bias summary 
6.3.1 Allocation (selection bias)   
Sequence Generation 
All four of the studies that we have included so far were randomised. Only one of these 
(Prayle 2016) studies listed their method of randomisation which was a remote web-based 
system and so we ranked this as low risk of bias for this domain. The other three studies 
(Al-Aloul 2014, Latzin 2008 and Conway 1997) did not provide any information 
regarding how they randomised participants. We have contacted the authors to clarify 
this but have ranked them as unclear risk of bias for now.  
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Allocation Concealment 
Three of our studies did not provide any information regarding concealment of allocation. 
(Latzin 2008, Al-Aloul 2014 and Conway 1997) We have contacted them for more 
information but for now we have ranked these studies to have an unclear risk of bias for 
this domain. As Prayle used a central web-based system it is impossible to predict what 
the next group assignment would be and so we ranked this domain as low risk of bias.  
6.3.2 Blinding (performance bias and detection bias)   
Both Prayle and Latzin’s study were open label and so there was no blinding of the 
participants or researchers. Al-Aloul study does not state it is open label but does not 
mention blinding of participants or researchers. Conway’s study describes blinding of 
outcome assessors but does not mention blinding of participants. We have contacted 
Conway and Al-Aloul for further information regarding blinding. As lack of blinding 
effects risk of bias in outcomes differently I will now describe my rankings for each 
outcome.  
Participants and personnel 
Nephrotoxicity - For all four studies we judged that for the outcome nephrotoxicity the 
risk of bias would be low, regardless of whether participants and personnel were blinded. 
This is because nephrotoxicity is objective and so lack of blinding is unlikely to affect 
this. However, one point we did consider was that personnel may give more fluids to a 
certain group than the other in order to minimize nephrotoxicity.  
Lung function - Similarly, for lung function, we judged that a lack of blinding would not 
affect the outcome therefore we rated all the four studies as low risk of bias for this 
domain. There is the risk that participants may put more or less effort in if they know 
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what group they are in. However, when lung function is conducted to ATS/ERS standard, 
this is effort independent once >90% maximum effort achieved. Therefore, we judged 
lack of blinding to be unlikely to affect this outcome. 
Adverse effects - In Latzin’s study the patients and personnel were not blinded and as 
adverse effects are very subjective lack of blinding could introduce bias. For example, if 
participants already have pre-conceived ideas about which treatment is best they may 
choose to report less adverse effects for this treatment, so we judged this domain to be 
high risk for bias. As Al-Aloul’s study compared nebulised antibiotics to intravenous 
antibiotics, participants and personnel could not be blinded. Therefore, this outcome is 
likely to be at high risk of bias in his study. We have contacted Conway for further 
information regarding blinding, so we judged this domain as unclear risk of bias for now.   
Participant reported symptom score - In Al-Aloul’s study participants could not be 
blinded as it was comparing nebulised to intravenous antibiotics. Participants may display 
response bias when completing the symptom score questionnaire. Therefore, we judged 
this outcome to be at high risk of bias.  
Outcome assessors  
Nephrotoxicity - For all four studies we judged this outcome to be at low risk of bias 
whether they were blinded or not. Nephrotoxicity involves laboratory measurements 
which are objective and so is unlikely to be affected by lack of blinding. 
Lung function - Again, for lung function we judged all studies to be at low risk of bias 
for this domain. This is because as mentioned above lung function is effort independent 
once >90% maximum effort achieved. One point we did consider was that if outcome 
assessors are aware of which group a participant is in they could get participants to repeat 
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lung function if they do not think it is satisfactory or may show more encouragement for 
one group than the other. 
Adverse effects - Latzin’s study is open label and lack of blinding of outcome assessors 
will introduce bias as they may prompt participants to report more adverse effects. 
Therefore, we judged his study to be of high risk for this domain. Al-Aloul does not report 
blinding of outcome assessors so we have contacted him for further information and so 
rate this as unclear risk of bias for now. Conway reports that the person asking about 
adverse effects is unaware of participants allocation, so we judged his study to be low 
risk of bias for this domain.  
Participant reported symptom scores - As above, Al-Aloul does not mention blinding of 
outcome assessors so we have contacted him for further information and judged this 
domain to have an unclear risk of bias.  
6.3.3 Incomplete outcome data (attrition bias)   
Prayle reported that originally 9 participants were randomised to each group. He reported 
lung function data for all 18 participants, so this domain is low risk of bias for this 
outcome. There were 4 withdrawals, with 3 being changed to a different antibiotic and 1 
withdrawing consent. It is possible that they were changed to a different antibiotic due to 
nephrotoxicity, so we will contact Prayle for more information. Nephrotoxicity data was 
only provided for 7 patients in each group due to the withdrawals. Although the number 
of withdrawals were equal between groups, we cannot tell exactly why patients were 
changed antibiotic and therefore it was hard to judge this domain and so we will rank it 
as unclear risk of bias for now.  
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Al-Aloul’s study had no withdrawals and he fully reported data for each outcome for 20 
participants in the nebulised group and 20 in the intravenous group. Therefore, we judged 
this domain as low risk for the outcomes, other than for eradication of infection. He did, 
however, report that only 15 sputum samples were collected and only 13 could be used. 
Therefore, we judged his study to be at high risk of bias for the eradication of infection 
outcome.   
Conway’s described 9 withdrawals and provided reasons for each of them. He also 
analysed the data as intention to treat so we judged this as low risk of bias.  
Latzin originally randomised 127 participants, 64 to the ceftazidime and 63 meropenem. 
He describes the reasons for the withdrawals (5 did not grow PA, 2 required additional 
oral antibiotics and 2 had their therapy changed during the trial). Latzin reported that 4 
withdrew from the ceftazidime group and 5 from the meropenem group. This would leave 
60 in the ceftazidime group and 58 in the meropenem group. However, he reported data 
for 59 participants in each group. We have contacted him for more information on this 
but have judged this domain as unclear for now.  
6.3.4 Selective reporting (reporting bias)  
For all 4 of the studies we were unable to retrieve the study protocol, so it was difficult 
to assess for selective outcome reporting. Prayle reported measuring FEV1/FVC ratio at 
the start and end of treatment but did not report this outcome so we judged this study to 
have high risk of bias for this domain. Conway reports collecting sputum samples twice 
weekly from each participant but does not present any results of this and so we rank this 
study to have a high risk of bias for this domain. Latzin reports measuring a clinical score 
and provides baseline clinical score data and reports there was a significant fall in both 
groups at day 5 and 12. However he does not provide the mean or standard deviation for 
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the scores at day 5 or 12 so we rank this study to have high risk of bias for this domain. 
Al-Aloul reports all outcomes that he states in the methods but as we were unable to 
access the protocol we judged this domain as unclear risk of bias.  
6.3.5 Other potential sources of bias   
In both Prayle and Al-Aloul’s study we did not identify any other potential sources of 
bias so we judged this domain to be low risk of bias.  
An issue that arose with Latzin’s study was that we did not calculate the same mean 
differences as him, so we contacted him for more information. This made interpreting the 
tables difficult, so we judged this to have high risk of bias.  
There was a unit of analysis issue in Conway’s study as participants were able to enrol 
twice into the study. There was also an issue of a different combinations of antibiotics 
used in the dual therapy group and there was no individual data for each of the 
combinations. We therefore judged Conway’s study to have a high risk of bias for this 
domain. 
6.4 Effects of interventions 
6.4.1 Intravenous meropenem & tobramycin versus intravenous 
ceftazidime & tobramycin 
This comparison of intravenous meropenem and intravenous tobramycin compared to 
intravenous ceftazidime and intravenous tobramycin included one trial, with 118 
participants data included in the analysis.251 For analysis of this data, I contacted the 
statistician for advice as we could not calculate the same mean difference as Latzin. The 
study provided us with pre and post treatment means and standard deviations for each 
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group and an overall mean difference with confidence intervals. As we were not provided 
with mean changes and standard deviations for each group overall, we were not able to 
input this data into RevMan in a normal manner. Therefore, the statistician advised us to 
use Latzin’s reported results and use the generic inverse variance (GIV) method on 
RevMan. This enabled us to input the mean difference and confidence intervals which 
allowed us to work out the standard error. 
Primary outcomes 
1. Nephrotoxicity 
a. serum (blood) creatinine levels 
Latzin reported the mean (SD) baseline creatinine to be 0.62 (0.20) and the post treatment 
mean (SD) to be 0.64 (0.25) in the meropenem group. In the ceftazidime group the mean 
(SD) baseline creatinine was 0.64 (0.23) and the post treatment mean (SD) was 0.65 
(0.23). Latzin did not report the mean change for each group or their standard deviations 
but reported the mean difference as 0.03 (95% CIs of -0.0.5 to 0.10). We used the generic 
inverse variance method to analyse this data. I used the fixed effect model as only one 
study is included in this analysis at the moment so there is no heterogeneity. As there is 
only one study included so far in this comparison, Cochrane recommends that you turn 
off the button to pool the data as there is no data to pool. Below is a screenshot of the 
data inputted into RevMan and the corresponding forest plot. (Figure 6.2) As the 
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confidence intervals cross the vertical line we can conclude there is no statistically 
significant difference between the effect of the treatments on creatinine levels.  
 
Figure 6.2 - Data analysis and forest plot of serum creatinine in Latzin’s study  
b. creatinine clearance 
Latzin did not measure or report creatinine clearance in this study.   
c. urinary excretion of protein 
Latzin did not measure or report urinary excretion of protein in this study.   
d. urinary excretion of biomarkers of proximal tubular toxicity 
Latzin did not measure or report urinary excretion of biomarkers of proximal tubular 
toxicity in this study.  
e. urine output (mL/kg/h) 
Latzin did not measure or report urine output in this study.  
Secondary outcomes 
1. Eradication of respiratory infection 
Latzin reported that sputum cultures were taken from participants before and after 
treatment. Although Latzin reported number of PA types and Pseudomonas coliform 
units (CFUs) this does not represent eradication of infection. In this study there was 3 
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different uses for the antibiotics; a group with chronic PA without an exacerbation where 
the antibiotics were used for suppression, a group with chronic PA experiencing an acute 
exacerbation and a final group who grew PA for the first time. Therefore, the outcome of 
eradication of infection was only relevant for group 3, however it was not reported. Latzin 
did, however, report the mean (SD) baseline Pseudomonas CFUs (108/g sputum) to be 
2.37 (2.73) and post treatment mean (SD) to be 1.26 (2.06) for the meropenem group. In 
the ceftazidime group the mean (SD) baseline Pseudomonas CFUs (108/g sputum) was 
2.07 (2.58) and post treatment mean (SD) to be 0.55 (0.94). Latzin did not report the 
mean change for each group or their standard deviations but reported the mean difference 
in Pseudomonas CFUs as 1.09 (95% CIs −0.12 to +2.30) and that it was not statistically 
significant. We were able to use this data in a generic inverse variance analysis which 
can be seen below. (Figure 6.3) As the confidence intervals cross the vertical line we can 
conclude there is no statistically significant difference between the effect of the 
treatments on Pseudomonas density.  
 
Figure 6.3 - Data analysis and forest plot of eradication of infection in Latzin’s study 
2. Participant-reported symptom scores 
Latzin did not measure or report participant reported symptom scores.    
3. Lung function parameters 
a. FEV1 
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Latzin reported the mean (SD) baseline FEV1 % predicted to be 52.2 (27.1) and post 
treatment mean (SD) to be 57.3 (26.8) in the meropenem group. In the ceftazidime group 
the mean (SD) baseline FEV1 % predicted was 55.3 (24.8) and the post treatment mean 
(SD) was 71.2 (21.0). Latzin did not report the mean change for each group or their 
standard deviations but did report the mean difference between the groups as 7.49 (95% 
CIs -10.44 to 25.43) and that it was not statistically significant. I inputted this data into a 
generic inverse variance analysis and this can be seen in the screenshot below along with 
the corresponding forest plot. (Figure 6.4) When looking at pre and post treatment FEV1 
% predicted it seems that ceftazidime improved it more than the meropenem. However, 
Latzin reports calculating the mean difference by Meropenem – Ceftazidime and gives a 
positive mean difference which would indicate that meropenem improves FEV1 % 
predicted the most. Even though I have used their results of mean difference into the 
analysis, I am still not convinced they are correct and so have contacted the author for 
more information on how they worked it out. As the confidence intervals cross the 
vertical line we can conclude there is no statistically significant difference between the 
effect of the treatments on FEV1.  
 
Figure 6.4 - Data analysis and forest plot of FEV1 in Latzin’s study 
b. FVC 
Latzin reported the mean (SD) baseline FVC % predicted to be 68.5 (24.9) and post 
treatment mean (SD) to be 72.4 (22.9) in the meropenem group. In the ceftazidime group 
the mean (SD) baseline FVC % predicted was 66.4 (20.6) and the post treatment mean 
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(SD) to be 71.2 (21.0). Latzin did not report the mean change for each group or their 
standard deviations but did report the mean difference as 1.22 (95% CIs -6.54 to 8.99) 
and that it was not statistically significant. Again, when looking at the results at a first 
glance it seems ceftazidime is better at increasing FVC % predicted and so I have 
contacted the author to clarify how he calculated the mean difference. Below is a 
screenshot of the data inputted and the corresponding forest plot. (Figure 6.5) As the 
confidence intervals cross the vertical line we can conclude there is no statistically 
significant difference between the effect of the treatments on FVC.  
 
Figure 6.5 - Data analysis and forest plot of FVC in Latzin’s study 
c. FEV1/FVC ratio 
Latzin did not measure or report FEV1/FVC ratio in this study.   
4. Participant-reported QoL scores 
Latzin did not measure or report participant-reported QoL scores in this study.   
5. Adverse effects of treatment 
Latzin reported 11 side effects in the meropenem group (nausea in 2 patients; headache 
in 2 patients; diarrhoea in 3 patients; allergic reactions in 2 patients; nose bleeding in 1 
patient and fatigue in 1 patient). Latzin reported 10 patients of the CEF group (nausea in 
3 patients, headache in 1 patient; diarrhoea in 3 patients; allergic reaction in 1 patient; 
acute pancreatitis in 1 patient and recurrent problems with the IV-line in 1 patient). Below 
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is the data inputted and the corresponding forest plot. (Figure 6.6) As the box is to the 
right of the graph that suggests that ceftazidime is favourable (i.e. gives less side effects). 
However, as the ‘whiskers’ which represent the confidence interval are cross the vertical 
line (line of no effect) this suggest that the result is not statistically significant.  
 
Figure 6.6 - Data analysis and forest plot of adverse effects in Latzin’s study 
 
6.4.2 Morning versus evening antibiotic dosing 
This comparison of morning versus evening dose of tobramycin included one trial, with 
18 participants data included in the analysis.252  
Primary outcomes 
1. Nephrotoxicity 
a. serum (blood) creatinine levels 
Prayle measured serum creatinine levels at the start of the study (baseline) and reported 
these. However, he did not measure or report serum creatinine levels at the end of the 
study, so we cannot calculate the mean change.    
b. creatinine clearance 
Prayle did not measure or report creatinine clearance in this study. 
c. urinary excretion of protein 
Prayle did not measure or report urinary excretion of protein in this study. 
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d. urinary excretion of biomarkers of proximal tubular toxicity 
Prayle provided mean change and standard deviation of biomarkers for 7 participants in 
the morning group and 7 participants in the evening group.  
Prayle reported the mean (CI) change in urinary excretion of KIM1/Cr in the morning 
tobramycin group to be 0.01 (-0.43 to 0.46) and 0.74 (0.26 to 1.22) for the evening group. 
Prayle reported a mean difference of 0.73 (95% CIs 0.14 to 1.32) with p=0.018. Below 
is a screenshot of the data inputted for analysis using the fixed effects model and the 
corresponding forest plot. (Figure 6.7) We used the fixed effects model as only one trial 
is included in the analysis and so there is no heterogeneity. As the p value is <0.05 we 
can conclude that the time of day of tobramycin dosing has a statistically significant effect 
on KIM1 level.  
 
Figure 6.7 - Data analysis and forest plot of KIM1 in Prayle’s study 
Prayle reported the mean (CI) change in urinary excretion of CysC/Cr in the morning 
tobramycin group to be -16.6 (95% CIs -51.0 to 17.8) and 29.6 (- 45.2 to 104.3) for the 
evening group. Prayle reports a mean difference of 46.2 (95% CIs -30.7 to 123.0) with 
p=0.20. Below is a screenshot of this data and the forest plot. (Figure 6.8) As the p value 
is above 0.05 the effect of time of dosing does not have a statistically significant effect 
on the CysC/Cr levels.  
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Figure 6.8 - Data analysis and forest plot of CysC in Prayle’s study 
Prayle reported the mean (CI) change in urinary excretion of NGAL/Cr in the morning 
tobramycin group to be 10.1 (-144.7 to 164.9) and 12.9 (-76.9 to 102.8) for the evening 
group. Prayle reports a mean difference of -0.01 (95% CIs -2.47 to 2.43) with p=0.99 
which is therefore not statistically significant. From entering the data into RevMan we 
get a mean difference of -2.80 (95% CIs -146.19 to 140.59) with a p value= 0.9701. The 
difference in calculations is because Prayle performed a log transform to the data before 
performing the t-test.  Either way the treatment effect is not statistically significant. 
Below is a screenshot of the data and forest plot on RevMan. (Figure 6.9)  
 
Figure 6.9 - Data analysis and forest plot of NGAL in Prayle’s study 
Prayle reported the mean (CI) change in urinary excretion of IL-18/Cr in the morning 
tobramycin group to be -5.72 (-34.3 to 22.9) and 139.3 (-221.1 to 499.7) for the evening 
group. Prayle reports a mean difference of 0.2 (95% CIs -0.6 to 1.0) with p=0.59. From 
entering the data into RevMan using a fixed effects model we get a mean difference of    
-145.02 (95% CIs -434.61 to 144.57), p=0.3457. Again, the difference in calculations is 
because Prayle performed a log transform to the data before performing the t-test. Either 
way the p value is greater than 0.05 meaning it is not statistically significant. Below is 
the screenshot of data inputted into RevMan with the corresponding forest plot. (Figure 
6.10) 
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Figure 6.10 - Data analysis and forest plot of IL-18 in Prayle’s study 
Prayle reported the mean (CI) change in urinary excretion of NAG/Cr in the morning 
tobramycin group to be 0.037 (0.002 to 0.07) and 0.052 (-0.001 to 1.034) for the evening 
group. Prayle reports a mean difference of 0.79 (95% CIs -0.94 to 2.52) with p=0.33. 
From entering the data into RevMan using a fixed effects model we get a mean difference 
of -0.01 (95% CIs -0.07 to 0.04), p=0.5739. The difference in calculations is because 
Prayle performed a log transform to the data before performing the t-test.  Either way the 
p value is greater than 0.05 meaning it is not statistically significant. Below is a screenshot 
of the data inputted and the forest plot. (Figure 6.11) 
 
Figure 6.11 - Data analysis and forest plot of NAG in Prayle’s study 
e. urine output (mL/kg/h) 
Prayle did not measure or report urine output in this study. 
Secondary outcomes 
1. Eradication of respiratory infection 
Prayle did not measure or report eradication of respiratory infection in this study. 
2. Participant-reported symptom scores 
Prayle did not measure or report participant reported symptom scores in this study. 
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3. Lung function parameters 
a. FEV1 
As the FEV1 (L) was provided as the median change and interquartile range it may 
suggest the data is skewed. Therefore, we chose to report this narratively as it may not be 
appropriate to use in an analysis. FEV1 data was provided for 9 participants in the 
morning group and 9 participants in the evening group. Prayle reports the median (IQR) 
change (end - initial) in the FEV1 (L) of the morning group as 0.19 (0.07 to 2.20) 
compared to 0.23 (0.19 to 0.28) in the evening group.  
b. FVC 
FVC data was provided for 9 participants in the morning group and 9 participants in the 
evening group. The FVC (L) is also presented as the median change from baseline and 
an interquartile range and was 0.32 (-0.01 to 0.38) for the morning group and 0.18 (-0.01 
to 0.29) for the evening group.  
c. FEV1/FVC ratio 
Prayle stated that he measured FEV1/FVC however did not report this.  
4. Participant-reported QoL scores 
Prayle did not measure or report Participant-reported QoL scores in this study. 
5. Adverse effects of treatment 
Prayle did not measure or report adverse effects of treatment as far as we are aware in 
this study. 
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6.4.3 Nebulised versus intravenous antibiotics 
This comparison of nebulised versus intravenous antibiotics included one trial, with 10 
participants in each group. However, as it was a cross-over trial, all participants received 
both treatment arms therefore there was 20 participants’ data for each arm.253   
Primary outcomes 
1. Nephrotoxicity 
a. serum (blood) creatinine levels 
Al-Aloul reported the mean and standard deviation of baseline serum creatinine levels 
and also percentage change in serum creatinine from baseline. In the nebulised group 
there was a mean change (SD) in serum creatinine of 4.3% (9.4) and 3.6% (10.4) in the 
intravenous group. He reported a mean difference between treatments of 0.7 (95% CIs    
-6.8 to 5.4), p=0.83. Below is a screenshot of the data inputted for analysis using the fixed 
effects model and the corresponding forest plot. (Figure 6.12) We used the fixed effects 
model as only one trial is included in the analysis and so there is no heterogeneity. As the 
p value is >0.05 we can conclude that there is no statistically significant difference 
between the use of nebulised or intravenous antibiotics on the serum creatinine levels.  
 
Figure 6.12 - Data analysis and forest plot of serum creatinine in Al-Aloul’s study 
b. creatinine clearance 
Al-Aloul reported the mean and standard deviation of baseline creatinine clearance and 
percentage change in creatinine clearance from baseline. In the nebulised group there was 
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a mean change (SD) in creatinine clearance of 23.9% (48.4) and 26.1% (35.0) in the 
intravenous group. He reported a mean difference between treatments of 2.2 (95% CIs    
-24.0 to 28.4), p=0.87. Below is a screenshot of the data inputted for analysis and the 
corresponding forest plot. (Figure 6.13) As the p value is >0.05 we can conclude that 
there is no statistically significant difference between the use of nebulised or intravenous 
antibiotics on the creatine clearance. 
 
Figure 6.13 - Data analysis and forest plot of creatinine clearance in Al-Aloul’s study 
c. urinary excretion of protein 
Al-Aloul reported the mean (SD) change in urinary excretion of protein in the nebulised 
group to be 0.003 (0.16) and 0.59 (0.63) in the intravenous group. Al-Aloul reported a 
mean difference of 0.58 (95% CIs 0.30 to 0.87), p=0.0005. Below is a screenshot showing 
the data inputted in RevMan and the corresponding forest plot. (Figure 6.14) As the p 
value is <0.05 we can conclude that the use of intravenous compared to nebulised 
antibiotics has a statistically significant effect on urinary excretion of protein. 
 
Figure 6.14 - Data analysis and forest plot of urinary protein excretion in Al-Aloul’s study 
d. urinary excretion of biomarkers of proximal tubular toxicity 
Al-Aloul reported the mean (SD) change in urinary excretion of NAG in the nebulised 
group to be 0.02 (0.51) and 0.74 (0.44) in the intravenous group. Al-Aloul reported a 
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mean difference of 0.72 (95% CIs 0.37 to 1.07), p=0.0004 between the two groups. Below 
is a screenshot of this data and the forest plot. (Figure 6.15) As the p value is <0.05 we 
can conclude that the use of nebulised compared to intravenous antibiotics has a 
statistically significant effect on urinary excretion of NAG.  
 
Figure 6.15 - Data analysis and forest plot of NAG in Al-Aloul’s study 
 
Al-Aloul reported the mean (SD) change in urinary excretion of AAP in the nebulised 
group to be -0.37 (0.69) and 0.82 (0.62) in the intravenous group. Al-Aloul reported a 
mean difference of 1.19 (95% CIs 0.70 to 1.68), p=0.0001 between the two groups. Below 
is a screenshot of this data and the forest plot. (Figure 6.16) As the p value is <0.05 we 
can conclude that the use of nebulised compared to intravenous antibiotics has a 
statistically significant effect on urinary excretion of AAP.  
 
Figure 6.16 - Data analysis and forest plot of AAP in Al-Aloul’s study 
Al-Aloul reported the mean (SD) change in urinary excretion of β2 Microglobulin in the 
nebulised group to be 0.20 (0.41) and 0.64 (0.50) in the intravenous group. Al-Aloul 
reported a mean difference of 0.44 (95% CIs 0.16 to 0.72), p=0.0046 between the two 
groups. Below is a screenshot of this data and the forest plot. (Figure 6.17) As the p value 
is <0.05 we can conclude that the use of nebulised compared to intravenous antibiotics 
has a statistically significant effect on urinary excretion of β2 Microglobulin.  
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Figure 6.17 - Data analysis and forest plot of β2 Microglobulin in Al-Aloul’s study 
Al-Aloul reported the mean (SD) change in urinary excretion of Collagen IV in the 
nebulised group to be 0.16 (0.33) and 0.31 (0.41) in the intravenous group. Al-Aloul 
reported a mean difference of 0.15 (95% CIs 0.13 to 0.43), p=0.29 between the two 
groups. Below is a screenshot of this data and the forest plot. (Figure 6.18) As the p value 
is above 0.05 we can conclude that the use of nebulised compared to intravenous 
antibiotics does not have a statistically significant effect on urinary excretion of Collagen 
IV.  
 
Figure 6.18 - Data analysis and forest plot of Collagen IV in Al-Aloul’s study 
e. urine output (mL/kg/h) 
Al-Aloul did not measure or report urine output in this study. 
Secondary outcomes 
1. Eradication of respiratory infection 
Al-Aloul did not report eradication of infection as such but reported Pseudomonas CFUs. 
Only 13 sputum samples could be analysed but it does not state which groups they were 
from and so we have contacted Al-Aloul for more information regarding this. Al-Aloul 
reported the mean (SD) baseline PA density to be 7.31 log10 cfu/mL (3.11) and post 
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treatment mean (SD) to be -2.41 log10 cfu/mL (0.97) for the nebulised group. In the 
intravenous group the mean (SD) baseline PA density was 6.92 log10 cfu/mL (1.93) and 
post treatment mean (SD) to be -1.56 log10 cfu/mL (1.31). Al-Aloul did not report the 
mean change for each group or their standard deviations but reported the mean difference 
in PA density as 0.85 log10 cfu/mL (95% CIs 0.03 to 1.67), p=0.05. As we did not have 
the mean change for each group, I had to use the GIV to input this data into my analysis. 
As for all other outcomes they have calculated the mean difference the opposite way 
around to us, I had to change the labels on this graph around so that it would be the right 
direction for entering their numbers straight into. Below is a screenshot of my data 
inputted into RevMan and corresponding forest plot. (Figure 6.19) As the confidence 
interval touches the line and their p value is not less than 0.05 then there is no statistically 
significant difference between treatments on PA density.  
 
Figure 6.19 - Data analysis and forest plot of eradication of infection in Al-Aloul’s study 
2. Participant-reported symptom scores 
Al-Aloul reported the mean and standard deviation participant reported symptom scores 
that were obtained at the end of the treatment. The mean (SD) participants reported 
symptom score for the nebulised group was 8.1 (1.3) and 8.5 (1.1) for the intravenous 
group. Al-Aloul reported the mean difference between treatments as 0.4 (95% CIs -0.34 
to 1.14), p=0.29. Below is a screenshot of my data inputted into RevMan and 
corresponding forest plot. (Figure 6.20) There is no significant difference between 
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nebulised antibiotics when compared to intravenous antibiotics on participant reported 
symptom score.   
 
Figure 6.20 - Data analysis and forest plot of participant reported symptom scores in Al-
Aloul’s study 
3. Lung function parameters 
a. FEV1 
Al-Aloul reported the mean (SD) change in FEV1 (% of predicted) across the course of 
the treatment to be 19.9 (11.3) for the nebulised group and 16.4 (8.5) for the intravenous 
group. The mean difference between the two groups was reported as 3.6 (95% CIs 9.7 to 
2.6), p=0.26. As the p value is above 0.05 we can conclude there is no statistically 
significant difference between the effect of the two treatments on FEV1 (% predicted). 
See screenshot below for my data analysis and forest plot. (Figure 6.21) 
 
Figure 6.21 - Data analysis and forest plot of FEV1 in Al-Aloul’s study 
b. FVC 
Al-Aloul reported the mean (SD) change in FVC (% of predicted) across the course of 
the treatment to be 18.6 (14.6) for the nebulised group and 13.1 (8.6) for the intravenous 
group. The mean difference between the two groups was reported as 5.5 (95% CIs -2.9 
to 1.9), p=0.16. As the p value is above 0.05 we can conclude there is no statistically 
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significant difference between the effect of the two treatments on FVC (% of predicted). 
See below for my data analysis and forest plot. (Figure 6.22) 
 
Figure 6.22 - Data analysis and forest plot of FVC in Al-Aloul’s study 
c. FEV1/FVC ratio 
Al-Aloul did not measure or report FEV1/FVC ratio in this study. 
4. Participant-reported QoL scores 
Al-Aloul did not measure or report Participant-reported QoL scores in this study. 
5. Adverse effects of treatment 
Al-Aloul reported 11 adverse effects in the nebulised group and 9 adverse effects in the 
intravenous group. As the confidence interval crosses the vertical line (line of no effect) 
we can conclude that there is no statistically significant difference between treatments on 
adverse effects. Below is the data inputted into RevMan and the corresponding forest 
plot. (Figure 6.23) 
 
Figure 6.23 - Data analysis and forest plot of adverse effects in Al-Aloul’s study 
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6.4.4 Single IV antibiotic vs combination IV antibiotics 
This comparison of a single intravenous antibiotic compared to a combination of 
intravenous antibiotics included one trial, with 71 participants data included in the 
analysis.254 Conway only reported the mean and standard deviation of the outcomes at 
different time points. He did not report mean changes for any of the outcomes or mean 
differences between the groups. I contacted the CRG’s statistician, AK, for further advice 
and she suggested I would not be able to include these results in analysis and so should 
report them narratively. We have contacted Conway to ask if he will provide individual 
patient data but as this study was carried out in 1997, it is unlikely he will respond. 
Primary outcomes 
1. Nephrotoxicity 
a. serum (blood) creatinine levels 
to be completed 
For the single IV antibiotic group Conway reported the mean (SD) serum creatinine on 
day 1 was 70 (16) and on day 12 was 72 (13). Although Conway did not report the mean 
change, he states that the difference is non-significant. For the combination IV antibiotic 
group, the mean (SD) serum creatinine on day 1 was 73 (10) and on day 12 was 71 (14). 
Again, Conway reports that the difference between creatinine between the time points is 
not statistically significant.  
b. creatinine clearance 
For the single IV antibiotic group Conway reported the mean (SD) creatinine clearance 
on day 1 was 109 (54) and on day 12 was 94 (29). Although Conway did not report the 
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mean change, he states that the difference is non-significant. For the combination IV 
antibiotic group, the mean (SD) serum creatinine on day 1 was 109 (42) and on day 12 
was 91 (34). Conway reports that the difference in creatinine clearance between the time 
points in the combination IV group is less than 0.01 and so is statistically significant.  
c. urinary excretion of protein 
Conway did not measure or report urinary excretion of protein in this study. 
d. urinary excretion of biomarkers of proximal tubular toxicity 
Conway did not measure or report urinary excretion of biomarkers of proximal tubular 
toxicity in this study. 
e. urine output (mL/kg/h) 
Conway did not measure or report urine output in this study. 
Secondary outcomes 
1. Eradication of respiratory infection 
Sputum cultures were collected twice weekly for microscopy, culture, and sensitivity 
however they were not reported.  
2. Participant-reported symptom scores 
Conway did not measure, or report participant reported symptom scores in this study. 
3. Lung function parameters 
a. FEV1 
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Conway reported the mean (SD) FEV1 (L) for the single IV group as 1.52 (0.68) for day 
1, 1.58 (0.75) for day 5 and 1.66 (0.82) for day 12. Conway reported the mean (SD) FEV1 
(L) for the combination IV group as 1.62 (0.78) for day 1, 1.87 (0.93) for day 5 and 1.92 
(0.89) for day 12. Conway reports that there was no statistically significant difference in 
the FEV1 between the two groups on day 1, day 5 or day 12.  
b. FVC 
Conway reported the mean (SD) FVC (L) for the single IV group as 2.44 (1.04) for day 
1, 2.45 (1.04) for day 5 and 2.56 (1.21) for day 12. He reported the mean (SD) FVC (L) 
for the combination IV group as 2.34 (1.0) for day 1, 2.74 (1.05) for day 5 and 2.93 (1.12) 
for day 12. Conway reports that there was no statistically significant difference in the 
FVC between the two groups on day 1, day 5 or day 12.  
c. FEV1/FVC ratio 
Conway did not measure or report urinary FEV1/FVC ratio in this study.  
4. Participant-reported QoL scores 
Conway did not measure or report participant-reported QoL scores in this study.  
5. Adverse effects of treatment 
Conway reported that there were 37 reports of adverse effects in 33 participants for the 
single IV group compared to 37 adverse effects in 26 participants in the combination IV 
group.  
6.5 Discussion 
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6.5.1 Summary of main findings 
Our review so far includes 4 studies looking at different strategies that may prevent 
kidney injury in CF patients that is caused by intravenous antibiotics. As none of these 4 
studies look at the same comparison we could not include them in a meta-analysis. I will 
now summarize the main findings of my review so far for each comparison.  
IV Meropenem & IV Tobramycin versus IV Ceftazidime & IV Tobramycin 
Latzin’s study which randomised 118 participants failed to demonstrate a superior 
antibiotic combination for reducing nephrotoxicity. He compared intravenous 
meropenem plus tobramycin to intravenous ceftazidime and tobramycin but there was no 
significant difference in serum creatinine levels between the two groups.  There was also 
no significant different in efficacy, lung function or adverse effects between the two 
groups.  
Morning versus evening antibiotic dosing 
Prayle’s study which randomised 18 participants demonstrated a statistically significant 
rise in urinary excretion of KIM1 when tobramycin is administered in the evening 
compared to administration in the morning. Administering antibiotics in the evening may 
cause an increase in the risk of nephrotoxicity. Glomerular filtration is highest in the 
daytime compared to the night time which means it has a circadian rhythm.255 At night 
time, GFR is reduced meaning that the kidneys are exposed to tobramycin for longer 
which may cause an increase in proximal tubule damage. However, there was not a 
statistically significant difference between the two groups in any other urinary biomarkers 
of proximal tubular toxicity. Prayle was only able to collect urine samples from 14 
participants in total and so a limitation of this study was the small sample size. There was 
a greater median increase in FEV1 in the evening group but a greater median increase in 
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FVC in the morning group, however neither of these results were statistically significant. 
Although Prayle looked at lung function, he did not address effect on PA density, 
participant reported symptom score or adverse effects. However, as the same dose and 
antibiotic was used it is unlikely that just by changing the time of the day it is 
administered that there would be an effect on these outcomes. 
Nebulised versus intravenous antibiotics 
Al-Aloul’s cross-over study which randomised 10 participants to each group originally 
failed to demonstrate any difference in serum creatinine levels or creatinine levels, when 
comparing nebulised tobramycin to intravenous tobramycin in an acute exacerbation. Al-
Aloul demonstrated a significant increase in urinary excretion of protein in the 
intravenous tobramycin group compared to the nebulised tobramycin group. He also 
concluded that there was a significant increase in urinary excretion of three biomarkers 
of proximal tubular toxicity (NAG, AAP, β2 Microglobulin) in the intravenous group 
compared to the nebulised group. This suggests that a strategy to reduce nephrotoxicity 
is to use of nebulised tobramycin in an acute exacerbation rather than intravenous 
antibiotics. Interestingly, nebulised antibiotics increased lung function and reduced 
sputum PA density more than the intravenous antibiotics although there was not a 
significant difference between the two groups. Interestingly though, there was a higher 
mean participant reported symptom score (participants felt more back to normal) for the 
intravenous group compared to the nebulised group. There were less adverse effects seen 
in the intravenous group than the nebulised group, but this was not statistically 
significant. 
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Single intravenous antibiotic versus combination intravenous antibiotics 
Conway’s study which randomised 71 participants reported a statistically significant 
decrease in creatinine clearance in the combination of intravenous antibiotics group over 
the course of the treatment. He did not, however, directly compare the creatinine 
clearance in the single antibiotic group but states there was no significant difference in 
the change over the course of the treatment. There was no significant difference in serum 
creatinine levels over the course of the treatment in either the single or combination 
group. There was no statistical difference between the FEV1 or FVC between the two 
groups on day 1, day 5 or day 12. 
6.5.2 Overall completeness and applicability of the evidence 
At this present time, the evidence for this review is not complete as there may be other 
studies that can be included in the comparisons, however, we are still waiting for 
additional information from the authors. Therefore, I will assess the completeness and 
applicability of the studies we have included so far.  
As far as we can tell so far, there is lack of evidence on dosing regimens and lack of 
studies regarding the use of fluids. There is also only one ongoing study addressing the 
use of statins. Therefore, the evidence so far does not allow us to address all the strategies 
that may exist to minimise nephrotoxicity caused by intravenous antibiotics. 
Both Al-Aloul and Conway only included adult participants in their study and so we 
cannot generalise the results of this study to children, as it may only be applicable to 
adults. Prayle’s study only included children, and again we do not know whether his 
results are applicable to adults. Latzin however included both adults and children in his 
study and so they are more applicable.   
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All studies in this review have a small sample size, in particular Prayle’s study who only 
included 18 participants. A small sample size may mean we cannot be certain about the 
true treatment effects and the results may not be representative. 
Although the four studies in this study address nephrotoxicity, they only look at it during 
or at the end of treatment. There are no studies that address nephrotoxicity as a long-term 
outcome and therefore the results are only applicable to acute exacerbations.  
Although Al-Aloul’s trial allowed us to compare the use of nebulised versus intravenous 
antibiotics in acute exacerbation, it is important to remember that he only looked at 
tobramycin. Just because nebulised tobramycin seems to reduce risk of nephrotoxicity 
when compared to intravenous use it does not mean that all nebulised antibiotics would 
have this same effect.  
Results from some of the trials included in this review may be less applicable now as they 
were conducted over 10 years, particularly Conway’s trial that was conducted over 20 
years ago.  
6.5.3 Quality of the evidence 
As we have not yet been able to assess all the evidence as we are awaiting further 
information from authors, it would be inappropriate at this stage to comment on the 
overall quality of the evidence for each comparison.  
When we have all the evidence for each comparison we will be able to create a summary 
of findings table for the individual comparisons. We will create the summary of findings 
table using the GradePro software. For each outcome, I will report the illustrative risk 
with the intervention and then the risk with the comparison (control or placebo).  I will 
then give the relative effect (RR or MD) with the 95% confidence intervals. I will state 
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how many studies and participants contributed to this. Where an outcome is not reported, 
I would specify this in the table with the description, “data not reported”. 
I will assess the overall quality of the evidence for each outcome using the Grading of 
Recommendations Assessment, Development and Evaluation (GRADE).256 The domains 
assessed with this tool include risk of bias, inconsistency, indirectness, imprecision, risk 
of publication bias and other factors such as dose response and large effect. For each 
outcome we will rank it as high, moderate, low, or very low along with comments 
explaining our choice. For a problem in any of the five areas assessed, you must class it 
as ‘serious’ or ‘very serious’. If you class it as ‘serious’, you must downgrade the quality 
rating by one level, whereas for ‘very serious’, you must downgrade it by two levels.  
We will assess risk of bias individually for each outcome by mainly looking at our risk 
of bias tool. We will assess evidence risk of bias by looking at sequence generation, 
allocation concealment, blinding, incomplete outcome data, selective outcome reporting 
and use of ITT analysis.   
We will assess for inconsistency by looking at how much heterogeneity there is between 
the studies. Clinical heterogeneity is where there are differences between the participants, 
interventions, or outcomes. Whereas methodological heterogeneity refers to 
inconsistencies between the study designs. Both types of heterogeneity can then create 
statistical heterogeneity. We may suspect heterogeneity if different studies report 
opposite effects of an intervention or different size of effects. We can also use statistical 
tests to identify heterogeneity.  
There are two types of indirectness that we will assess for; indirect comparison and 
indirect population or intervention or outcome. An indirect comparison is where two 
interventions you are interested in are both compared to another intervention and so rather 
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than being able to make a head to head comparison you have to make an indirect 
comparison. Indirect population may arise if the study only addresses adults, but you 
were also interested in children. Indirect intervention may arise if they only address a 
certain dose of a drug and indirect outcomes may occur if they only look at an endpoint 
rather than a change in an outcome over time.  
Imprecision may arise when the sample size is small or there are few dichotomous 
outcome events or if there are wide confidence intervals around the effect estimate. This 
can mean that you are less certain of what the exact effect of a treatment is.   
We will assess for publication bias by looking at whether there is a difference in effect of 
treatment in unpublished compared to published work. Publication bias arises when 
researchers only publish work that shows a significant effect of treatment. Funnel plots 
can also be used to test for publication bias as I mentioned earlier in this thesis.  
6.5.4 Potential biases in the review process 
Strengths 
Both myself and WC screened the studies, extracted the data, and assessed the risk of 
bias in the included the studies. By using two authors for screening it reduces the risk of 
excluding relevant studies.257 
Myself and WC individually extracted data from the included studies by hand using a 
data extraction form provided to us by our CRG. I then checked both forms for any 
differences or any mistakes and then was able to enter this data onto the online data 
extraction form on Covidence. By checking the data extraction forms it reduces the 
chance of errors.  
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Weaknesses  
Originally when screening the studies, I was overly inclusive in my approach. For 
example, if a study compared two types of nebulised treatments but a few participants 
also required intravenous antibiotics during the course, I included it. Being over inclusive 
led to a high number of conflicts on Covidence between myself and WC. However, when 
we met up to discuss the discrepancies WC reminded me that in the protocol we stated 
that all participants in at least one of the groups must be receiving intravenous antibiotics 
for it to be included. Even though some patients may be on IV antibiotics and nebulised 
antibiotics not all patients in one group were on this. Therefore, we would be unable to 
compare the two groups as they would have had different number of participants on IVs 
in the two groups and some patients may have had more courses of IV antibiotics 
throughout the trial than others. Therefore, we decided to exclude any studies looking at 
long term use of nebulised or oral antibiotics for prophylaxis as intravenous antibiotics 
may or may not be used in these studies and we cannot control for this. 
In the protocol we listed ‘eradication of infection’ as of our outcomes and stated that this 
would be a dichotomous outcome i.e. was the infection eradicated, yes or no. However, 
when looking at studies to be included, many of them were simply looking at antibiotic 
strategies for an acute exacerbation rather than eradication regimes. Therefore, the 
outcome eradication of infection was technically incorrect. Studies looking at eradication 
regimens may have looked at eradication of infection as a dichotomous outcome. 
However, the studies we have included so far look at PA sputum density instead which 
is a continuous outcome. It may be more appropriate to use the broader term 
‘microbiology’ as an outcome instead of ‘eradication of infection’ as this would 
encompass both eradication and sputum organism density.  
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6.6 Summary 
In this chapter I have discussed my methods, results, and findings of my Cochrane review, 
‘Strategies to prevent kidney injury from antibiotics in people with cystic fibrosis’. The 
results of this review so far have suggested that morning dosing of tobramycin rather than 
evening dosing may help to reduce kidney injury from intravenous antibiotics. It is also 
possible that using nebulised tobramycin in an acute exacerbation may reduce the risk of 
kidney injury rather than intravenous tobramycin. When I obtain more information from 
other study authors it may be possible that identify other effective strategies that can 
reduce the risk of kidney injury.  
In the next chapter, I will discuss the findings of my survey on antibiotic choice for CF 
patients in the UK.  
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CHAPTER 7: UK SURVEY TO ASSESS 
WHICH IV ANTIBIOTICS ARE USED TO 
TREAT CF RESPIRATORY 
EXACERBATIONS 
7.1 Background to the questionnaire 
7.1.1 Introduction 
In addition to undertaking our Cochrane Systematic Review, I thought it would be helpful 
to find out what antibiotics are being used for respiratory exacerbations. I thought this 
may depend on the organisms that were growing and whether they had ever grown 
Pseudomonas aeruginosa (PA) before. This may vary between hospital to hospital but 
may also vary between doctor to doctor.  
7.1.2 Overview of existing guidelines 
First, I looked online for any information in the guidelines regarding what antibiotics 
should be used. For unidentified organisms, the National Institute for Health and Care 
Excellence (NICE) guidelines in particular are very vague regarding antibiotic use in 
respiratory infection. They suggest using broad spectrum oral antibiotics or, if the 
infection is more severe, intravenous antibiotics, however, they do not specifically state 
which ones to use. The UK CF Trust lists specific intravenous antibiotics that should be 
used if an organism is identified and for most organisms a single agent can be used. It 
also lists specific criteria for when intravenous antibiotics are indicated e.g. fever, 
increased productive cough, fall in respiratory function or new signs on chest 
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auscultation. However, again there is no recommendations as to what intravenous 
antibiotic should be used in an acute exacerbation if the organism is unidentified. 
Therefore, we designed a questionnaire that would determine the most commonly used 
antibiotics in practice in this scenario.  
There is clear guidance from the CF Trust that in a clinically well patient with a new 
growth of PA, nebulised colistin and oral ciprofloxacin should be used. They suggest 
using intravenous anti-pseudomonal antibiotics before commencing eradication therapy 
if the patient is unwell. NICE in this case suggests using intravenous antibiotics alongside 
inhaled antibiotics. As there is clear guidance provided by the CF trust on eradication 
regimes for a new growth of PA that from our knowledge most centres follow, we felt 
there was no need to investigate this further.  
As mentioned above NICE suggests using inhaled antibiotics alongside intravenous 
antibiotics, however the UK CF trust recognises that most centres stop inhaled antibiotics 
in these instances. This is because it is thought that although there is little systemic 
absorption of inhaled aminoglycosides, it may contribute to renal toxicity, but data is 
conflicting on this issue. There have been cases of acute kidney injury in patients on 
inhaled aminoglycosides but other studies found no increase in risk of renal toxicity when 
on them.187,258 It may have been interesting to see whether centres use inhaled and 
intravenous aminoglycosides concomitantly for new growths of PA but we will not 
consider this in our questionnaire as our review is not looking at eradication regimes.   
For patients who are chronically infected with PA and that are unwell with an acute 
exacerbation NICE recommends that they should be treated with an oral antibiotic or two 
intravenous antibiotics of different classes. The CF Trust recommends for acute 
exacerbations with PA, a combination of 2 antibiotics with different mechanisms should 
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be used. A β-lactam (e.g. ceftazidime) or an anti-pseudomonal penicillin (e.g. 
Piperacillin-Tazobactam) should be used along with an aminoglycoside (e.g. 
tobramycin). The anti-pseudomonal colistin can be used but this is only usually used in 
more resistant strains of PA or if tobramycin is contraindicated.259 The UK CF Trust does 
not include gentamicin in its list of suitable PA treatments because as we know it is more 
harmful to the kidneys than tobramycin.260 
We can take away clear guidance on which specific antibiotics to use for new growth of 
PA. However, we have no guidance on what to use for unidentified organisms in a 
respiratory exacerbation. Also, we have a long list of antibiotics that can be used for PA 
infections (not the first growth) with not two specific ones being identified as best.  
We know from anecdotal reports that some centres are using renal toxic antibiotics 
(Ceftazidime and Tobramycin) as a standard IV regimen for all CF respiratory 
exacerbations, not just those associated with PA. We wanted to establish how widespread 
this practice was. Therefore, we thought it would be important to find out the UK practice 
on which specific intravenous antibiotics are used in different circumstances and if they 
use anything else alongside this. We were interested to see if any centres used any 
therapies that may protect the kidneys or any therapies that may increase the risk of 
kidney during intravenous antibiotic. To investigate this, I designed two online surveys 
that were sent out to paediatric and adult CF centres in UK centres. I will now go on to 
describe the methods I used to produce and distribute the survey and the results that were 
found.  
7.2 Methods  
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7.2.1 Audience 
Our target audience for the survey was the main adult and paediatric CF centres in the 
UK. The centres were listed on the CF Trust directory in the annual report and from this 
we were able to construct a list with their names and then later added their email 
addresses. There are 25 adult centres and 27 paediatric centres providing specialist care 
for CF according to the 2016 annual data report.1  
7.2.2 Designing the questions 
PA is the most common organism causing chronic infection and definitions have been 
invented based on infection status with this organism that are used to categorise 
patients.261 I designed the questionnaire based on these definitions which I have listed 
below.  
Definitions262  
Never – PA never cultured from sputum or cough swab. 
Free of infection – No growth of PA during the previous twelve months, having 
previously had a positive culture for PA. 
Intermittent infection – When 50% or less of months, when samples had been taken, were 
PA culture positive 
Chronic infection – When more than 50% of months, when samples had been taken, were 
PA culture positive. 
 
My questions were based on a short case vignette with similar scenarios but with patients 
of different ages in the adults one compared to the paediatric one. Case vignettes were 
used as FG advised me that it was easier to get across how unwell the patient was, and he 
thought it would make it more interesting for the doctors to read. The scenario in both 
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surveys highlighted that the patient would need intravenous antibiotics due to an 
unresolving respiratory exacerbation.   
I asked which antibiotics the centres would prescribe if the patient was in the ‘never’ 
category, ‘free of infection’ category and the ‘chronic infection’ category. I was 
interested to see whether some centres would start patients on anti-pseudomonal agents 
even though the patient had never grown PA before. I was also interested in the ‘free of 
infection’ category as to whether the time since the patient last grew PA would affect 
what they treated the patient with. Perhaps the more recently the patient grew PA, the 
more likely they would be to give anti-pseudomonal agents. 
For each of the three categories (‘never’, ‘free of infection’ and ‘chronic infection’) I 
asked if they would add in any other medication or therapies alongside the intravenous 
antibiotics. This question was non-specific as I wanted to know whether they added in 
any other antibiotics (oral or nebulised) or if they added in any renal protective agents 
e.g. fluids or statins.  
Next, we asked about renal function; whether they monitored it, how they monitored it 
and when. I asked if they would monitor it when on intravenous antibiotics rather than 
asking if they monitored it while on aminoglycosides. This is because they may not have 
given any answers saying aminoglycosides and I did not want this to lead them to go back 
and change their answers. Finally, we asked about whether they monitor hearing function 
and when. Please see appendix 1 and 2 for the paediatric and adult surveys, respectively.  
For the questions asking about what intravenous antibiotics they used we decided to use 
a text entry style format with an essay box. We chose this over multiple-choice answers 
as there are many different antibiotics that can be used and in many different 
combinations. We thought that if we wrote all these possible combinations out then the 
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list would be so long that they may struggle to find their answer. We discussed this at 
length and FG and myself decided that it would be much easier and quicker to give them 
an essay text box where they can write as much or as little as they like.  
For the question regarding what other medications or therapies they would add in we also 
chose to use a text box entry. This is because we did not want them to see our suggestions 
such as adding in statins or adding in fluids because this may create response bias with 
them answering how they think we want them to answer.  
For questions like do you test renal function we thought it would be much simpler to give 
them multiple choice options, for example ‘yes’ or ‘no’. As there are only two answers it 
is quick and easy to answer by simply clicking on their chosen option.  
7.2.3 Qualtrics software 
I created the surveys on the Qualtrics software which is a website that I was shown how 
to use by FG. The software has many different useful features which I will now go on to 
describe.  
First, I used the ‘Look & Feel’ icon which brought up the text box as seen in Figure 7.1. 
I was able to change the survey so that it only displayed one question per page. FG 
suggested this as he thought some doctors may answer the questionnaire on their mobile 
phones. By changing it so that there is one question per page, it prevents the need to scroll 
down the page and hopefully reduces the chance of people missing questions by mistake. 
On the ‘Look & Feel’ icon I was also able to change the text font, font size and colour to 
a style of my choice. I was also able to add in a back button which I thought would be 
useful in case the doctors had forgotten their previous answer.  
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Figure 7.1 Screenshot of ‘Look & Feel’ feature on Qualtrics 
 
When you highlight each individual question, there is an option that you can tick called 
‘force response’. If this button is ticked like as seen in Figure 7.2, then it ensures the 
respondent answers that question before they can move on to the next question. I chose 
to have turn on ‘force response’ for all my questions. I thought this would prevent 
respondents accidentally skipping a question or skipping questions they did not want to 
answer.  
 
Figure 7.2 – Screenshot of ‘Force Response’ feature on Qualtrics 
‘Display Logic’ feature allows you to only show certain questions to respondents who 
answer a previous question in a certain way. For example, for my question ‘Would you 
add in any other medications or therapies alongside the intravenous antibiotics?’, I set it 
up so that only if the respondent answered ‘Yes’ would they see the next question 
regarding what they would add in. If they answered ‘No’ then it would not show the 
respondent this second question as it was irrelevant to them and so would go straight to 
the next question after that. To do this I highlighted the question and simply clicked ‘Add 
Display Logic’. I then asked it to only display Q5 if they answered yes to Q4 as seen 
below in Figure 7.3  
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Figure 7.3 – Screenshot showing the ‘Display Logic’ feature on Qualtrics 
7.2.4 Survey distribution  
Qualtrics provided us a link for each of the two surveys which were emailed to the lead 
clinicians at each of the 27 paediatric and 25 adult centres. The results of the completed 
survey were recorded on Qualtrics. We emailed the survey on the 17/04/2018 to all 
centres and sent reminder emails on 14/05/2018 to those who had not completed the 
survey.  
7.2.5 Data collection 
On 07/06/2018 I exported the survey responses from Qualtrics into spreadsheets on 
Microsoft Excel. I used Microsoft Excel to collate the answers and analyse the results. 
We obtained responses from 23/27 paediatric centres and 15/25 of the adult centres. 
7.3 Results  
7.3.1 Data analysis  
The choice of IV antibiotics used by paediatric and adult CF centres in patients who had 
never grown PA is shown in Figure 7.4. 9/23 (39%) paediatric centres and 6/15 (40%) 
reported using tobramycin and ceftazidime in combination. 
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Figure 7.4 – Bar chart to show IV antibiotic use in paediatric and adult CF centres in the UK 
for a patient experiencing a respiratory exacerbation that has never grown Pseudomonas 
aeruginosa 
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been free from PA ever is shown in Figure 7.5. 13/23 (57%) paediatric centres and 10/15 
(67%) reported using tobramycin and ceftazidime in combination.  
 
Figure 7.5 - Bar chart to show IV antibiotic use in paediatric and adult CF centres in the UK 
for a patient experiencing a respiratory exacerbation that is ‘free of’ Pseudomonas aeruginosa 
infection 
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were mentioned. Other centres did not refer to a cut off time but for example said ‘More 
recent growth- more inclined for antipseudomonal antibiotics’. 
The choice of IV antibiotics used by paediatric and adult CF centres in patients who have 
chronic PA infection is shown in Figure 7.6. 23/23 (100%) paediatric centres and 12/15 
(80%) reported using tobramycin and ceftazidime in combination.  
 
Figure 7.6 - Bar chart to show IV antibiotic use in paediatric and adult CF centres in the UK for 
a patient experiencing a respiratory exacerbation that has a chronic Pseudomonas aeruginosa 
infection 
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physiotherapy. Other adult centres mentioned exercise, paracetamol, overnight fluids, 
and aminophylline. 4 paediatric centres mentioned that they would add in colistin 
nebulisers if they weren’t already on them. One adult centre said they would remove 
nebulised and oral antibiotics while the patient was on intravenous antibiotic and another 
said they would review nebulised antibiotics. 
19/22 (86%) paediatric centres said they monitor renal function in those on intravenous 
antibiotics compared to 15/15 (100%) adult centres. In all CF centres that monitor renal 
function, they do so by monitoring serum urea and creatinine. 14/19 (74%) paediatric 
centres also mentioned looking at tobramycin levels compared to only 4/15 (27%) adult 
centres. Out of the centres that monitor renal function 11/19 (58%) and 8/15 (53%) of 
them do it at baseline, before starting intravenous antibiotics. 
18/22 (82%) of the paediatric centres assess hearing in those on intravenous antibiotics 
with 10 out of the 18 centres assessing it annually. In those that monitor it but do not 
assess it annually, they suggested they would only test hearing in those that receive 
frequent IVs, those about to begin NTM eradication, those with high serum 
aminoglycoside levels or those with symptoms. Only 4/15 (27%) of the adult centres that 
responded to the questionnaire test for hearing. Out of these 4, one centre test it annually 
and the other 3 centres test it if symptoms appear.  
7.4 Discussion 
7.4.1 Main findings 
It was interesting that many centres chose to prescribe anti-pseudomonal antibiotics to 
the patient in the ‘never’ category even though there was no evidence of PA infection. 
As discussed, tobramycin is associated with kidney injury and cumulative lifetime dose 
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is associated with risk of renal disease. It seems more reasonable to use tobramycin and 
ceftazidime in adult centres, as the older the patient the more likely they are to grow PA. 
As well as this if this is their first growth of PA they are unlikely to have received many 
courses of anti-pseudomonals and so their cumulative lifetime dose is low. There was 
much more variation in the antibiotics selected by the adult CF centres compared to the 
paediatric centres.  
There was an increase in the use of tobramycin and ceftazidime in combination for the 
patient that was ‘free of infection’ compared to the patient in the ‘never’ category.  This 
is likely since the patient has grown PA before, the doctors are presuming it is PA again. 
However, the use of tobramycin if it is not PA may be harmful and unnecessary.  
Interestingly for the patient who had chronic growth of PA experiencing an acute 
respiratory exacerbation all paediatric centres indicated that they would use intravenous 
tobramycin and ceftazidime in combination. This complies with the guidelines set out by 
NICE and CF Trust which suggest using combination of 2 intravenous antibiotics, one 
being an aminoglycoside and the other being a β-lactam (e.g. ceftazidime) or an anti-
pseudomonal penicillin (e.g. Piperacillin-Tazobactam). There was more variation in 
antibiotic combinations used in adult centres for chronic PA infections which can be seen 
in the bar charts above. 
One centre mentioned using overnight fluids when patients are on intravenous antibiotics 
and we wondered whether they used the overnight fluids as a strategy to minimise the 
risk of nephrotoxicity or if there was another reason behind this and so I aimed to contact 
them for more information. There were conflicting views as to whether nebulised 
antibiotics should be continued or withdrawn while patients are receiving intravenous 
antibiotics. The CF trust recognises that most centres stop nebulised antibiotics while 
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using intravenous antibiotics due to the risk of nephrotoxicity however the questionnaires 
demonstrates a variety of practices. This highlights why our Cochrane review is so 
important in order to determine whether nebulised antibiotics can be used safely 
alongside intravenous antibiotics.  
I was surprised by the three paediatric centres that said they did not monitor renal function 
in patients on intravenous antibiotics because they all mentioned tobramycin in at least 
one of their previous answers. The CF Trust describes in its guidelines that those on 
tobramycin should have their renal function checked at the start and states that 
tobramycin can cause nephrotoxicity. With most antibiotics the guidance recommends 
reducing the dose in renal impairment and these centres may be missing this by not 
checking.  
All centres that monitored renal function did so by looking at U&E. Some centres also 
mentioned measuring tobramycin levels. The paediatric centres commonly mentioned 
taking the U&Es at the same time as the tobramycin levels, probably to decrease the 
number of times the child would have to be exposed to a needle. The CF trust states in 
the guidelines that renal function should be assessed at baseline in those about receive a 
course of intravenous tobramycin.  In the paediatric centres that monitor renal function 
there was a variety of monitoring regimes with some centres only assessing it once overall 
throughout the course of antibiotics all the way up to some centres monitoring it twice 
weekly. Similarly, in the adult centres, there was no concordance being monitoring renal 
function with it ranging from weekly to three times weekly.  
There is no mention in the guidelines as when or how to test hearing, but it does clearly 
state that ototoxicity is a side effect of aminoglycoside. Therefore, I would have thought 
that all centres screened for it but was particularly surprised by how few adult centres 
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monitored for this given they are likely to have been exposed to a higher number of IV 
anti-pseudomonals over their lifetime. 
7.4.2 Strengths of the survey  
One of the strengths of the surveys was we got a high response rate in particular from the 
paediatric centres. The paediatric response rate was 85% compared to the adult survey 
which was only 60%. High response rates reduce the risk of non-response bias and so the 
answers are more likely to be valid and representative of the population.  
A further strength of our survey was that it was relatively quick to answer. Qualtrics 
provided an estimation time of 5 minutes to answer but we also tested the questionnaire 
ourselves to make sure it was not too long. By making the questionnaire as short as 
possible it increases the likelihood that the doctors will complete it.  
Another strength of our survey was that we used clinical cases. This made it more 
interesting for the doctors to read and also made it more relatable. If the doctors find the 
questionnaire interesting they are more likely to complete it and so helps maximise the 
response rate.  
In the questionnaire I used to free text box rather than ticking answers that I had provided. 
I think this is better as if I had provided the answers, I may have missed off a combination 
that is used somewhere. Therefore, we get a truer picture of what antibiotics they actually 
use and so it is more accurate. 
7.4.3 Weaknesses of the survey 
Unfortunately, we did not get responses from all centres. For the paediatric centre 
survey, we did not receive responses from Bristol, Aberdeen, Wishaw, or Tayside. In 
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the adult centre survey, we did not receive results from Frimley, St James’, St 
Bartholomew’s, Kings college, Norwich, Nottingham, Southampton, York, Belfast and 
UHNM. This means that the results are more difficult to interpret. 
Another weakness of the survey is that it was only conducted in the UK. Therefore, 
these results are only representative of the UK as the rest of the world may have 
completely different practices when it comes to prescribing antibiotics. By only looking 
at the UK it also means there is a fairly small sample size as there are only limited 
number of CF centres in the UK.  
A disadvantage of using the free text boxes was that people were able to write long 
answers that sometimes included many different antibiotics that they would use in 
different scenarios. Therefore, for some centres we did not necessarily which one they 
would use first line in the given scenario. 
The question asking if they would add anything else alongside the intravenous 
antibiotics was very broad. Therefore, it was hard to know whether we got all the 
answers that we wanted or whether they did not think to tell us, for example, about the 
statins they use. However, if we were to have asked a few more narrower questions e.g. 
did you add in statins if using an aminoglycoside or did you give nebulised antibiotics 
as well, then they may have uncovered the aims of the study. This would give biased 
results as they may give answers that they think you want to hear.  
7.5 Conclusions 
Antibiotic prescribing depends on national/local guidelines, antibiotic sensitivities, 
availability, and cost. There is a lack of guidance particularly in those that have never 
grown PA. We identified high use of nephrotoxic anti-pseudomonals (tobramycin) in 
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patients who had never grown PA. As discussed, cumulative lifetime aminoglycoside 
dose correlates with risk of kidney disease. These patients are therefore being put at an 
unnecessary risk of future renal disease.    
There was a wide variation in the time reported since last PA isolate that would affect 
whether centres chose to use anti-pseudomonals or not. The definition of ‘free from’ uses 
the time point of 12 months which was the most commonly reported time. There needs 
to be clear guidance on this which would require further research.  
From the results of the survey we can see that although there is guidance provided by the 
CF Trust that renal function should be monitored, there are still 3 paediatric centres in 
the UK that do not monitor renal function. The CF Trust also recommends that this renal 
function is monitored at baseline, however around half of the centres do not measure it 
then. This highlights a need for more education to doctors regarding monitoring renal 
function in those on intravenous antibiotics. Other than measuring renal function at 
baseline the CF Trust does not highlight need to monitor renal function at any other time. 
By measuring renal function at baseline, you can identify pre-existing renal problems 
which may affect which antibiotics you give the patient. However, I also think that it 
should be recommended that renal function is monitored throughout treatment to check 
that function is not deteriorating. There needs to be more guidance on this so that doctors 
know when to monitor it. By identifying deteriorating renal function early, the antibiotics 
can be stopped, and it may reduce the risk of acute kidney injury.  
Relating this survey back to our Cochrane review we identified one centre that used fluids 
overnight while patients are receiving intravenous antibiotics. This is a strategy we said 
we would look at to see if reduces nephrotoxicity but currently there are no studies 
addressing this. The survey revealed conflicting views on the use of inhaled and oral 
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antibiotics alongside intravenous antibiotics. Although the CF trust identifies that many 
centres stop nebulised antibiotics, NICE advises to keep them going. Our review is 
important in determining whether the use of inhaled and oral antibiotics alongside 
intravenous antibiotics is safe so that appropriate guidelines can be produced. 
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CHAPTER 8: CONCLUSIONS 
8.1 Main findings from my thesis 
On writing my thesis it has become evident to me that CF is becoming a condition where 
individuals die in their adult life as oppose to during their childhood. There is a vast 
amount of research regarding the management of pulmonary complications in CF. With 
better management of respiratory complications, life expectancy is increasing year upon 
year. However, it is important to remember that some of the treatments that we use can 
have detrimental effects on other organs. As individuals with CF are now surviving into 
their 40’s, it is important to address long term consequences of these treatments and to 
minimise them where possible.  In my thesis, I discussed how the kidneys are injured in 
CF patients, most frequently by intravenous antibiotics. Kidney injury can progress to 
chronic kidney disease which can then have many negative implications on the 
individual’s heath. The objectives of my thesis included performing a Cochrane review 
examining strategies that may reduce the risk of kidney injury caused by intravenous 
antibiotics and to conduct a survey to look at the use of intravenous antibiotics in the UK. 
From the search there seems to be many studies that compare different combinations of 
different antibiotics although we have not yet been able to analyse this data. The 
Cochrane review revealed a lack of evidence for other strategies that we considered that 
may reduce kidney injury. For example, at the moment we have not yet identified any 
studies that look at the use of fluids alongside antibiotics. The review as yet is not 
complete as we are still awaiting further information from authors, however, at this stage 
we have been able to include four studies in our review.  
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There was evidence that administering tobramycin intravenously in the morning in 
children reduced the urinary excretion of a biomarker KIM1 compared to administering 
it in the evening. This may suggest that evening dosing of tobramycin may increase the 
risk of nephrotoxicity and therefore a strategy to minimise kidney injury would be to 
always administer intravenous antibiotics in the morning. 
Al-Aloul’s study demonstrated that using nebulised tobramycin for an acute exacerbation 
reduced the urinary excretion of protein and biomarkers NAG, AAP and β2 
Microglobulin compared to when using intravenous antibiotics. This suggests that using 
nebulised antibiotics instead of an intravenous antibiotic for an acute respiratory 
exacerbation may reduce the risk of kidney injury.  
The survey demonstrated a lack of evidence on consensus of what antibiotic should be 
used for an unidentified infection in a CF patient who has never grown PA. There was no 
consensus on how long since last PA isolation that it is appropriate to not use anti-
pseudomonals. Other than one adult centre that used overnight fluids when patients are 
on intravenous antibiotics there was no other use of fluids or statins to minimise 
nephrotoxicity. There was some use of nebulised antibiotics alongside intravenous 
antibiotics whereas some centres stopped oral and nebulised antibiotics. This highlighted 
the importance of my Cochrane review in determining whether using nebulised 
antibiotics alongside intravenous antibiotics may contribute to nephrotoxicity.   
8.2 Implications for future practice 
Although Prayle’s study size had a very small sample size, it may be appropriate for us 
to suggest use of tobramycin in the morning rather than the evening. It is unlikely that by 
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doing this we would cause any harm as they are still receiving the same antibiotic and 
same dose. 
In future we may be able to recommend using nebulised tobramycin over intravenous 
tobramycin to reduce nephrotoxicity. However, the study was only small and did not hold 
enough power to recommend this. Although it suggested that nebulised tobramycin is as 
effective at resolving the respiratory exacerbation, we cannot be sure due to the small 
sample size and it could be dangerous if the results weren’t correct.  It is important that 
when looking at strategies that may reduce nephrotoxicity, the strategy must be as 
successful at treating the respiratory exacerbation. 
8.3 Implications for future research 
There is a lack of studies looking at adjuvant medication such as fluids or statins 
alongside the intravenous antibiotic. More research is needed to look at these potential 
strategies to minimise nephrotoxicity.   
Although this review so far has highlighted that morning dose of tobramycin may be 
better for the kidneys than an evening dose, a limitation of this study was that it had a 
small sample size. A further limitation was that it only addressed children and not adults. 
Before guidance can advise the use of morning dosing a much larger randomised 
controlled trial is needed that also includes adults. As well as this the effect seen may 
only be limited to tobramycin and so further randomised controlled trials are needed to 
see if other antibiotics have the same effect.  
Similarly, before we can advise using nebulised tobramycin instead of intravenous 
tobramycin a larger randomised controlled trial is required that also looks at children. 
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This trial only addresses tobramycin and so further research is required looking at other 
antibiotics administered by nebuliser rather than intravenously.   
Ideally further research should be placebo-controlled randomised trials that have large 
sample sizes hence the evidence is more robust.  
8.4 Reflections on intercalating  
The most difficult aspect of my masters this year has been timing. I found it frustrating 
that I was often waiting around before I could begin the next part of the Cochrane review. 
For example, I waited for a long time before the protocol was published. This prevented 
me from running the searches and beginning data extraction. While I was awaiting 
publication, I spent this time focusing on my questionnaire. I worried about sending 
reminder emails asking if tasks were completed. On reflection, if tasks had been rushed 
then they may not have been completed to the same high quality. By the end of the year 
I started worrying less about the Cochrane review being completed as I did not want to 
compromise on quality. In conclusion, I learnt that research can take time and is not 
something that can be rushed. Careful planning is required so that there are other tasks 
that you can be on with while waiting for other people to complete their tasks. 
Before starting my masters, I was already keen to pursue a career in paediatrics. This year 
has confirmed that desire further. I have thoroughly enjoyed working with the CF team 
at University Hospital of North Midlands. I particularly enjoyed seeing patients more 
than once and building up rapport with them. I was happy to see increases in lung function 
and less symptoms from one clinic to the next in some patient. Being able to treat patients 
and increase their life expectancy to beyond what was ever imaginable reminded me how 
important Medicine as a subject is. In conclusion, I am certain I would like to pursue a 
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career in paediatrics, particularly in a sub speciality that allows me to work with chronic 
conditions.  
Before beginning this year, I was always intrigued by research but was unsure whether I 
would enjoy it or not. I have always been the medical student that would ask ‘why?’. 
However, I did not predict that I would enjoy research as much as I did. I have found 
myself submerged in topic areas at times during the year. On reflection, this has prompted 
me to think about a career in research. I have decided I should apply for the academic 
foundation programme. I am also keen to get involved in more research projects in the 
near future.  
Being an undergraduate student, I had no previous experience in systematic reviews, 
meta-analysis, or scientific writing. This year has been a very steep learning curve for 
myself, but I have enjoyed it and I know these skills will be valuable for years to come. 
At times I have been overwhelmed by the enormity of the task, particularly when the 
search returned over 6000 results that I had to screen. The Cochrane review training 
course was helpful, but it was not until I started working on my own Cochrane review 
that the knowledge was cemented. I asked countless questions over the course of the year 
to my supervisors, WC and FG and also to the support team at Cochrane, NJ, TR, and 
AK. I have learnt a great deal about critical appraisal of studies and my statistical 
knowledge has vastly improved. I now feel able to not only look at a study and interpret 
the results but also to be critical of it and highlight potential problems with it. I am now 
able to produce, distribute and analyse the results of a survey.  
To conclude, I have gained a lot of experience from doing an MPhil and have enjoyed it. 
I have learnt many skills that I hope to use in the future.  I am proud to have been involved 
in a Cochrane review that will hopefully contribute to research that can help to prevent 
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kidney disease from antibiotics in CF patients. I have been inspired to get involved in 
more research and I am certain I would like to pursue a career in Paediatrics.  
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APPENDICES  
Appendix 1: Paediatric centre survey to assess 
which IV antibiotics are used to treat CF 
respiratory exacerbations 
 
Intravenous Antibiotic Choice - Paeds 
 
Q1 Many thanks for taking the time to complete this short survey. 
  
 Our team is currently undertaking a Cochrane Systematic Review on optimal antibiotic 
strategies for respiratory infections in individuals with Cystic Fibrosis. To complement 
this, we thought it would be useful to ascertain what the current UK practice is for the 
treatment of respiratory infections with intravenous antibiotics.     
 
The survey is based around short case vignettes and should only take around 5 minutes 
to compete.  
 
 
 
Q2 Which centre are you from? 
________________________________________________________________ 
 
 
 
Q3 Tommy is a 6 year old boy with Cystic Fibrosis. He has developed a nasty wet 
cough that did not respond to a two week course of oral antibiotics. Although he sounds 
productive, he does not expectorate sputum as he swallows it. Cough swabs have only 
isolated normal respiratory tract flora. He is saturating at 93% and has a temperature of 
37.8. You decide to start him on intravenous antibiotics. He has no known drug 
allergies.  
 
 
Please list the intravenous antibiotic(s) you would start him on in the following 
scenarios. 
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Q4 Scenario 1   
Tommy has never grown Pseudomonas aeruginosa before.  
    
Please list the intravenous antibiotic(s) that you would start him on for his current 
infective exacerbation.  
________________________________________________________________ 
________________________________________________________________ 
________________________________________________________________ 
________________________________________________________________ 
________________________________________________________________ 
 
 
 
Q5 Would you add in any other medication or therapies alongside the intravenous 
antibiotics? 
o Yes  (1)  
o No  (2)  
 
 
Display This Question: 
If Would you add in any other medication or therapies alongside the intravenous antibiotics? = Yes 
 
Q6 What would you add in?  
________________________________________________________________ 
________________________________________________________________ 
________________________________________________________________ 
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________________________________________________________________ 
________________________________________________________________ 
 
 
 
Q7 Scenario 2   
Tommy isolated Pseudomonas aeruginosa from a cough swab 18 months ago. He 
received eradication therapy for this and subsequent cough swabs (10 in total) have 
been negative.    
    
Please list the intravenous antibiotic(s) that you would start him on for his current 
infective exacerbation.  
________________________________________________________________ 
________________________________________________________________ 
________________________________________________________________ 
________________________________________________________________ 
________________________________________________________________ 
 
 
 
Q8 Would you add in any other medication or therapies alongside the intravenous 
antibiotics? 
o Yes  (1)  
o No  (2)  
 
 
Display This Question: 
If Would you add in any other medication or therapies alongside the intravenous antibiotics? = Yes 
 
Q9 What would you add in?  
________________________________________________________________ 
________________________________________________________________ 
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________________________________________________________________ 
________________________________________________________________ 
________________________________________________________________ 
 
 
 
Q10 Does the time duration since his last isolate of Pseudomonas aeruginosa influence 
your choice of intravenous antibiotics? 
o Yes  (1)  
o No  (2)  
 
 
Display This Question: 
If Does the time duration since his last isolate of Pseudomonas aeruginosa influence your choice 
of... = Yes 
 
Q11 Please explain how time duration since last isolate of Pseudomonas 
aeruginosa influences your choice of intravenous antibiotics. 
________________________________________________________________ 
________________________________________________________________ 
________________________________________________________________ 
________________________________________________________________ 
________________________________________________________________ 
 
 
 
Q12 Scenario 3   
Tommy has chronic Pseudomonas aeruginosa growth with a fully sensitive organism.    
    
Please list the intravenous antibiotic(s) that you would initially start him on.  
________________________________________________________________ 
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________________________________________________________________ 
________________________________________________________________ 
________________________________________________________________ 
________________________________________________________________ 
 
 
 
Q13 Would you add in any other medications or therapies alongside the intravenous 
antibiotics?  
o Yes  (1)  
o No  (2)  
 
 
Display This Question: 
If Would you add in any other medications or therapies alongside the intravenous antibiotics?  = Yes 
 
Q14 What would you add in? 
________________________________________________________________ 
________________________________________________________________ 
________________________________________________________________ 
________________________________________________________________ 
________________________________________________________________ 
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Q15 Do you monitor renal function in those on intravenous antibiotics?  
o Yes  (1)  
o No  (2)  
 
 
Display This Question: 
If Do you monitor renal function in those on intravenous antibiotics?  = Yes 
 
Q16 How do you do this? 
________________________________________________________________ 
________________________________________________________________ 
________________________________________________________________ 
________________________________________________________________ 
________________________________________________________________ 
 
 
Display This Question: 
If Do you monitor renal function in those on intravenous antibiotics?  = Yes 
 
Q17 When do you do this? 
________________________________________________________________ 
________________________________________________________________ 
________________________________________________________________ 
________________________________________________________________ 
________________________________________________________________ 
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Q18 Do you monitor hearing in those on intravenous antibiotics? 
o Yes  (1)  
o No  (2)  
 
 
Display This Question: 
If Do you monitor hearing in those on intravenous antibiotics? = Yes 
 
Q19 When do you monitor for this? 
________________________________________________________________ 
________________________________________________________________ 
________________________________________________________________ 
________________________________________________________________ 
________________________________________________________________ 
 
 
 
Q20 Many thanks for taking the time to complete this survey. 
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Appendix 2: Adult centre survey to assess which 
IV antibiotics are used to treat CF respiratory 
exacerbations 
 
Intravenous Antibiotic Choice - Adults 
 
Q1 Many thanks for taking the time to complete this short survey. 
  
 Our team is currently undertaking a Cochrane Systematic Review on optimal antibiotic 
strategies for respiratory infections in individuals with Cystic Fibrosis.  To complement 
this, we thought it would be useful to ascertain what the current UK practice is for the 
treatment of respiratory infections with intravenous antibiotics. 
    
 The survey is based around short case vignettes and should only take around 5 minutes 
to compete.  
 
 
 
Q2 Which centre are you from? 
________________________________________________________________ 
 
 
 
Q3 Jenny is a 29 year old female with Cystic Fibrosis. She has developed a nasty wet 
cough that did not respond to a two week course of oral antibiotics. She expectorates 
sputum but the sputum cultures have only isolated normal respiratory tract flora. She is 
saturating at 93% and has a temperature of 37.8. You decide to start her on intravenous 
antibiotics. She has no known drug allergies.  
 
 
Please list the intravenous antibiotic(s) you would start her on in the following 
scenarios. 
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Q4 Scenario 1   
Jenny has never grown Pseudomonas aeruginosa before.    
 
 Please list the intravenous antibiotic(s) that you would start her on for her current 
infective exacerbation. 
________________________________________________________________ 
________________________________________________________________ 
________________________________________________________________ 
________________________________________________________________ 
________________________________________________________________ 
 
 
 
Q5 Would you add in any other medication or therapies alongside the intravenous 
antibiotics? 
o Yes  (1)  
o No  (2)  
 
 
Display This Question: 
If Would you add in any other medication or therapies alongside the intravenous antibiotics? = Yes 
 
Q6 What would you add in?  
________________________________________________________________ 
________________________________________________________________ 
________________________________________________________________ 
________________________________________________________________ 
________________________________________________________________ 
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Q7 Scenario 2 
 Jenny isolated Pseudomonas aeruginosa from a cough swab 18 months ago. She 
received eradication therapy for this and subsequent cough swabs (10 in total) have 
been negative.    
    
Please list the intravenous antibiotic(s) that you would start her on for her current 
infective exacerbation. 
________________________________________________________________ 
________________________________________________________________ 
________________________________________________________________ 
________________________________________________________________ 
________________________________________________________________ 
 
 
 
Q8 Would you add in any other medication or therapies alongside the intravenous 
antibiotics? 
o Yes  (1)  
o No  (2)  
 
 
Display This Question: 
If Would you add in any other medication or therapies alongside the intravenous antibiotics? = Yes 
 
Q9 What would you add in?  
________________________________________________________________ 
________________________________________________________________ 
________________________________________________________________ 
________________________________________________________________ 
________________________________________________________________ 
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Q10 Does the time duration since her last isolate of Pseudomonas aeruginosa influence 
your choice of intravenous antibiotics? 
o Yes  (1)  
o No  (2)  
 
 
Display This Question: 
If Does the time duration since her last isolate of Pseudomonas aeruginosa influence your choice 
of... = Yes 
 
Q11 Please explain how time duration since last isolate of Pseudomonas 
aeruginosa influences your choice of intravenous antibiotics. 
________________________________________________________________ 
________________________________________________________________ 
________________________________________________________________ 
________________________________________________________________ 
________________________________________________________________ 
 
 
 
Q12 Scenario 3 
 Jenny has chronic Pseudomonas aeruginosa growth with a fully sensitive organism.      
    
Please list the intravenous antibiotic(s) that you would initially start her on. 
________________________________________________________________ 
________________________________________________________________ 
________________________________________________________________ 
________________________________________________________________ 
________________________________________________________________ 
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Q13 Would you add in any other medications or therapies alongside the intravenous 
antibiotics?  
o Yes  (1)  
o No  (2)  
 
 
Display This Question: 
If Would you add in any other medications or therapies alongside the intravenous antibiotics?  = Yes 
 
Q14 What would you add in? 
________________________________________________________________ 
________________________________________________________________ 
________________________________________________________________ 
________________________________________________________________ 
________________________________________________________________ 
 
 
 
Q15 Do you monitor renal function in those on intravenous antibiotics?  
o Yes  (1)  
o No  (2)  
 
 
Display This Question: 
If Do you monitor renal function in those on intravenous antibiotics?  = Yes 
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Q16 How do you do this? 
________________________________________________________________ 
________________________________________________________________ 
________________________________________________________________ 
________________________________________________________________ 
________________________________________________________________ 
 
 
Display This Question: 
If Do you monitor renal function in those on intravenous antibiotics?  = Yes 
 
Q17 When do you do this? 
________________________________________________________________ 
________________________________________________________________ 
________________________________________________________________ 
________________________________________________________________ 
________________________________________________________________ 
 
 
 
Q18 Do you monitor hearing in those on intravenous antibiotics? 
o Yes  (1)  
o No  (2)  
 
 
Display This Question: 
If Do you monitor hearing in those on intravenous antibiotics? = Yes 
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Q19 When do you monitor for this? 
________________________________________________________________ 
________________________________________________________________ 
________________________________________________________________ 
________________________________________________________________ 
________________________________________________________________ 
 
 
 
Q20 Many thanks for taking the time to complete this survey. 
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Appendix 3: Protocol for Cochrane Review - 
Strategies to prevent kidney injury from 
antibiotics in people with cystic fibrosis 
 
The protocol can be accessed online at:  
https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD013032/full  
